
<html lang="en"     class="pb-page"  data-request-id="9c9050b3-a539-47de-9eef-9ae2e98dc5ee"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.9b01439;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-6"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of a Gut-Restricted JAK Inhibitor for the Treatment of Inflammatory Bowel Disease" /></meta><meta name="dc.Creator" content="Kristi A.  Leonard" /></meta><meta name="dc.Creator" content="Lisa A.  Madge" /></meta><meta name="dc.Creator" content="Paul J.  Krawczuk" /></meta><meta name="dc.Creator" content="Aihua  Wang" /></meta><meta name="dc.Creator" content="Kevin D.  Kreutter" /></meta><meta name="dc.Creator" content="Genesis M.  Bacani" /></meta><meta name="dc.Creator" content="Wenying  Chai" /></meta><meta name="dc.Creator" content="Russell C.  Smith" /></meta><meta name="dc.Creator" content="Mark S.  Tichenor" /></meta><meta name="dc.Creator" content="Michael C.  Harris" /></meta><meta name="dc.Creator" content="Ravi  Malaviya" /></meta><meta name="dc.Creator" content="Mark  Seierstad" /></meta><meta name="dc.Creator" content="Marguerite E.  Johnson" /></meta><meta name="dc.Creator" content="Jennifer D.  Venable" /></meta><meta name="dc.Creator" content="Suzie  Kim" /></meta><meta name="dc.Creator" content="Gavin C.  Hirst" /></meta><meta name="dc.Creator" content="Ashok S.  Mathur" /></meta><meta name="dc.Creator" content="Tadimeti S.  Rao" /></meta><meta name="dc.Creator" content="James P.  Edwards" /></meta><meta name="dc.Creator" content="Michele C.  Rizzolio" /></meta><meta name="dc.Creator" content="Tatiana  Koudriakova" /></meta><meta name="dc.Description" content="To identify Janus kinase (JAK) inhibitors that selectively target gastrointestinal tissues with limited systemic exposures, a class of imidazopyrrolopyridines with a range of physical properties wa..." /></meta><meta name="Description" content="To identify Janus kinase (JAK) inhibitors that selectively target gastrointestinal tissues with limited systemic exposures, a class of imidazopyrrolopyridines with a range of physical properties wa..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 5, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01439" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01439" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01439" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01439" /></link>
        
    
    

<title>Discovery of a Gut-Restricted JAK Inhibitor for the Treatment of Inflammatory Bowel Disease | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01439" /></meta><meta property="og:title" content="Discovery of a Gut-Restricted JAK Inhibitor for the Treatment of Inflammatory Bowel Disease" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0011.jpeg" /></meta><meta property="og:description" content="To identify Janus kinase (JAK) inhibitors that selectively target gastrointestinal tissues with limited systemic exposures, a class of imidazopyrrolopyridines with a range of physical properties was prepared and evaluated. We identified compounds with low intrinsic permeability and determined a correlation between permeability and physicochemical properties, clogP and tPSA, for a subset of compounds. This low intrinsic permeability translated into compounds displaying high colonic exposure and low systemic exposure after oral dosing at 25 mg/kg in mouse. In a mouse PK/PD model, oral dosing of lead compound 2 demonstrated dose-dependent inhibition of pSTAT phosphorylation in colonic explants post-oral dose but low systemic exposure and no measurable systemic pharmacodynamic activity. We thus demonstrate the utility of JAK inhibitors with low intrinsic permeability as a feasible approach to develop gut-restricted, pharmacologically active molecules with a potential advantage over systemically available compounds that are limited by systemic on-target adverse events." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="To identify Janus kinase (JAK) inhibitors that selectively target gastrointestinal tissues with limited systemic exposures, a class of imidazopyrrolopyridines with a range of physical properties was prepared and evaluated. We identified compounds with low intrinsic permeability and determined a correlation between permeability and physicochemical properties, clogP and tPSA, for a subset of compounds. This low intrinsic permeability translated into compounds displaying high colonic exposure and low systemic exposure after oral dosing at 25 mg/kg in mouse. In a mouse PK/PD model, oral dosing of lead compound 2 demonstrated dose-dependent inhibition of pSTAT phosphorylation in colonic explants post-oral dose but low systemic exposure and no measurable systemic pharmacodynamic activity. We thus demonstrate the utility of JAK inhibitors with low intrinsic permeability as a feasible approach to develop gut-restricted, pharmacologically active molecules with a potential advantage over systemically available compounds that are limited by systemic on-target adverse events." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0011.jpeg" /></meta><meta name="twitter:title" content="Discovery of a Gut-Restricted JAK Inhibitor for the Treatment of Inflammatory Bowel Disease" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01439"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01439">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01439&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01439&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01439&amp;href=/doi/10.1021/acs.jmedchem.9b01439" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 6</span><span class="cit-fg-pageRange">, 2915-2929</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/6" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b01391" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b01420" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of a Gut-Restricted JAK Inhibitor for the Treatment of Inflammatory Bowel Disease</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Kristi A. Leonard</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kristi A. Leonard</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research and Development, 1400 McKean Road, Spring House, Pennsylvania 19477, United States</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#2a61664f45444b581b6a435e590440444004494547"><span class="__cf_email__" data-cfemail="d3989fb6bcbdb2a1e293baa7a0fdb9bdb9fdb0bcbe">[email protected]</span></a> (K.L.).</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kristi+A.++Leonard">Kristi A. Leonard</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9398-3354" title="Orcid link">http://orcid.org/0000-0002-9398-3354</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lisa A. Madge</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lisa A. Madge</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research and Development, 1400 McKean Road, Spring House, Pennsylvania 19477, United States</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#5b17163a3f3c3e1b322f287531353175383436"><span class="__cf_email__" data-cfemail="e0acad81848785a0899493ce8a8e8ace838f8d">[email protected]</span></a> (L.M.).</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lisa+A.++Madge">Lisa A. Madge</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paul J. Krawczuk</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paul J. Krawczuk</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research and Development, 1400 McKean Road, Spring House, Pennsylvania 19477, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paul+J.++Krawczuk">Paul J. Krawczuk</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0413-3655" title="Orcid link">http://orcid.org/0000-0003-0413-3655</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Aihua Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Aihua Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research and Development, 1400 McKean Road, Spring House, Pennsylvania 19477, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Aihua++Wang">Aihua Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kevin D. Kreutter</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kevin D. Kreutter</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research and Development, 1400 McKean Road, Spring House, Pennsylvania 19477, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kevin+D.++Kreutter">Kevin D. Kreutter</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Genesis M. Bacani</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Genesis M. Bacani</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research and Development, 3210 Merryfield Row, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Genesis+M.++Bacani">Genesis M. Bacani</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wenying Chai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wenying Chai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research and Development, 3210 Merryfield Row, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wenying++Chai">Wenying Chai</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Russell C. Smith</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Russell C. Smith</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research and Development, 3210 Merryfield Row, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Russell+C.++Smith">Russell C. Smith</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mark S. Tichenor</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mark S. Tichenor</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research and Development, 3210 Merryfield Row, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mark+S.++Tichenor">Mark S. Tichenor</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael C. Harris</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael C. Harris</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research and Development, 1400 McKean Road, Spring House, Pennsylvania 19477, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael+C.++Harris">Michael C. Harris</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ravi Malaviya</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ravi Malaviya</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research and Development, 1400 McKean Road, Spring House, Pennsylvania 19477, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ravi++Malaviya">Ravi Malaviya</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mark Seierstad</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mark Seierstad</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research and Development, 3210 Merryfield Row, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mark++Seierstad">Mark Seierstad</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6734-4316" title="Orcid link">http://orcid.org/0000-0001-6734-4316</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Marguerite E. Johnson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marguerite E. Johnson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research and Development, 1400 McKean Road, Spring House, Pennsylvania 19477, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marguerite+E.++Johnson">Marguerite E. Johnson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jennifer D. Venable</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jennifer D. Venable</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research and Development, 3210 Merryfield Row, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jennifer+D.++Venable">Jennifer D. Venable</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Suzie Kim</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Suzie Kim</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research and Development, 3210 Merryfield Row, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Suzie++Kim">Suzie Kim</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gavin C. Hirst</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gavin C. Hirst</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research and Development, 3210 Merryfield Row, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gavin+C.++Hirst">Gavin C. Hirst</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ashok S. Mathur</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ashok S. Mathur</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research and Development, 1400 McKean Road, Spring House, Pennsylvania 19477, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ashok+S.++Mathur">Ashok S. Mathur</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tadimeti S. Rao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tadimeti S. Rao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research and Development, 3210 Merryfield Row, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tadimeti+S.++Rao">Tadimeti S. Rao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">James P. Edwards</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James P. Edwards</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research and Development, 1400 McKean Road, Spring House, Pennsylvania 19477, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James+P.++Edwards">James P. Edwards</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michele C. Rizzolio</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michele C. Rizzolio</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research and Development, 3210 Merryfield Row, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michele+C.++Rizzolio">Michele C. Rizzolio</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Tatiana Koudriakova</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tatiana Koudriakova</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research and Development, 3210 Merryfield Row, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tatiana++Koudriakova">Tatiana Koudriakova</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01439&amp;href=/doi/10.1021%2Facs.jmedchem.9b01439" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 6</span><span class="cit-pageRange">, 2915–2929</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 5, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>30 August 2019</li><li><span class="item_label"><b>Published</b> online</span>5 March 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 March 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01439" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01439</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2915%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DKristi%2BA.%2BLeonard%252C%2BLisa%2BA.%2BMadge%252C%2BPaul%2BJ.%2BKrawczuk%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D6%26contentID%3Dacs.jmedchem.9b01439%26title%3DDiscovery%2Bof%2Ba%2BGut-Restricted%2BJAK%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BInflammatory%2BBowel%2BDisease%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2929%26publicationDate%3DMarch%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01439"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2755</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">2</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01439" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of a Gut-Restricted JAK Inhibitor for the Treatment of Inflammatory Bowel Disease&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Kristi&quot;,&quot;last_name&quot;:&quot;A. Leonard&quot;},{&quot;first_name&quot;:&quot;Lisa&quot;,&quot;last_name&quot;:&quot;A. Madge&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;J. Krawczuk&quot;},{&quot;first_name&quot;:&quot;Aihua&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;D. Kreutter&quot;},{&quot;first_name&quot;:&quot;Genesis&quot;,&quot;last_name&quot;:&quot;M. Bacani&quot;},{&quot;first_name&quot;:&quot;Wenying&quot;,&quot;last_name&quot;:&quot;Chai&quot;},{&quot;first_name&quot;:&quot;Russell&quot;,&quot;last_name&quot;:&quot;C. Smith&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;S. Tichenor&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;C. Harris&quot;},{&quot;first_name&quot;:&quot;Ravi&quot;,&quot;last_name&quot;:&quot;Malaviya&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;Seierstad&quot;},{&quot;first_name&quot;:&quot;Marguerite&quot;,&quot;last_name&quot;:&quot;E. Johnson&quot;},{&quot;first_name&quot;:&quot;Jennifer&quot;,&quot;last_name&quot;:&quot;D. Venable&quot;},{&quot;first_name&quot;:&quot;Suzie&quot;,&quot;last_name&quot;:&quot;Kim&quot;},{&quot;first_name&quot;:&quot;Gavin&quot;,&quot;last_name&quot;:&quot;C. Hirst&quot;},{&quot;first_name&quot;:&quot;Ashok&quot;,&quot;last_name&quot;:&quot;S. Mathur&quot;},{&quot;first_name&quot;:&quot;Tadimeti&quot;,&quot;last_name&quot;:&quot;S. Rao&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;P. Edwards&quot;},{&quot;first_name&quot;:&quot;Michele&quot;,&quot;last_name&quot;:&quot;C. Rizzolio&quot;},{&quot;first_name&quot;:&quot;Tatiana&quot;,&quot;last_name&quot;:&quot;Koudriakova&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;05&quot;,&quot;issue&quot;:&quot;6&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;2915-2929&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01439&quot;},&quot;abstract&quot;:&quot;To identify Janus kinase (JAK) inhibitors that selectively target gastrointestinal tissues with limited systemic exposures, a class of imidazopyrrolopyridines with a range of physical properties was prepared and evaluated. We identified compounds with low intrinsic permeability and determined a correlation between permeability and physicochemical properties, clogP and tPSA, for a subset of compounds. This low intrinsic permeability translated into compounds displaying high colonic exposure and low systemic exposure after oral dosing at 25 mg/kg in mouse. In a mouse PK/PD model, oral dosing of lead compound 2 demonstrated dose-dependent inhibition of pSTAT phosphorylation in colonic explants post-oral dose but low systemic exposure and no measurable systemic pharmacodynamic activity. We thus demonstrate the utility of JAK inhibitors with low intrinsic permeability as a feasible approach to develop gut-restricted, pharmacologically active molecules with a potential advantage over systemically available compound&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01439&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01439" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01439&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01439" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01439&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01439" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01439&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01439&amp;href=/doi/10.1021/acs.jmedchem.9b01439" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01439" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01439" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01439%26sid%3Dliteratum%253Aachs%26pmid%3D32134643%26genre%3Darticle%26aulast%3DLeonard%26date%3D2020%26atitle%3DDiscovery%2Bof%2Ba%2BGut-Restricted%2BJAK%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BInflammatory%2BBowel%2BDisease%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D6%26spage%3D2915%26epage%3D2929%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292504" title="Permeability">Permeability</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/6" title="Go to Volume 63, Issue 6"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/jmcmar.2020.63.issue-6/20200326/jmcmar.2020.63.issue-6.largecover.jpg" alt="Go to Volume 63, Issue 6"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/medium/jm9b01439_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01439&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">To identify Janus kinase (JAK) inhibitors that selectively target gastrointestinal tissues with limited systemic exposures, a class of imidazopyrrolopyridines with a range of physical properties was prepared and evaluated. We identified compounds with low intrinsic permeability and determined a correlation between permeability and physicochemical properties, clogP and tPSA, for a subset of compounds. This low intrinsic permeability translated into compounds displaying high colonic exposure and low systemic exposure after oral dosing at 25 mg/kg in mouse. In a mouse PK/PD model, oral dosing of lead compound <b>2</b> demonstrated dose-dependent inhibition of pSTAT phosphorylation in colonic explants post-oral dose but low systemic exposure and no measurable systemic pharmacodynamic activity. We thus demonstrate the utility of JAK inhibitors with low intrinsic permeability as a feasible approach to develop gut-restricted, pharmacologically active molecules with a potential advantage over systemically available compounds that are limited by systemic on-target adverse events.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70075" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70075" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are characterized by recurrent intestinal inflammation, disruption of the epithelial barrier, and microbial dysbiosis. The excessive inflammatory response in the gastrointestinal (GI) tract is mediated by inflammatory cytokines such as TNFα, IFN-γ, IL-1, IL-6, IL-12, IL-21, and IL-23 that exert their effects on cells of the innate and adaptive immune system including T and B lymphocytes, epithelial cells, macrophages, and dendritic cells (DC).<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1−3)</a> The Janus kinase (JAK) family, JAK1, JAK2, JAK3, and Tyk2, are nonreceptor tyrosine kinases that play a pivotal role in the response to many such cytokines.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Following receptor ligation, associated JAK homo- or heterodimers are phosphorylated and activated, enabling the subsequent recruitment, phosphorylation, and activation of the signal transducers and activators of transcription (STAT) family of transcription factors. Phosphorylated STATs (pSTATs) translocate to the nucleus and induce gene transcription of several chemokines, cytokines and proteases implicated in the pathogenesis of IBD.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></div><div class="NLM_p">Genetic studies in patients with IBD have identified polymorphisms in several proteins associated with the JAK/STAT pathway such as IL-23R, IL-12B, JAK2, Tyk2, and STAT3 as risk factors for IBD.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Since the JAK/STAT pathway is common to multiple inflammatory cytokine responses (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), it offers an attractive therapeutic target to prevent the excessive inflammatory response associated with IBD. In support of this data, several JAK inhibitors such as tofacitinib and filgotinib are currently in clinical development for IBD.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Cytokines That Signal through JAK Homo- and Heterodimers.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cytokines</th><th class="colsep0 rowsep0" align="center">JAKs</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IL-2, −4, −7, −9, −15, −21</td><td class="colsep0 rowsep0" align="left">JAK1/JAK3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IFNγ</td><td class="colsep0 rowsep0" align="left">JAK1/JAK2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IL-10, IFNα</td><td class="colsep0 rowsep0" align="left">JAK1/Tyk2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IL-12, IL-23</td><td class="colsep0 rowsep0" align="left">JAK2/Tyk2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IL-6, −11, −13, −27, −31, −35</td><td class="colsep0 rowsep0" align="left">JAK1/Tyk2 or JAK1/JAK2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EPO, GM-CSF, IL-3, IL-5, TPO</td><td class="colsep0 rowsep0" align="left">JAK2/JAK2</td></tr></tbody></table></div></div><div class="NLM_p">Tofacitinib is approved in the United States for the treatment of rheumatoid arthritis (RA) and UC.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> Tofacitinib was also in clinical development for the treatment of CD; however, further development for this indication was discontinued due to failure to achieve significant clinical efficacy in a 4 week, phase 2 clinical trial in moderate to severe CD.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Despite positive evidence of target engagement based on biomarker analysis, it is currently unclear whether the lack of efficacy of tofacitinib in CD relates to clinical study design, mechanistic differences between UC and CD, or dose-limiting systemic adverse events (AEs) that prevent adequate exposure to intestinal tissue.<a onclick="showRef(event, 'ref1 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref1 ref9 ref10">(1,9,10)</a> Common to both phase 2 and phase 3 IBD clinical trials with tofacitinib, systemic adverse events (AEs) included decreased hemoglobin, decreased absolute neutrophil count (ANC), elevated total cholesterol (low and high density lipid) and infection.<a onclick="showRef(event, 'ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9">(7−9)</a> Such AEs are consistent with those observed following tofacitinib treatment in RA patients<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> and are consistent with JAK2-dependent inhibition of EPO, TPO, and granulocyte monocyte colony stimulating factor (GM-CSF) and/or JAK1-dependent inhibition of IL-6.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a> On the basis of results of an ongoing post-marketing safety trial with tofacitinib, the FDA recently approved a black box warning regarding increased risk of blood clots and death with the utility of tofacitinib at 10 mg with twice daily dosing. In the ongoing trial, dosing at 10 mg was stopped but continues to be evaluated at 5 mg twice daily dose. In patients with UC, the FDA recommends tofacitinib at 5 mg twice daily and restriction to those patients who have failed or are intolerant to TNF blockers.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><div class="NLM_p">There are several potential approaches to overcome systemic AEs driven by JAK inhibition. One such approach would be to develop orally available inhibitors that show less activity against JAK2. Such an approach is utilized by JAK1 selective inhibitors such as filgotinib and upadacitinib currently in phase 3 clinical trial for CD and UC. Despite the theoretical safety advantage of a JAK1 selective molecule, the recent approval of upadacitinib for RA at a dose of 15 mg twice daily also has a black box warning from the FDA pertaining to a risk of thrombosis.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> An alternative approach would be to restrict exposure of the inhibitor to the GI tract to maximize the intestinal tissue exposure of a JAK inhibitor while sparing systemic exposure that can lead to on-target side effects.</div><div class="NLM_p">Our objective was to develop a JAK inhibitor with similar cellular potency to tofacitinib yet with exposure limited to the intestinal tract. We hypothesized that improved efficacy in both UC and CD could be driven by increased intestinal exposure while preventing dose-limiting side effects that are associated with systemic pan-JAK inhibition.</div><div class="NLM_p last">Several gut tissue targeting strategies have been employed to increase intestinal tissue exposure while reducing systemic exposure.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> One common approach is to use a formulation to release the compound at different regions of the GI tract.<a onclick="showRef(event, 'ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18">(16−18)</a> Another approach is to modify the physicochemical properties of the molecules to limit systemic exposure. Compounds can be made with high cLogP that are rapidly metabolized or with high molecular weight and polar surface areas that limit intestinal permeability.<a onclick="showRef(event, 'ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18">(16−18)</a> An alternative strategy is to use a prodrug that is converted to an active metabolite in the intestines.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11072" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11072" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We envisaged developing potent, cell-active JAK inhibitors with physicochemical properties that lead to limited systemic exposure after oral dosing but maintain the ability to inhibit cytokine signaling locally in the intestinal tissues. We set out to identify molecules with low intrinsic permeability as determined in a Madin Darby canine kidney cell with the <i>MDR1</i> gene [the gene encoding for the efflux protein P-glycoprotein (P-gp)].<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> This (MDCK-<i>MDR1</i>) assay focuses specifically on the intrinsic permeability as measured by apical to basolateral permeability rate in the presence of a P-gp inhibitor, elacridar (A → B (+P-gp inhibitor)).<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> It is important to note that in order to target JAK kinases, which are expressed in inflammatory cells within the lamina propria, some degree of uptake into the GI tract is required to achieve the desired pharmacological effects. Molecules with intrinsic permeability that is too low would result in decreased systemic exposure but would also lead to decreased penetration to the target tissue and lack of efficacy. Therefore, finding a balance in lowering permeability while maintaining cell and tissue-based activity was essential.</div><div class="NLM_p">To identify JAK inhibitors with the appropriate physicochemical properties that would limit systemic exposure while maintaining cell permeability and the ability to penetrate intestinal tissue, compound <b>1</b><a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> was used as a starting point. As shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, compound <b>1</b> is a potent pan-JAK inhibitor with high intrinsic permeability. This permeability results in compound <b>1</b> having a systemic exposure of 1.18 μM measured 30 min post-oral dose at 25 mg/kg in mice. Our approach focused on making changes to the portion of the molecule with a vector toward the solvent exposed region of the JAK proteins. We hypothesized that changes to this portion of the molecule would have a high probability of maintaining sufficient enzyme inhibition activity, while allowing for the evaluation of analogues with a wide range of physicochemical properties that could lead to intestinal tissue-targeting properties. On the basis of the crystal structure of similar molecules from this series,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> we proposed that the C2-position of the imidazole would be the most effective position to build chemical diversity and that any loss in JAK enzyme potency or isoform selectivity would be due to dynamic interactions not described by the static crystal structure. The structural modifications made at the C2-position of the imidazole are shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> (this position is in the solvent exposed region; see <a class="ref internalNav" href="#notes1" aria-label="Figure S1">Figure S1</a>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/medium/jm9b01439_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Enzyme potency (JAK1, JAK2, JAK3, and Tyk2), intrinsic permeability in MDCK-<i>MDR1</i> permeability assay, and systemic exposure at 0.5 h after oral dosing in mouse of Compound <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01439&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/medium/jm9b01439_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Analogues of compound <b>1</b> synthesized to evaluate a range of physicochemical properties through substitution at the C2-position of the imidazole. See <a class="ref internalNav" href="#notes1" aria-label="Supporting Information">Supporting Information</a> for details.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01439&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">By varying the moiety at the C2-position, a set of 187 compounds was obtained with a range of physical properties including cLogP (0.22–5.73), H-bond donors (1–4), tPSA (70–149 Å<sup>2</sup>), and molecular weight (MW) (323–579), as shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>. This broad range of properties obtained allowed us to assess specific features responsible for lowering the intrinsic permeability of these molecules.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/medium/jm9b01439_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Range of properties of analogues from <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, including cLogP, tPSA, H-bond donors, and MW, that create a diverse set of physicochemical properties.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01439&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Within this entire set of analogues, trends were not sufficiently robust to consistently predict the physicochemical properties that were responsible for low intrinsic permeability, with the exception that four compounds with four H-bond donors all had low intrinsic permeability (defined here as A → B (+P-gp inhibitor) < 2<i>P</i><sub>app</sub> × 10<sup>–6</sup> cm/s). However, among a subset of 94 analogues containing −CH<sub>2</sub>CONRR and −CH<sub>2</sub>NRCOR substitution at the C2-position of the imidazole moiety, a clear permeability trend was observed that correlated to cLogP and tPSA (see <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a> and <a class="ref internalNav" href="#notes1" aria-label="Table S2">Table S2</a>). For the corresponding analysis of permeability in relation to cLogP and tPSA properties for all other analogues, see <a class="ref internalNav" href="#notes1" aria-label="Table S1">Table S1</a>. The parameters determined to correlate to low intrinsic permeability of <2<i>P</i><sub>app</sub> × 10<sup>–6</sup> cm/s within this series are cLogP < 2.5 and tPSA > 99 Å<sup>2</sup>. Compounds with tPSA < 99 Å<sup>2</sup> were more likely to have an intrinsic permeability >2<i>P</i><sub>app</sub> × 10<sup>–6</sup> cm/s.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/medium/jm9b01439_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Correlation between instrinsic permeability (measured by MDCK-<i>MDR1</i> (A → B (+P-gp inhibitor))) and clogP and tPSA (logarithmic scale used on <i>y</i>-axis) of compounds with −CH<sub>2</sub>CONRR and −CH<sub>2</sub>NRCOR substituents at the C2-position of the imidazole.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01439&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">An analysis of the JAK1 enzyme potency of these molecules demonstrated that substitution at C2-position of the imidazole generally had a detrimental impact on JAK1 inhibition (see <a class="ref internalNav" href="#notes1" aria-label="Supporting Information">Supporting Information</a>). However, most molecules were no more than 10- to 15-fold less potent than compound <b>1</b>, and 60% of these compounds inhibited JAK1 with single-digit nM potency. Also, the isoform selectivity across the JAK-family was generally preserved (see <a class="ref internalNav" href="#notes1" aria-label="Figures S3–S5">Figures S3–S5</a>). This level of <i>in vitro</i> potency, combined with the analysis of the physicochemical properties, allowed us to select molecules for <i>in vivo</i> evaluation.</div><div class="NLM_p">To support the selection of compounds for <i>in vivo</i> mouse pharmacokinetic/pharmacodynamic (PK/PD) studies, we chose compounds with a range of intrinsic permeability values and measured plasma exposures following a single 25 mg/kg oral dose in mice. Plasma exposures were determined at 0.5 h (approximate systemic T<sub>max</sub>) in addition to measurement at 4 h when colon exposure was also determined (approximate colon T<sub>max</sub>, data not shown). To support selection for further <i>in vivo</i> studies, compounds that achieved systemic concentrations below 100 nM at 0.5 and 4 h were considered for further profiling. Compounds were prioritized based on this threshold of 100 nM such that systemic exposures were expected to be less than the whole blood IC<sub>50</sub>. As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, the results of the screen established a correlation between plasma exposures and intrinsic permeability. Compounds with intrinsic permeability less than 1.5<i>P</i><sub>app</sub> × 10<sup>–6</sup> cm/s were more likely to have low systemic exposure (defined as <100 nM) at 0.5 h. This correlation demonstrates that, for this subset of compounds, calculated physicochemical properties (cLogP and tPSA) can be used to identify compounds that achieve low intrinsic permeability, and this low intrinsic permeability translates into compounds with low systemic exposure <i>in vivo</i>.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/medium/jm9b01439_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. A comparison of mouse plasma exposure at 0.5 h following oral dosing to intrinsic permeability (MDCK-<i>MDR1</i> A → B (+P-gp inhibitor)) (logarithmic scale used on <i>y</i>-axis).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01439&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">There are a number of publications establishing correlations between physicochemical properties and permeability. The Lipinski “rule of five” is one method of assessing the likelihood that a small molecule will be orally bioavailable based on calculated physiochemical properties.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Compounds having a MW < 500, cLogP < 5, five or fewer hydrogen bond donors, and ten or fewer hydrogen bond acceptors have a higher probability of oral bioavailability. A more recent analysis by Paolini et al. identified a calculated centroid in the same physicochemical parameters of 617 oral drugs at MW = 316, cLogP = 2.3, 2 hydrogen bond donors, and 4 hydrogen bond acceptors.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The physicochemical properties of the JAK inhibitors in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> range from 2–3 H-bond donors, 103–128 tPSA, 389–490 MW, and 0.24–2.79 cLogP, suggesting that many of these compounds would have been expected to be in good physicochemical space for permeability and bioavailability based on known criteria for assessing these parameters.</div><div class="NLM_p">The permeability, enzyme and cellular potency, and plasma exposure after <i>per os</i> (p.o.) dosing in mice of select compounds from <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a> are shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. These data show that many molecules with low intrinsic permeability and low systemic exposure can maintain good cell potency in IL-2-, IFNα-, and GM-CSF-stimulated peripheral blood mononuclear cells (PBMCs) (compounds <b>2</b>–<b>9</b>). However, we did obtain compounds that lost a significant amount of potency in PBMCs compared to their enzyme activity, as exemplified by compounds <b>10</b> and <b>11</b>. Although we were unable to determine a direct correlation of permeability and cell activity (compare, for example, entries 3 and 11, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>), empirically we were able to successfully discover molecules with potent cell activity and modest absorption after oral administration. All compounds tested had low but quantifiable levels of systemic exposure at 0.5 h; all but compound <b>3</b> had quantifiable plasma levels at 4 h. At this 4 h time point, exposures in the colon tissue were also measured and in every case were found to be high (1335–16717 ng/g). We also assessed metabolic stability in mouse liver microsomes expressed as extraction ratios (E.R.) for all compounds, which demonstrates that metabolism is not a major contributor to reduced systemic exposure. This is exemplified by compounds <b>1</b> and <b>2</b> that have similar extraction ratios (0.34 vs 0.37, respectively) but have a large difference in exposure at 0.5 h (1.18 μM vs 0.032 μM, respectively), which correlates to intrinsic permeability.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Enzyme, Cell-Based Data, Mouse Extraction Ratios, and Intrinsic Permeability Data in Addition to Mouse PK Exposures after a Single Dose of 25 mg/kg for Tofacitinib and Compounds <b>1</b>–<b>11</b><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/medium/jm9b01439_0010.gif" alt="" id="gr10" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">BLOQ = below limit of quantification; NT = not tested; NA = not applicable; tofa = tofacitinib.</p></div></div><div></div></div><div class="NLM_p">On the basis of cell potency, low systemic exposures (0.5 and 4 h post-dose) and high colonic exposure (4 h post-dose) following a 25 mg/kg dose in mouse, compound <b>2</b> was chosen for further profiling <i>in vitro</i> and <i>in vivo</i>. Head-to-head comparison studies with tofacitinib and compound <b>2</b> demonstrated that the potency of compound <b>2</b> is similar to tofacitinib in PBMC assays measuring either STAT4 or STAT5 phosphorylation in response to a range of cytokine stimulants (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Compound <b>2</b> had comparable potency to tofacitinib in an IFNα-stimulated STAT4 (54 nM and 31 nM, respectively) and an IL-12-stimulated STAT4 (257 nM and 440 nM, respectively) assay. In contrast, compound <b>2</b> was 5–6-fold less potent in GM-CSF-stimulated pSTAT5 (303 nM and 51 nM, respectively) and IL-2-stimulated pSTAT5 (61 nM and 12 nM, respectively) assays.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Head-to-Head Comparison Studies of Compound <b>2</b> with Tofacitinib in PBMC Assays Stimulated with Cytokines IL-2, IFNα, IL-12, and GM-CSF<a class="ref internalNav" href="#tbl3-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char=" " /></col><col align="char" char=" " /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">PBMC assay</th><th class="colsep0 rowsep0" align="center" char=" ">compound <b>2</b> (IC<sub>50</sub>, nM) mean (95% CI)</th><th class="colsep0 rowsep0" align="center" char=" ">tofacitinib (IC<sub>50</sub>, nM) mean (95% CI)</th><th class="colsep0 rowsep0" align="center" char="."><i>n</i></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IL-2/pSTAT5</td><td class="colsep0 rowsep0" align="char" char=" ">61 (46–80)</td><td class="colsep0 rowsep0" align="char" char=" ">12 (9–17)</td><td class="colsep0 rowsep0" align="char" char=".">3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IFNα/pSTAT4</td><td class="colsep0 rowsep0" align="char" char=" ">54 (28–108)</td><td class="colsep0 rowsep0" align="char" char=" ">31 (20–49)</td><td class="colsep0 rowsep0" align="char" char=".">5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IL-12/pSTAT4</td><td class="colsep0 rowsep0" align="char" char=" ">257 (153–432)</td><td class="colsep0 rowsep0" align="char" char=" ">440 (201–961)</td><td class="colsep0 rowsep0" align="char" char=".">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GM-CSF/pSTAT5</td><td class="colsep0 rowsep0" align="char" char=" ">303 (160–576)</td><td class="colsep0 rowsep0" align="char" char=" ">51 (36–72)</td><td class="colsep0 rowsep0" align="char" char=".">3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl3-fn1"><div class="footnote" id="tbl3-fn1"><sup><sup>a</sup></sup><p class="last">CI = confidence interval. <i>n</i> = 2–5 independent experiments.</p></div></div></div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Chemistry</h3><div class="NLM_p">The route used to synthesize these JAK inhibitors (compounds presented in this article were also described in the following patent application publications: refs <a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> and <a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a>) corresponded to the type of linker attached to the 2 position of the imidazole. Compounds <b>2</b>–<b>7</b> and <b>9</b>–<b>11</b>, containing the −CH<sub>2</sub>CONRR linker, were accessed using the synthetic sequence outlined in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Chloro-pyrrolopyridine intermediate <b>12</b> reacted with 2-((1<i>r</i>,4<i>r</i>)-4-aminocyclohexyl)acetonitrile hydrochloride in the presence of DIPEA in DMA at 80 °C to give intermediate <b>13</b> in 95% yield. A subsequent nitro reduction of <b>13</b> generated diamino compound <b>14</b> by passing a solution of <b>13</b> in 1:1 THF and MeOH through a 10% Pd/C cartridge at 80 °C in a continuous-flow hydrogenation reactor (Thales Nano H-Cube). Condensation of diamino compound <b>14</b> with ethyl 3-ethoxy-3-iminopropanoate in EtOH at 90 °C afforded the versatile ester <b>15</b>. From this key intermediate, a variety of amines were attached by aminolysis of the ester <b>15</b> via heating in DMA to give the amide, followed by removal of the sulfonyl protecting group by treatment with KOH in water and dioxane to give the final −CH<sub>2</sub>CONRR compounds. Alternatively, ester <b>15</b> can be saponified with NaOH to give the sodium salt <b>15a</b>, followed by PyBrOP coupling conditions with amines.</div><figure id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/medium/jm9b01439_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>2</b>–<b>7</b> and <b>9</b>–<b>11</b> (Containing the −CH<sub>2</sub>CONRR Linker)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01439&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) DIPEA, DMA, 80 °C; (b) Pd/C, 1 atm H<sub>2</sub> (via H-Cube), THF/MeOH (1:1), 80 °C; (c) EtOH, 90 °C; (d) (1) R<sub>1</sub>R<sub>2</sub>NH, DMA, 125 °C, (2) 3 M KOH in water, dioxane, 80 °C; (e) (1) 1 M NaOH in water, MeOH/THF (1:1), (2) R<sub>1</sub>R<sub>2</sub>NH, PyBrOP, DIPEA, DMF.</p></p></figure><div class="NLM_p">Compound <b>8</b>, with the −CH<sub>2</sub>NHCOR linker, was synthesized using the route shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. In a single pot, intermediate nitro <b>13</b> and <i>tert</i>-butyl (2-oxoethyl)carbamate were combined directly using sodium hydrosulfite to afford the tricyclic intermediate <b>16</b>. After removal of the sulfonyl and Boc protecting groups, HATU-promoted amidation with cyclopropylacetic acid afforded compound <b>8</b>.</div><figure id="sch2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/medium/jm9b01439_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compound <b>8</b> (with the −CH<sub>2</sub>NHCOR Linker)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01439&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Na<sub>2</sub>S<sub>2</sub>O<sub>4</sub>, DMSO/MeOH/water, 100 °C; (b) 3 M KOH in water, dioxane, 80 °C; (c) 4 M HCl in dioxane, DCM; (d) HATU, DIPEA, DCM.</p></p></figure><div class="NLM_p">To determine whether compound <b>2</b> achieved systemic activity <i>in vivo</i>, mice were dosed orally with either vehicle (20% HPβCD), compound <b>2</b> (25 mg/kg), or tofacitinib (25 mg/kg). At 0.5 h post-dose, serum drug levels were determined. Observed mean serum levels of compound <b>2</b> and tofacitinib were 5.1 ± 1.6 nM and 2166 ± 314 nM, respectively. To confirm that the low level of exposure of compound <b>2</b> had no measurable systemic activity, whole blood taken 0.5 h post-oral dose was stimulated with IFNα. This cytokine stimulation induced a significant increase in pSTAT3 and pSTAT4 in whole blood from vehicle-treated mice and the response was significantly inhibited by tofacitinib. Corresponding with the low systemic exposure observed for compound <b>2</b> post-oral dose, no inhibition of IFNα-induced pSTAT4 (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) or pSTAT3 (data not shown) could be observed in blood. Compound <b>2</b> and tofacitinib inhibited the IFNα-induced pSTAT3 response when directly added to murine whole blood with an average IC<sub>50</sub> of 299 (95% CI 121–733) nM and 112 (95% CI 51–249) nM, respectively (data not shown).</div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/medium/jm9b01439_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Comparative activity of compound <b>2</b> and tofacitinib in mouse whole blood post-oral dose. Mice were dosed orally with compound <b>2</b> and tofacitinib at 25 mg/kg. Control mice received equal volume of 20% of 2-hydroxypropyl-β-cyclodextrin (HPβCD) in the similar fashion. After 0.5 h, the animals were sacrificed, and their blood was collected and stimulated with IFNα as described in <a class="ref internalNav" href="#sec5" aria-label="Methods">Methods</a>. pSTAT4 levels were measured following 30 min of stimulation and expressed as a percentage of the IFNα-induced pSTAT4 response observed relative to the vehicle-treated group. Data are presented as mean ± SEM; <i>N</i> = 4 mice/group. Statistics are derived from ANOVA analysis of pSTAT4 raw relative luminescent values (RLU) and are applicable to data presented as percent inhibition. ** = <i>P</i> < 0.001 vs cytokine simulated vehicle. <sup>##</sup> = <i>P</i> < 0.001 vs unstimulated vehicle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01439&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To demonstrate target engagement in the colon, which is a unique tissue-based assay, we examined the effect of orally administered compound <b>2</b> on the pSTAT3 response elicited by a cocktail of pro-inflammatory cytokines (IL-22, IL-6, IFNα). We selected this cytokine cocktail based on its ability to elicit a robust response in gut tissue when given exogenously to murine colonic explants in culture. Robust increases in colonic pSTAT3 were observed in explant tissue collected from mice predosed with vehicle (HPβCD) (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A). Tofacitinib (25 mg/kg p.o.), used as a control, demonstrated inhibition of both baseline (unstimulated) (87.3% inhibition) and IL-22/IL-6/IFNα-stimulated (91.2% inhibition) pSTAT3 (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A). Compound <b>2</b> inhibited baseline and IL-22/IL-6/IFNα-induced pSTAT3 in a dose-dependent manner (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A). Basal pSTAT3 was inhibited by 36.7, 66.2, 71.3, and 83.8% at 0.5, 2.5, 5, and 25 mg/kg doses of compound <b>2</b>, respectively. Similarly, compound <b>2</b> inhibited IL-22/IL-6/IFNα-stimulated pSTAT3 by 5.5, 62.0, 68.1, and 89.8% in 0.5, 2.5, 5, and 25 mg/kg dosed mice, respectively. Thus, compound <b>2</b> demonstrates robust target engagement in the colon tissue <i>ex vivo</i> through the inhibition of the IL-22/IL-6/IFNα-induced pSTAT3 response at doses with limited systemic exposure.</div><figure id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/medium/jm9b01439_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Dose response of compound 2 effect on basal and IL-22/IL-6/IFNα-induced pSTAT3 in mouse colon explants. Mice were dosed orally with compound <b>2</b> or tofacitinib at indicated doses. Control mice received equal volumes of 20% HPβCD (Veh) in the similar fashion. At 4 h post-dose, animals were sacrificed, and colon tissue was harvested as detailed in <a class="ref internalNav" href="#sec5" aria-label="Methods">Methods</a>. (A) pSTAT3 levels were measured in the proximal colon explants following <i>ex vivo</i> stimulation with the IL-22/IL-6/IFNα cytokine cocktail for 1 h. Control explants (no stimulation) were treated with media alone. Data are presented as mean ± SEM; <i>N</i> = 5 mice/group. ** = <i>p</i> < 0.01; **** = <i>p</i> < 0.00001; ns = not significant. (B) Colonic tissue levels of compound <b>2</b> from all mice dosed 0.5–25 mg/kg were measured by the liquid chromatography-triple quadrupole mass spectrometry (LC MS/MS) method and corresponding inhibition of IL-22/IL-6/IFNα responses for each explant plotted.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01439&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Finally, to establish a PK/PD relationship, the terminal colonic exposure of compound <b>2</b> was measured. Colonic exposure of compound <b>2</b> increased in a dose-dependent fashion and was correlated with the inhibition of the cytokine-induced pSTAT3 response, as illustrated in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B. According to this linear relationship, more than 50% of the pSTAT3 response in tissue can be inhibited at colonic concentrations greater than 897 ng/g of tissue.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34376" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34376" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In conclusion, correlations between the physicochemical properties (cLogP and tPSA) of a series of imidazopyrrolopyridines and their measured intrinsic permeability were derived. The correlations developed from these imidazopyrrolopyridines allowed for the identification of gut-restricted pan-JAK inhibitors that maintained cellular activity despite their low intrinsic permeabilities. Compound <b>2</b> demonstrated dose-dependent pharmacological activity in a PK/PD study, demonstrating that it is a GI tract-restricted JAK inhibitor that selectively inhibited cytokine responses in colonic tissue and not in plasma. Compound <b>2</b> is therefore a candidate therapeutic for IBD indications that would benefit from selective inhibition of cytokine responses driven by the JAK/STAT pathway in the GI tract.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80667" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80667" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> General Experimental</h3><div class="NLM_p last">Anhydrous solvents and reagents were used as supplied by the manufacturer. Unless otherwise stated, reaction mixtures were magnetically stirred at room temperature (rt). Where solutions are “dried”, they are generally dried over a drying agent such as Na<sub>2</sub>SO<sub>4</sub> or MgSO<sub>4</sub>. Concentrated refers to concentrated using a rotary evaporator under reduced pressure. Unless specified otherwise, normal-phase flash column chromatography (FCC) was performed on silica gel (SiO<sub>2</sub>). The calculated (calcd) mass corresponds to the exact mass. HRMS was obtained on an Agilent Technologies 6230 series TOF-MSD, using ESI in positive mode. Nuclear magnetic resonance (NMR) spectra were obtained on Bruker model DRX spectrometers. Chemical shifts (δ) are expressed in parts per million, relative to internal tetramethylsilane; coupling constants (<i>J</i>) are in hertz (Hz). The following abbreviations are used to describe peak patterns when appropriate: s (singlet), d (doublet), t (triplet), q (quartet), qt (quintet), m (multiplet), app (apparent), and br (broad). HPLC–MS chromatograms and spectra were obtained using one of the following methods: (1) Agilent 1200 HPLC and G6100 system on X-Bridge ShieldRP18 (50 × 2.1 mm, 5 μm) and a gradient system of 0.05% NH<sub>4</sub>OH in H<sub>2</sub>O/CH<sub>3</sub>CN, 100:0 to 5:95 over 7.5 min, then 100:0 for 2.5 min at a temperature of 40 °C; (2) Agilent 1200 HPLC and G6100 system on Phenomenex Luna-C18 (50 × 2 mm, 5 μm) and a gradient system of 0.1% TFA in H<sub>2</sub>O/0.05% TFA in CH<sub>3</sub>CN, 100:0 to 15:85 over 7.5 min, then 100:0 for 2.5 min at a temperature of 50 °C; or (3) Agilent 1100 HPLC and G1367A system on X-Bridge C18 (100 × 3 mm, 3.5uM) and a gradient system of 20 mM NH<sub>4</sub>OH in H<sub>2</sub>O/CH<sub>3</sub>CN 90:10 over 2 min, then 0:100 for 1 min at a flow rate of 2.4 mL/min at a temperature of 45 °C. All compounds tested were of a minimum of 95% purity as determined by HPLC. None of the prepared compounds contain PAINS moieties.<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25,26)</a></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Chemistry: Preparation of Intermediates <b>13</b>–<b>17</b></h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> Intermediate <b>13</b></h4><div id="sec4_2_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i15" class="anchor-spacer"></div><h5 class="article-section__title" id="_i15"> 2-((1<i>r</i>,4<i>r</i>)-4-((5-Nitro-1-(phenylsulfonyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-yl)amino)cyclohexyl)acetonitrile</h5><div class="NLM_p">Step A: tert-butyl <i>N</i>-[(1<i>r</i>,4<i>r</i>)-4-(Hydroxymethyl)cyclohexyl]carbamate. To a 20 L 4-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen was placed (1<i>r</i>,4<i>r</i>)-4-[[(tert-butoxy)carbonyl]amino]cyclohexane-1-carboxylic acid (1066 g, 4.38 mol, 1.00 equiv) and THF (10 L). This was followed by the addition of BH<sub>3</sub>-Me<sub>2</sub>S (10 mol/L) (660 mL) dropwise with stirring at −10 °C over 1 h. The resulting solution was stirred for 3 h at 15 °C. This reaction was performed three times in parallel, and the reaction mixtures were combined. The reaction mixture was then quenched by the addition of 2 L of methanol. The resulting mixture was concentrated under vacuum. This resulted in 3000 g (99.6%) of tert-butyl <i>N</i>-[(1<i>r</i>,4<i>r</i>)-4-(hydroxymethyl)cyclohexyl]carbamate as a white solid. MS (ESI): mass calcd. for C<sub>12</sub>H<sub>23</sub>NO<sub>3</sub>, 229.32; <i>m</i>/<i>z</i> found, 215.2 [M-tBu + MeCN + H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 4.40 (s, 1H), 3.45 (d, <i>J</i> = 6.3 Hz, 2H), 3.38 (s, 1H), 2.05–2.02 (m, 2H), 1.84–1.81 (m, 2H), 1.44 (s, 10H), 1.17–1.01 (m, 4H).</div><div class="NLM_p">Step B: tert-butyl <i>N</i>-[(1<i>r</i>,4<i>r</i>)-4-[(methanesulfonyloxy)methyl]cyclohexyl]carbamate. To a 20 L 4-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen was placed tert-butyl <i>N</i>-[(1<i>r</i>,4<i>r</i>)-4-(hydroxymethyl)cyclohexyl]carbamate (1000 g, 4.36 mol, 1.00 equiv), dichloromethane (10 L), pyridine (1380 g, 17.5 mol, 4.00 equiv). This was followed by the addition of MsCl (1000 g, 8.73 mol, 2.00 equiv) dropwise with stirring at −15 °C. The resulting solution was stirred overnight at 25 °C. This reaction was performed in parallel 3 times. The reaction mixture was then quenched by the addition of 2 L of water. The water phase was extracted with ethyl acetate (1 × 9 L). The organic layer was separated and washed with 1 M HCl (3 × 10 L), NaHCO<sub>3</sub>(aq.) (2 × 10 L), water (1 × 10 L), and brine (1 × 10 L). The mixture was dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. This resulted in 3300 g (82%) of tert-butyl <i>N</i>-[(1<i>r</i>,4<i>r</i>)-4-[(methanesulfonyloxy)methyl]cyclohexyl]carbamate as a white solid. LC-MS MS (ESI): mass calcd. for C<sub>13</sub>H<sub>25</sub>NO<sub>5</sub>S, 307.15; <i>m</i>/<i>z</i> found 292.1, [M-tBu+MeCN+H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 4.03 (d, <i>J</i> = 6.6 Hz, 2H), 3.38 (s, 1H), 3.00 (s, 3H), 2.07–2.05 (m, 2H), 1.87–1.84 (m, 2H), 1.72–1.69 (m, 1H), 1.44 (s, 9H), 1.19–1.04 (m, 4H).</div><div class="NLM_p">Step C: tert-butyl <i>N</i>-[(1<i>r</i>,4<i>r</i>)-4-(cyanomethyl)cyclohexyl]carbamate. To a 10 L 4-necked round-bottom flask was placed tert-butyl <i>N</i>-[(1<i>r</i>,4<i>r</i>)-4-[(methanesulfonyloxy)methyl]cyclohexyl]carbamate (1100 g, 3.58 mol, 1.00 equiv), DMSO (5500 mL), and NaCN (406 g, 8.29 mol, 2.30 equiv). The resulting solution was stirred for 5 h at 90 °C. This reaction was performed in parallel 3 times. The reaction mixture was then quenched by the addition of 15 L of water/ice. The solids were collected by filtration. The solids were washed with water (3 × 10 L). This resulted in 2480 g (97%) of tert-butyl <i>N</i>-[(1<i>r</i>,4<i>r</i>)-4-(cyanomethyl)cyclohexyl]carbamate as a white solid. MS (ESI): mass calcd. for C<sub>13</sub>H<sub>22</sub>N<sub>2</sub>O<sub>2</sub>, 238.17; <i>m</i>/<i>z</i> found 224 [M-tBu + MeCN + H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 4.39 (s, 1H), 3.38 (s, 1H), 2.26 (d, <i>J</i> = 6.9 Hz, 2H), 2.08–2.04 (m, 2H), 1.92–1.88 (m, 2H), 1.67–1.61 (m, 1H), 1.44 (s, 9H), 1.26–1.06 (m, 4H).</div><div class="NLM_p">Step D: 2-[(1<i>r,</i>4<i>r)</i>-4-aminocyclohexyl]acetonitrile hydrochloride. To a 10 L round-bottom flask was placed tert-butyl <i>N</i>-[(1<i>r</i>,4<i>r</i>)-4-(cyanomethyl)cyclohexyl]carbamate (620 g, 2.60 mol, 1.00 equiv) and 1,4-dioxane (2 L). This was followed by the addition of a solution of HCl in 1,4-dioxane (5 L, 4 mol/L) dropwise with stirring at 10 °C. The resulting solution was stirred overnight at 25 °C. This reaction was performed 4 times. The solids were collected by filtration. The solids were washed with 1,4-dioxane (3 × 3 L), ethyl acetate (3 × 3 L), and hexane (3 × 3 L). This resulted in 1,753 g (96%) of 2-[(1<i>r,</i>4<i>r</i>)-4-aminocyclohexyl]acetonitrile hydrochloride as a white solid. MS (ESI): mass calcd. for C<sub>8</sub>H<sub>14</sub>N<sub>2</sub>, 138.12; <i>m</i>/<i>z</i> found 139.25, [M + 1]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub><i>6</i></sub>): δ 8.14 (s, 3H), 2.96–2.84 (m, 1H), 2.46 (d, <i>J</i> = 6.3 Hz, 2H), 1.98 (d, <i>J</i> = 11.1 Hz, 2H), 1.79 (d, <i>J</i> = 12.0 Hz, 2H), 1.64–1.49 (m, 1H), 1.42–1.29 (m, 2H), 1.18–1.04 (m, 2H).</div><div class="NLM_p last">Step E: 2-((1<i>r</i>,4<i>r</i>)-4-((5-Nitro-1-(phenylsulfonyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-yl)amino)cyclohexyl)acetonitrile. To a 1000 mL round-bottom flask containing 2-((1<i>r</i>,4<i>r</i>)-4-aminocyclohexyl)acetonitrile hydrochloride (29.10 g, 166.6 mmol) was added DMA (400 mL). The resulting suspension was treated with 4-chloro-5-nitro-1-(phenylsulfonyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (51.53 g, 152.6 mmol), followed by DIPEA (63.0 mL, 366 mmol). The reaction mixture was placed under N<sub>2</sub> and heated at 80 °C for 4 h. The crude reaction mixture was cooled to room temperature and slowly poured into a vigorously stirred 2-L flask containing 1.6 L of water. The resulting suspension was stirred for 15 min at room temperature and then filtered and dried for 16 h in a vacuum oven with heating at 70 °C to provide the title compound (63.37 g, 95% yield) as a yellow solid. MS (ESI): mass calcd. for C<sub>21</sub>H<sub>21</sub>N<sub>5</sub>O<sub>4</sub>S, 439.1; <i>m</i>/<i>z</i> found, 440.1 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 9.10 (s, 1H), 8.99 (d, <i>J</i> = 7.8 Hz, 1H), 8.23–8.15 (m, 2H), 7.66–7.59 (m, 2H), 7.56–7.49 (m, 2H), 6.67 (d, <i>J</i> = 4.2 Hz, 1H), 3.95–3.79 (m, 1H), 2.38 (d, <i>J</i> = 6.2 Hz, 2H), 2.32–2.21 (m, 2H), 2.08–1.98 (m, 2H), 1.88–1.76 (m, 1H), 1.60–1.32 (m, 4H).</div></div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> Intermediate <b>14</b></h4><div id="sec4_2_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i17" class="anchor-spacer"></div><h5 class="article-section__title" id="_i17"> 2-((1<i>r</i>,4<i>r</i>)-4-((5-Amino-1-(phenylsulfonyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-yl)amino)cyclohexyl)acetonitrile</h5><div class="NLM_p last">2-((1<i>r</i>,4<i>r</i>)-4-((5-Nitro-1-(phenylsulfonyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-yl)amino)cyclohexyl)acetonitrile (<b>13</b>, 58.60 g, 133.3 mmol) was dissolved in THF/MeOH (1:1, 4800 mL). The mixture was passed through a continuous-flow hydrogenation reactor, such as a Thales Nano H-Cube, at 10 mL/min with 100% hydrogen (atmospheric pressure, 80 °C) through a 10% Pd/C cartridge and then concentrated to dryness to provide a purple solid. The resulting purple solid was suspended in EtOAc (400 mL) and was stirred vigorously at room temperature for 5 min. The solid was filtered off, and the solid was resuspended in 200 mL of MeOH and stirred vigorously at room temperature for 3 h. The solid was filtered off to separate the solid from the MeOH. The solvent was removed <i>in vacuo</i>, and the residue was purified by flash column chromatography to provide the title compound (54.12 g, 99% yield). MS (ESI): mass calcd. for C<sub>21</sub>H<sub>23</sub>N<sub>5</sub>O<sub>2</sub>S, 409.2; <i>m</i>/<i>z</i> found, 410.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.10–8.03 (m, 2H), 7.76 (s, 1H), 7.51–7.43 (m, 1H), 7.43–7.34 (m, 3H), 6.44 (d, <i>J</i> = 4.2 Hz, 1H), 4.61 (d, <i>J</i> = 8.5 Hz, 1H), 3.65–3.51 (m, 1H), 2.74 (s, 2H), 2.26 (d, <i>J</i> = 6.4 Hz, 2H), 2.19–2.05 (m, 2H), 1.97–1.86 (m, 2H), 1.76–1.59 (m, 1H), 1.33–1.12 (m, 4H).</div></div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> Intermediate <b>15</b></h4><div id="sec4_2_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i19" class="anchor-spacer"></div><h5 class="article-section__title" id="_i19"> Ethyl 2-(1-((1<i>r,</i>4<i>r)-</i>4-(Cyanomethyl)cyclohexyl)-6-(phenylsulfonyl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-2-yl)acetate</h5><div class="NLM_p last">To a 1000 mL round-bottom flask containing a stir bar and 2-((1<i>r</i>,4<i>r</i>)-4-((5-amino-1-(phenylsulfonyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-yl)amino)cyclohexyl)acetonitrile (<b>14</b>, 58.31 g, 142.4 mmol) was added ethyl 3-ethoxy-3-iminopropanoate (60.51 g, 309.3 mmol), followed by EtOH (600 mL, dried over 3 Å molecular sieves for 48 h). A reflux condenser was attached to the reaction flask; the reaction mixture was purged with N<sub>2</sub> and was heated at 90 °C for 9 h. The reaction mixture was cooled to room temperature and left to stand for 30 h where the product crystallized out as brown needles. The solids were broken up with a spatula, and the reaction mixture was transferred to a 2 L flask. Water (1.4 L) was added slowly via a separatory funnel with vigorous stirring. After the addition of water was complete, the suspension was stirred for 30 min. The brown needles were isolated by filtration and then dried by pulling air through the filter for 1 h. The product was transferred to a 500 mL flask and treated with EtOAc (200 mL). A small quantity of seed crystals was added, which induced the formation of a white solid precipitate. The suspension was stirred for 30 min at room temperature, filtered, rinsed with EtOAc (25 mL), and dried under vacuum to provide the product as a white solid (48.65 g, 68% yield). MS (ESI): mass calcd. for C<sub>26</sub>H<sub>27</sub>N<sub>5</sub>O<sub>4</sub>S, 505.2; <i>m</i>/<i>z</i> found, 506.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.85 (s, 1H), 8.28–8.19 (m, 2H), 7.84 (d, <i>J</i> = 4.0 Hz, 1H), 7.61–7.53 (m, 1H), 7.52–7.43 (m, 2H), 6.84 (d, <i>J</i> = 4.1 Hz, 1H), 4.32 (s, 1H), 4.20 (q, <i>J</i> = 7.1 Hz, 2H), 4.09 (s, 2H), 2.44 (d, <i>J</i> = 6.2 Hz, 2H), 2.40–2.27 (m, 2H), 2.16 (d, <i>J</i> = 13.3 Hz, 2H), 2.12–1.96 (m, 3H), 1.54–1.38 (m, 2H), 1.27 (t, <i>J</i> = 7.1 Hz, 3H).</div></div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> Intermediate <b>15a</b></h4><div id="sec4_2_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i21" class="anchor-spacer"></div><h5 class="article-section__title" id="_i21"> Sodium 2-(1-((1<i>r</i>,4<i>r</i>)-4-(Cyanomethyl)cyclohexyl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-2-yl)acetate</h5><div class="NLM_p last">To a solution of ethyl 2-(1-((1<i>r</i>,4<i>r</i>)-4-(cyanomethyl)cyclohexyl)-6-(phenylsulfonyl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-2-yl)acetate (<b>15</b>, 9.50 g, 18.8 mmol) in MeOH (30 mL) and THF (30 mL) was added sodium hydroxide (aqueous) (56.4 mL, 56.4 mmol, 1 M) and was stirred at room temperature for 14 h. The solvent was removed under reduced pressure at room temperature to provide the title compound (7 g) as a brown solid, which was used for next step without further purification. MS (ESI): mass calcd. for C<sub>18</sub>H<sub>18</sub>N<sub>5</sub>NaO<sub>2</sub>, 359.1; <i>m</i>/<i>z</i> found, 337.9 [M + H – Na]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.52–8.47 (m, 1H), 7.85–7.81 (m, 2H), 7.46–7.41 (m, 4H), 6.85–6.81 (m, 1H), 4.60–4.46 (m, 1H), 3.96 (s, 2H), 2.59–2.49 (m, 4H), 2.19–2.05 (m, 6H), 1.56–1.43 (m, 2H) (a 1:1 mixture of the title compound and benzenesulfonic acid).</div></div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Intermediate <b>17</b></h4><div id="sec4_2_5_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i23" class="anchor-spacer"></div><h5 class="article-section__title" id="_i23"> 2-((1<i>r</i>,4<i>r</i>)-4-(2-(Aminomethyl)imidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-1(6<i>H</i>)-yl)cyclohexyl)acetonitrile Hydrochloride</h5><div class="NLM_p">Step A: <i>tert</i>-Butyl ((1-((1<i>r</i>,4<i>r</i>)-4-(cyanomethyl)cyclohexyl)-6-(phenylsulfonyl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-2-yl)methyl)carbamate (<b>16</b>) and 2-((1<i>r</i>,4<i>r</i>)-4-(2-(aminomethyl)-6-(phenylsulfonyl)imidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-1(6<i>H</i>)-yl)cyclohexyl)acetonitrile. A solution of 2-((1<i>r</i>,4<i>r</i>)-4-((5-nitro-1-(phenylsulfonyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-yl)amino)cyclohexyl)acetonitrile (<b>13</b>, 1.50 g, 3.41 mmol), <i>tert</i>-butyl (2-oxoethyl)carbamate (1.47 g, 7.85 mmol), sodium hydrosulfite (2.97 g, 17.1 mmol), DMSO (3 mL), methanol (10 mL), and water (5 mL) was stirred for 2.5 h at 100 °C. A mixture of two products, <i>tert</i>-butyl ((1-((1<i>r</i>,4<i>r</i>)-4-(cyanomethyl)cyclohexyl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-2-yl)methyl)carbamate (<b>16</b>) and 2-((1<i>r</i>,4<i>r</i>)-4-(2-(aminomethyl)imidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-1(6<i>H</i>)-yl)cyclohexyl)acetonitrile, were found. The reaction mixture was used in the next step directly.</div><div class="NLM_p">Step B: <i>tert</i>-Butyl ((1-((1<i>r</i>,4<i>r</i>)-4-(cyanomethyl)cyclohexyl)-6-(phenylsulfonyl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-2-yl)methyl)carbamate (<b>16</b>). (Boc)<sub>2</sub>O (1.04 g, 4.78 mmol) was added to a mixture of <i>tert</i>-butyl ((1-((1<i>r</i>,4<i>r</i>)-4-(cyanomethyl)cyclohexyl)-6-(phenylsulfonyl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-2-yl)methyl)carbamate, 2-((1<i>r</i>,4<i>r</i>)-4-(2-(aminomethyl)-6-(phenylsulfonyl)imidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-1(6<i>H</i>)-yl)cyclohexyl)acetonitrile (36 mL of the reaction mixture, 6.826 mmol), Na<sub>2</sub>CO<sub>3</sub> (2.17 g, 20.5 mmol), and methanol (50 mL) and was stirred for 2 h at 12 °C. The reaction mixture was concentrated under vacuum to dryness; the aqueous layer was diluted with water (30 mL) and extracted with ethyl acetate (50 mL × 2). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to dryness. The residue was purified by flash column chromatography to provide the title compound (2.4 g, 63% over two steps) as a light yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.83 (s, 1H), 8.23 (d, <i>J</i> = 7.6 Hz, 2H), 7.84 (d, <i>J</i> = 4.0 Hz, 1H), 7.60–7.52 (m, 1H), 7.52–7.44 (m, 2H), 6.83 (d, <i>J</i> = 4.0 Hz, 1H), 5.36 (br s, 1H), 4.67 (d, <i>J</i> = 5.6 Hz, 2H), 4.65–4.59 (m, 1H), 2.40 (d, <i>J</i> = 6.4 Hz, 2H), 2.37–2.22 (m, 2H), 2.20–2.09 (m, 2H), 2.04–1.87 (m, 3H), 1.53–1.39 (m, 11H).</div><div class="NLM_p">Step C: <i>tert</i>-Butyl ((1-((1<i>r</i>,4<i>r</i>)-4-(cyanomethyl)cyclohexyl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-2-yl)methyl)carbamate. Aqueous KOH (4.37 mL, 13.1 mmol) was added to a solution consisting of <i>tert</i>-butyl ((1-((1<i>r</i>,4<i>r</i>)-4-(cyanomethyl)cyclohexyl)-6-(phenylsulfonyl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-2-yl)methyl)carbamate (<b>16</b>, 2.40 g, 4.37 mmol) and dioxane (25 mL) and was stirred for 2 h at 80 °C. The reaction mixture was adjusted to pH = 7–8 with 1 M HCl, and the volatile solvents were removed under vacuum. The aqueous phase was diluted with water (20 mL) and extracted with ethyl acetate (50 mL × 2). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to dryness to provide the title compound (2 g, 100% yield) as a light yellow solid, which was used in the next step without further purification. MS (ESI): mass calcd. for C<sub>22</sub>H<sub>28</sub>N<sub>6</sub>O<sub>2</sub>, 408.2; <i>m</i>/<i>z</i> found, 409.1 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.86 (s, 1H), 8.51 (s, 1H), 7.56–7.49 (m, 1H), 7.47 (t, <i>J</i> = 2.8 Hz, 1H), 6.74–6.68 (m, 1H), 4.66–4.58 (m, 1H), 4.53 (d, <i>J</i> = 5.6 Hz, 2H), 2.58 (d, <i>J</i> = 5.6 Hz, 2H), 2.41–2.28 (m, 2H), 2.08–1.94 (m, 3H), 1.93–1.83 (m, 2H), 1.54–1.23 (m, 11H).</div><div class="NLM_p last">Step D: 2-((1<i>r</i>,4<i>r</i>)-4-(2-(Aminomethyl)imidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-1(6<i>H</i>)-yl)cyclohexyl)acetonitrile hydrochloride (<b>17</b>). HCl/dioxane (10 mL, 40 mmol, 4 M) was added to a solution of <i>tert</i>-butyl ((1-((1<i>r</i>,4<i>r</i>)-4-(cyanomethyl)cyclohexyl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-2-yl)methyl)carbamate (2.0 g, 4.9 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) at 0 °C and was stirred for 30 min at 10 °C. The reaction mixture was concentrated to dryness to provide the title compound (1.7 g, 100% yield) as a pale white solid, which was used without further purification. MS (ESI): mass calcd. for C<sub>17</sub>H<sub>20</sub>ClN<sub>6</sub>, 308.2; <i>m</i>/<i>z</i> found, 308.9 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub><i>6</i></sub>): δ 12.53 (s, 1H), 8.88 (s, 1H), 8.86 (br. s, 3H), 7.67 (t, <i>J</i> = 3.2 Hz, 1H), 6.93 (s, 1H), 4.71–4.63 (m, 2H), 4.60–4.42 (m, 1H), 2.60 (d, <i>J</i> = 6.0 Hz, 2H), 2.36–2.21 (m, 2H), 2.12–1.93 (m, 5H), 1.56–1.42 (m, 2H).</div></div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Synthesis of Compounds <b>2</b>–<b>11</b></h3><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Compound <b>2</b></h4><div id="sec4_3_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i26" class="anchor-spacer"></div><h5 class="article-section__title" id="_i26"> 2-(1-((1<i>r</i>,4<i>r</i>)-4-(Cyanomethyl)cyclohexyl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-2-yl)-<i>N</i>-(2-hydroxy-2-methylpropyl)acetamide</h5><div class="NLM_p">Step A: 2-(1-((1<i>r</i>,4<i>r</i>)-4-(Cyanomethyl)cyclohexyl)-6-(phenylsulfonyl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-2-yl)-<i>N</i>-(2-hydroxy-2-methylpropyl)acetamide. To ensure a dry starting material, ethyl 2-(1-((1<i>r</i>,4<i>r</i>)-4-(cyanomethyl)cyclohexyl)-6-(phenylsulfonyl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-2-yl)acetate (<b>15</b>) was heated under vacuum at 50 °C for 18 h prior to the reaction. In a 1 L flask, ethyl 2-(1-((1<i>r</i>,4<i>r</i>)-4-(cyanomethyl)cyclohexyl)-6-(phenylsulfonyl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-2-yl)acetate (<b>15</b>, 52.59 g, 104.0 mmol) was suspended in DMA (50 mL). 1-Amino-2-methylpropan-2-ol (50 mL) was added, and the reaction mixture was heated to 110 °C for 45 min and then to 125 °C for 5 h. The reaction mixture was cooled to room temperature and diluted with EtOAc (800 mL). The organic layer was extracted 3 times (1 L of water plus 50 mL of brine). The aqueous layers were back extracted with EtOAc (2 × 600 mL). The combined organic layers were dried over anhydrous MgSO<sub>4</sub>, filtered, concentrated to dryness, and then dried for 3 days under vacuum to provide the title compound (65.9 g, 98% yield) as a yellow foam. The product was taken to the next step with no further purification. MS (ESI): mass calcd. for C<sub>28</sub>H<sub>32</sub>N<sub>6</sub>O<sub>4</sub>S, 548.22; <i>m</i>/<i>z</i> found, 549.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.76 (s, 1H), 8.26–8.19 (m, 2H), 7.84 (d, <i>J</i> = 4.1 Hz, 1H), 7.60–7.53 (m, 1H), 7.50–7.44 (m, 2H), 6.84 (d, <i>J</i> = 4.2 Hz, 1H), 4.76–4.61 (m, 1H), 3.97 (s, 2H), 3.45 (s, 1H), 3.27 (d, <i>J</i> = 5.9 Hz, 2H), 2.41 (d, <i>J</i> = 6.5 Hz, 2H), 2.38–2.25 (m, 2H), 2.23–2.12 (m, 2H), 2.09–1.94 (m, 4H), 1.48 (qd, <i>J</i> = 13.6, 4.0 Hz, 2H), 1.21 (s, 6H).</div><div class="NLM_p last">Step B: 2-(1-((1<i>r</i>,4<i>r</i>)-4-(Cyanomethyl)cyclohexyl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-2-yl)-<i>N</i>-(2-hydroxy-2-methylpropyl)acetamide. 2-(1-((1<i>r</i>,4<i>r</i>)-4-(Cyanomethyl)cyclohexyl)-6-(phenylsulfonyl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-2-yl)-<i>N</i>-(2-hydroxy-2-methylpropyl)acetamide (65.90 g, 102.1 mmol) was added to a 1 L flask containing a stir bar. Dioxane (300 mL) was added, followed by KOH in water (3 M, 150 mL). The reaction mixture was heated at 80 °C for 2 h. The reaction mixture was cooled to room temperature, and the solvent volume was reduced to about 200 mL on a rotovap. The residue was treated with 100 mL of water plus 100 mL of brine and then extracted 2 times with 10% MeOH in CH<sub>2</sub>Cl<sub>2</sub> (1000 mL). The organic layers were combined, dried over anhydrous MgSO<sub>4</sub>, filtered, and concentrated to dryness to provide a yellow solid. The solid was suspended in 200 mL of CH<sub>2</sub>Cl<sub>2</sub>, stirred vigorously for 30 min, and then filtered. The solid was rinsed with 100 mL of CH<sub>2</sub>Cl<sub>2</sub>, dried by pulling air through the filter, and then further dried under vacuum at room temperature for 16 h to provide the title compound (42.59 g, 89% yield) as a white solid. MS (ESI): mass calcd. for C<sub>22</sub>H<sub>28</sub>N<sub>6</sub>O<sub>2</sub>, 408.23; <i>m</i>/<i>z</i> found, 409.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.85 (s, 1H), 8.50 (s, 1H), 8.21–8.10 (m, 1H), 7.49–7.43 (m, 1H), 6.74–6.65 (m, 1H), 4.53–4.42 (m, 2H), 4.07 (s, 2H), 3.08 (d, <i>J</i> = 6.0 Hz, 2H), 2.58 (d, <i>J</i> = 6.1 Hz, 2H), 2.41–2.28 (m, 2H), 2.09–1.92 (m, 5H), 1.42–1.31 (m, 2H), 1.09 (s, 6H).</div></div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Compound <b>3</b></h4><div id="sec4_3_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> 2-(1-((1<i>r</i>,4<i>r</i>)-4-(Cyanomethyl)cyclohexyl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-2-yl)-<i>N</i>-(1-isobutylpiperidin-4-yl)acetamide</h5><div class="NLM_p last">A mixture of ethyl 2-(1-((1<i>r</i>,4<i>r</i>)-4-(cyanomethyl)cyclohexyl)-6-(phenylsulfonyl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-2-yl)acetate (<b>15</b>, 300 mg, 0.59 mmol) and 1-isobutylpiperidin-4-amine (976 mg, 5.93 mmol) was heated at 125 °C in the microwave for 22 h. The reaction mixture was cooled to room temp, and then, 1,4-dioxane (2.4 mL) and 3 M KOH (1.6 mL) aqueous solution were added. The vial was heated at 80 °C for 2 h in the microwave and then purified by basic HPLC using a Xbridge Prep OBD C<sub>18</sub> 50 mm × 100 mm, 5 μm column (eluent = 0–100% aq NH<sub>4</sub>OH/ACN (10 min)) to yield the title compound (111 mg, 39% yield). MS (ESI): mass calcd. for C<sub>27</sub>H<sub>37</sub>N<sub>7</sub>O, 475.31; <i>m</i>/<i>z</i> found, 476.3 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ 8.54 (s, 1H), 7.49 (d, <i>J</i> = 3.5 Hz, 1H), 6.86 (d, <i>J</i> = 3.5 Hz, 1H), 4.54 (s, 1H), 4.11–4.04 (m, 1H), 3.75–3.64 (m, 1H), 2.89 (d, <i>J</i> = 11.8 Hz, 2H), 2.63–2.54 (m, 3H), 2.19–1.78 (m, 13H), 1.69–1.44 (m, 4H), 0.97–0.88 (m, 7H).</div></div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> Compound <b>4</b></h4><div id="sec4_3_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> <i>N</i>-(2-Cyanoethyl)-2-(1-((1<i>r</i>,4<i>r</i>)-4-(cyanomethyl)cyclohexyl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-2-yl)acetamide</h5><div class="NLM_p last">To a solution of sodium 2-(1-((1<i>r</i>,4<i>r</i>)-4-(cyanomethyl)cyclohexyl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-2-yl)acetate (<b>15a</b>, 400 mg, 1.11 mmol) and 3-aminopropanenitrile (320 mg, 2.24 mmol) in DMF (5 mL) were added PyBOP (870 mg, 1.67 mmol) and DIPEA (0.60 mL, 3.5 mmol). The reaction mixture was stirred at room temperature for 40 h. After the removal of the DMF <i>in vacuo</i>, the residue was purified by flash column chromatography using 50–100% ethyl acetate in heptane. The collected fractions were concentrated <i>in vacuo</i> to a small volume, and the white solid, which had precipitated out, was filtered off, washed with 10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>, and dried to provide to provide the title compound (75 mg, 17% yield). The filtrate was concentrated to dryness and purified by reverse phase HPLC using a Varian Pursuit XR<sub>s</sub>5 Diphenyl 100 mm × 30 mm column (eluent 10–90% CH<sub>3</sub>CN in water, 0.1% TFA) to provide a clear oil. This material was dissolved in 10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>, passed through three 500 mg columns of SILICYCLE SPE-R66030B-03P Carbonate (SiliaBond acid scavenger solid phase extraction cartridge) to remove the TFA, and eluted with 10% MeOH in CH<sub>2</sub>Cl<sub>2</sub> to provide an additional fraction of the title compound (88 mg, 20% yield). The two fractions were combined to provide the final product (163 mg, 37% yield) as a white solid. MS (ESI): mass calcd. for C<sub>21</sub>H<sub>23</sub>N<sub>7</sub>O, 389.20; <i>m</i>/<i>z</i> found, 390.3 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.53 (s, 1H), 7.48 (d, <i>J</i> = 3.0 Hz, 1H), 6.84 (d, <i>J</i> = 3.5 Hz, 1H), 4.51 (br s, 1H), 4.12 (s, 2H), 3.50 (t, <i>J</i> = 6.6 Hz, 2H), 2.71 (t, <i>J</i> = 6.6 Hz, 2H), 2.45–2.63 (m, 4H), 2.03–2.19 (m, 5H), 1.44–1.57 (m, 2H).</div></div></div><div id="sec4_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> Compound <b>5</b></h4><div id="sec4_3_5_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> 2-((1<i>r</i>,<i>4r)</i>-4-(2-(2-(4-Morpholinopiperidin-1-yl)-2-oxoethyl)imidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-1(6<i>H</i>)-yl)cyclohexyl)acetonitrile</h5><div class="NLM_p last">A solution of sodium 2-(1-((1<i>r</i>,4<i>r</i>)-4-(cyanomethyl)cyclohexyl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-2-yl)acetate (<b>15a</b>, 200 mg, 0.557 mmol), 4-(piperidin-4-yl)morpholine (94.8 mg, 0.557 mmol), DIPEA (144 mg, 1.11 mmol), and DMF (5 mL) was stirred at 0 °C for 1 h. Then, PyBrOP (311 mg, 0.668 mmol) was added and stirred at room temperature overnight. The mixture was quenched with 10 mL of water and was purified by preparative acidic HPLC using a Boston Green ODS 150 mm × 30 mm, 5 μm column (eluent: water (0.05% HCl)-ACN from 0 to 30%, v/v) and then by preparative basic HPLC using a Kromasil 150 mm × 25 mm, 10 μm column (eluent: water (0.05% ammonia hydroxide v/v)-ACN from 10 to 40%, v/v) to provide the title compound (25 mg, 9% yield) as a white solid. MS (ESI): mass calcd. for C<sub>27</sub>H<sub>35</sub>N<sub>7</sub>O<sub>2</sub>, 489.29; <i>m</i>/<i>z</i> found, 490.3 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.85 (br s, 1H), 8.51–8.47 (m, 1H), 7.48–7.44 (m, 1H), 6.72–6.68 (m, 1H), 4.42–4.29 (m, 2H), 4.25 (d, <i>J</i> = 8.4 Hz, 2H), 4.16–4.07 (m, 1H), 3.59–3.52 (m, 4H), 3.15–3.05 (m, 1H), 2.69–2.63 (m, 1H), 2.58 (d, <i>J</i> = 6.0 Hz, 3H), 2.47–2.41 (m, 5H), 2.07–1.90 (m, 6H), 1.85–1.74 (m, 2H), 1.42–1.27 (m, 3H), 1.27–1.13 (m, 1H).</div></div></div><div id="sec4_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> Compound <b>6</b></h4><div id="sec4_3_6_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> <i>N</i>-(2-Cyano-2-methylpropyl)-2-(1-((1<i>r</i>,4<i>r</i>)-4-(cyanomethyl)cyclohexyl)-1,6-dihyroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-2-yl)acetamide</h5><div class="NLM_p last">A solution of sodium 2-(1-((1<i>r</i>,4<i>r</i>)-4-(cyanomethyl)cyclohexyl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-2-yl)acetate (<b>15a</b>, 300 mg, 0.835 mmol), 3-amino-2,2-dimethylpropanenitrile (82.0 mg, 0.835 mmol), DIPEA (216 mg, 1.67 mmol), and DMF (5 mL) was stirred at 0 °C for 1 h. Then, PyBrOP (467 mg, 1.00 mmol) was added, and the reaction mixture was stirred overnight at room temperature. The mixture was quenched with 10 mL of water and was purified by preparative HPLC using a Waters Xbridge Prep OBD C<sub>18</sub> 150 mm × 30 mm, 5 μm column (eluent: 28% water (0.05% NH<sub>4</sub>OH v/v)-ACN) to provide the title compound (58 mg, 16% yield) as a white solid. MS (ESI): mass calcd. for C<sub>23</sub>H<sub>27</sub>N<sub>7</sub>O, 417.23; <i>m</i>/<i>z</i> found, 418.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.86 (br s, 1H), 8.71–8.66 (m, 1H), 8.50 (s, 1H), 7.48–7.45 (m, 1H), 6.73–6.69 (m, 1H), 4.53–4.42 (m, 1H), 4.10 (s, 2H), 3.33–3.31 (m, 1H), 2.57 (d, <i>J</i> = 5.6 Hz, 2H), 2.41–2.27 (m, 2H), 2.05–1.93 (m, 5H), 1.45–1.26 (m, 9H).</div></div></div><div id="sec4_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Compound <b>7</b></h4><div id="sec4_3_7_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> 2-(1-((1<i>r</i>,4<i>r</i>)-4-(Cyanomethyl)cyclohexyl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-2-yl)-<i>N</i>-(2,2,2-trifluoroethyl)acetamide</h5><div class="NLM_p last">PyBrOP (311 mg, 0.670 mmol) was added to a 0 °C (ice/water) solution consisting of sodium 2-(1-((1<i>r</i>,4<i>r</i>)-4-(cyanomethyl)cyclohexyl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-2-yl)acetate (<b>15a</b>, 200 mg, 0.560 mmol), 2,2,2-trifluoroethylamine (55 mg, 0.56 mmol), <i>N</i>,<i>N</i>-diisopropylethylamine (144 mg, 1.11 mmol), and dimethylformamide (10 mL). The mixture was stirred overnight with gradual warming to room temperature before quenching with H<sub>2</sub>O (10 mL) and extracting with ethyl acetate (20 mL × 3). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to dryness under reduced pressure and were subsequently purified by preparative HPLC using a DuraShell 150 mm × 25 mm, 5 μm column (eluent: 20 to 50% (v/v) CH<sub>3</sub>CN and H<sub>2</sub>O with 0.05% NH<sub>3</sub>) to afford the pure product. The product was lyophilized to dryness to afford the title compound (14 mg, 6%) as a white solid. LCMS (ESI): <i>R</i><sub>T</sub> = 3.55 min, mass calcd. for C<sub>20</sub>H<sub>21</sub>F<sub>3</sub>N<sub>6</sub>O, 418.17; <i>m</i>/<i>z</i>, found 419.1 [M + H]<sup>+</sup>. Analytical reverse phase LC-MS was carried out using a Phenomenex Luna-C18, 50 × 2 mm, 5 μm column with a flow rate of 0.8 mL/min, eluting with a gradient of 0 to 85% acetonitrile containing 0.05% TFA (solvent B) and water containing 0.1% TFA (solvent A). The eluent composition was kept at 100% A for 1 min, followed by increasing to 60% B over the course of 4 min. The eluent was further increased to 85% B over the course of 2.5 min before returning to 100% A over the course of 2 min. The total run time was 10 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.86 (br s, 1H), 9.03–8.95 (m, 1H), 8.51 (s, 1H), 7.50–7.46 (m, 1H), 6.75–6.69 (m, 1H), 4.53–4.39 (m, 1H), 4.12 (s, 2H), 4.04–3.92 (m, 2H), 2.59 (d, <i>J</i> = 6.0 Hz, 2H), 2.43–2.26 (m, 2H), 2.11–1.91 (m, 5H), 1.48–1.30 (m, 2H).</div></div></div><div id="sec4_3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Compound <b>8</b></h4><div id="sec4_3_8_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> <i>N</i>-((1-((1<i>r</i>,4<i>r</i>)-4-(Cyanomethyl)cyclohexyl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-2-yl)methyl)-2-cyclopropylacetamide</h5><div class="NLM_p last">HATU (155 mg, 0.409 mmol) was added to a solution of 2-((1<i>r</i>,4<i>r</i>)-4-(2-(aminomethyl)imidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-1(6<i>H</i>)-yl)cyclohexyl)acetonitrile hydrochloride (<b>17</b>, 150 mg, 0.409 mmol, purity 94%), cyclopropylacetic acid (40.9 mg, 0.409 mmol), DIEA (0.356 mL, 2.04 mmol), and CH<sub>2</sub>Cl<sub>2</sub> (5 mL) and was stirred for 1 h at 10 °C. The reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> (10 mL), washed with water (10 mL), and concentrated to dryness. The residue was purified by preparative HPLC using a Gemini 150 mm × 25 mm, 5 μm column (eluent: 20 to 50% (v/v) CH<sub>3</sub>CN and H<sub>2</sub>O with 0.05% NH<sub>3</sub>) to provide the title compound (45 mg, 28% yield) as a white solid. MS (ESI): mass calcd. for C<sub>22</sub>H<sub>26</sub>N<sub>6</sub>O, 390.22; <i>m</i>/<i>z</i> found, 391.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.89 (s, 1H), 8.55 (s, 1H), 8.46 (t, <i>J</i> = 5.6 Hz, 1H), 7.48 (t, <i>J</i> = 2.4 Hz, 1H), 6.72 (s, 1H), 4.69 (d, <i>J</i> = 5.6 Hz, 2H), 4.62–4.49 (m, 1H), 2.59 (d, <i>J</i> = 6.0 Hz, 2H), 2.41–2.28 (m, 2H), 2.06 (d, <i>J</i> = 6.8 Hz, 2H), 2.04–1.87 (m, 5H), 1.45–1.30 (m, 2H), 1.05–0.94 (m, 1H), 0.46–0.40 (m, 2H), 0.16–0.09 (m, 2H).</div></div></div><div id="sec4_3_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Compound <b>9</b></h4><div id="sec4_3_9_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> 2-(1-((1<i>r</i>,4<i>r</i>)-4-(Cyanomethyl)cyclohexyl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-2-yl)-<i>N</i>-(4-fluorobenzyl)acetamide</h5><div class="NLM_p last">To a solution of sodium 2-(1-((1<i>r</i>,4<i>r</i>)-4-(cyanomethyl)cyclohexyl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-2-yl)acetate (<b>15a</b>, 100 mg, 0.278 mmol) and (4-fluorophenyl)methanamine (90 mg, 0.56 mmol) in DMF (1 mL) were added PyBOP (217 mg, 0.417 mmol) and DIPEA (0.192 mL, 1.11 mmol), which was then stirred at room temperature for 87 h. The reaction mixture was concentrated to dryness, and the residue was purified by flash column chromatography (12g silica gel column, 30–100% EtOAc in heptanes, and then 10% MeOH in DCM) and by reverse phase acidic HPLC using a Varian Pursuit XR<sub>s</sub>5 Diphenyl 100 × 30 mm column (eluent: 10 to 90% CH<sub>3</sub>CN in H<sub>2</sub>O, 0.1% TFA) to provide the title compound as the TFA salt. This material was dissolved in 10% MeOH in CH<sub>2</sub>Cl<sub>2</sub> and loaded onto a 500 mg column of SILICYCLE SPE-R66030B-03P Carbonate (SiliaBond acid scavenger solid phase extraction cartridge) to remove the TFA and to provide the title compound (43 mg, 35% yield) as a white solid. MS (ESI): mass calcd. for C<sub>25</sub>H<sub>25</sub>FN<sub>6</sub>O, 444.2; <i>m</i>/<i>z</i> found, 445.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 11.70 (br s, 1H), 8.58 (br s, 1H), 8.33 (br s, 1H), 7.47 (br s, 1H), 7.20 (t, <i>J</i> = 6.6 Hz, 2H), 6.98–6.87 (m, 2H), 6.78–6.71 (m, 1H), 4.71 (br s, 1H), 4.42 (d, <i>J</i> = 5.6 Hz, 2H), 4.11 (br s, 2H), 2.68–2.47 (m, 2H), 2.43 (d, <i>J</i> = 6.1 Hz, 2H), 2.25–1.82 (m, 5H), 1.58–1.40 (m, 2H).</div></div></div><div id="sec4_3_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Compound <b>10</b></h4><div id="sec4_3_10_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> 2-(1-((1<i>r</i>,4<i>r</i>)-4-(Cyanomethyl)cyclohexyl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-2-yl)-<i>N</i>-((1<i>r</i>,4<i>r</i>)-4-hydroxycyclohexyl)acetamide</h5><div class="NLM_p last">A solution of sodium 2-(1-((1<i>r</i>,4<i>r</i>)-4-(cyanomethyl)cyclohexyl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-2-yl)acetate (<b>15a</b>, 200 mg, 0.557 mmol), (1<i>r</i>,4<i>r</i>)-4-aminocyclohexanol (64.1 mg, 0.557 mmol), PyBrOP (311 mg, 0.668 mmol), DIPEA (144 mg, 1.11 mmol), and DMF (10 mL) was stirred overnight. The mixture was quenched with 20 mL of water and extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over anhydrous MgSO<sub>4</sub>, filtered, and concentrated to dryness. The residue was purified by preparative basic HPLC using a DuraShell 150 mm × 25 mm, 5 μm column (eluent: 15 to 45% (v/v) CH<sub>3</sub>CN and H<sub>2</sub>O with 0.05% NH<sub>3</sub>) to provide the title compound (27.9 mg, 11% yield) as a white solid. MS (ESI): mass calcd. for C<sub>24</sub>H<sub>30</sub>N<sub>6</sub>O<sub>2</sub>, 434.24; <i>m</i>/<i>z</i> found, 435.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.85 (br s, 1H), 8.49 (s, 1H), 8.22–8.19 (m, 1H), 7.47–7.45 (m, 1H), 6.71 (br s, 1H), 4.59 (d, <i>J</i> = 4.4 Hz, 1H), 4.55–4.39 (m, 1H), 3.95 (s, 2H), 2.60 (d, <i>J</i> = 5.7 Hz, 2H), 2.42–2.33 (m, 2H), 2.08–1.92 (m, 5H), 1.89–1.71 (m, 5H), 1.48–1.31 (m, 2H), 1.31–1.12 (m, 5H).</div></div></div><div id="sec4_3_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> Compound <b>11</b></h4><div id="sec4_3_11_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> 4-(2-(1-((1<i>r</i>,4<i>r</i>)-4-(Cyanomethyl)cyclohexyl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-2-yl)acetamido)bicyclo[2.2.2]octane-1-carboxamide</h5><div class="NLM_p">Step A: <i>tert</i>-Butyl (4-(chlorocarbonyl)bicyclo[2.2.2]octan-1-yl)carbamate. Oxalyl chloride (0.61 mL, 7.2 mmol) was added slowly to a solution of 4-((<i>tert</i>-butoxycarbonyl)amino)bicyclo[2.2.2]octane-1-carboxylic acid (1.3 g, 4.8 mol) and anhydrous CH<sub>2</sub>Cl<sub>2</sub> (30 mL) at 0 °C. Then, 4 drops of DMF was added, and the reaction mixture was stirred for 1.5 h at 0 °C. The reaction mixture was concentrated to dryness under reduced pressure to provide the title compound (1.36 g, 98% yield) as a white solid, which was used in the next step without further purification.</div><div class="NLM_p">Step B: <i>tert</i>-Butyl (4-carbamoylbicyclo[2.2.2]octan-1-yl)carbamate. <i>tert</i>-Butyl (4-(chlorocarbonyl)bicyclo[2.2.2]octan-1-yl)carbamate (1.36 g, 4.73 mmol) and anhydrous CH<sub>2</sub>Cl<sub>2</sub> (40 mL) was added to a 100 mL three-neck flask and was cooled to 0 °C (ice/water). Ammonia gas was bubbled through the reaction for 25 min, and it was stirred for 5 min at room temperature before diluting with water (20 mL). The organic layer was separated, and the aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (15 mL × 2). The combined organic extracts were washed with water (25 mL) and brine (25 mL) and were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to dryness to provide the title compound (260 mg, 20% yield), which was used without further purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 6.89 (br s, 1H), 6.66 (br s, 1H), 6.36 (br s, 1H), 1.73–1.59 (m, 12H), 1.32 (s, 9H).</div><div class="NLM_p">Step C: 4-Aminobicyclo[2.2.2]octane-1-carboxamide hydrochloride. To a solution of <i>tert</i>-butyl (4-carbamoylbicyclo[2.2.2]octan-1-yl)carbamate (260 mg, 0.969 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) was added HCl in ethyl acetate (4 M, 4 mL) at 0 °C, which was then stirred at 0 °C for 1 h. The reaction mixture was concentrated to dryness, dissolved in water (5 mL), and washed with ethyl acetate (5 mL × 2). The water phase was concentrated to dryness and lyophilized to provide the title compound (150 mg, 75% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.23 (br s, 3H), 7.05 (br s, 1H), 6.82 (br s, 1H), 1.71 (br s, 12H).</div><div class="NLM_p last">Step D: 4-(2-(1-((1<i>r</i>,4<i>r</i>)-4-(Cyanomethyl)cyclohexyl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-2-yl)acetamido)bicyclo[2.2.2]octane-1-carboxamide. To a solution of sodium 2-(1-((1<i>r</i>,4<i>r</i>)-4-(cyanomethyl)cyclohexyl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-2-yl)acetate (<b>15a</b>, 200 mg, 0.557 mmol), 4-aminobicyclo[2.2.2]octane-1-carboxamide hydrochloride (114 mg, 0.557 mmol), and DIPEA (0.291 mL, 1.67 mmol) in dry DMF (5 mL) was added PyBrOP (285 mg, 0.612 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 15 h. The mixture was quenched with 10 mL of water and was extracted with EtOAc (3 × 20 mL). Both the organic and water phases were concentrated, and the resulting residue was purified by preparative basic HPLC using a Waters Xbridge Prep OBD C<sub>18</sub> 150 × 30 mm, 5 μm column (eluent: 14 to 44% (v/v) MeOH and H<sub>2</sub>O with 0.05% NH<sub>3</sub>) to provide the title compound (39.5 mg, 14% yield) as a yellow solid. MS (ESI): mass calcd. for C<sub>27</sub>H<sub>33</sub>N<sub>7</sub>O<sub>2</sub>, 487.3; <i>m</i>/<i>z</i> found, 488.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.83 (br s, 1H), 8.48 (s, 1H), 7.90 (br s, 1H), 7.48–7.44 (m, 1H), 6.94 (br s, 1H), 6.74–6.67 (m, 2H), 4.41 (br s, 1H), 3.92 (s, 2H), 2.63–2.57 (m, 2H), 2.39–2.28 (m, 2H), 2.08–1.91 (m, 5H), 1.90–1.78 (m, 6H), 1.78–1.66 (m, 6H), 1.44–1.32 (m, 2H).</div></div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> Methods</h3><div id="sec5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> JAK1, JAK2, JAK3, and Tyk2 Enzymatic Inhibition Assay</h4><div id="sec5_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> Materials</h5><div class="NLM_p">The substrate (NH<sub>2</sub>–KGGEEEEYFELVKK–CO<sub>2</sub>), internal standard peptide (NH<sub>2</sub>–SWGAIETDKEYYTVKD-CO<sub>2</sub>), and product peptide (for standard curve only) (NH<sub>2</sub>–KGGEEEEY-Pi-FELVKK–CO<sub>2</sub>) were purchased from AnaSpec (Fremont, CA, USA). JAK1-JH1JH2 (574-1154 with a His-GST Tag and a C-terminal tev (ENLYFQ-G) cleavage site), JAK3-JH1JH2 (512-1124 with a GST Tag and a C-terminal tev (ENLYFQ-G) cleavage site), and Tyk2-JH1JH2 (8H_tev_580-1182-C936A-C1142A with a C-terminal tev (ENLYFQ-G) cleavage site) were purified internally. JAK2-JH1JH2 (532-1132 with a GST tag and C-terminal tev (ENLYFQ-G) cleavage site) was purchased from Invitrogen. LC/MS grade water and acetonitrile (ACN) were purchased from HoneyWell, Burdick & Jackson (Muskegon, MI, USA). Dimethylsulfoxide (99.8%, DMSO) and trifluoroacetic acid (99.5%, TFA) were purchased from EMD Chemical (Gibbstown, NJ, USA). Adenosine triphosphate (ATP), 4-morpholinepropanesulfonic acid (MOPS), magnesium chloride (MgCl<sub>2</sub>), ethylenediaminetetraacetic acid (EDTA), dithiothreitol (DTT), formic acid (>95%, FA), and Tween-20 were purchased from Sigma (St Louis, MO, USA). Additionally, 384-well polypropylene plates, Cat#781280, were purchased from Greiner (Monroe, NC, USA) with a RapidFireTM cartridge A C4 Column (Agilent Technologies, Santa Clara, CA, USA).</div><div class="NLM_p last">The HTMS experiments were performed in positive ionization mode on a RapidFire 300 instrument (Agilent Technologies), coupled with an ABSiex QTrap 4000 system with an electrospray ionization source (RF-MS) (Concord, ON, Canada). The RapidFire system was run with 3 Agilent 1200 series isocratic pumps from Agilent Technologies and one peristaltic pump model ISM832C from Ismatec (Wertheim, Germany). The entire system was operated using the RapidFire software interfaced with Analyst software for the mass spectrometer.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> Assay Protocol</h5><div class="NLM_p">The 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilution plates, the sample was transferred to a 384-well assay plate (#781280, Greiner) using Labcyte Echo (Sunnyvale, CA) or Biosero ATS (San Diego, CA). The compounds were tested in duplicate. Column 12 was used for positive controls, and column 24 contained negative controls with no enzyme added. A compound from our internal collection, with inhibitory activity for JAK isoforms, was used as a reference compound. The final concentration of DMSO was ≤0.25% in a 20 μL reaction mixture. Assay conditions for each of the proteins are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl3a" href="#tbl3a">Table <a class="ref showTableEvent internalNav" data-ID="tbl3a" href="#tbl3a">4</a></a>. The enzyme reaction was initiated by the addition of 10 μL of enzyme and a ATP mixture to 10 μL of a substrate solution prepared in the reaction buffer (50 mM MOPS pH 7.5, 10 mM MgCl<sub>2</sub>, 1 mM EDTA, 2 mM DTT, 0.002% Tween-20). The Tyk2 enzyme was preincubated with 2 mM ATP for 30 min prior to the reaction initiation. Immediately after the addition of the enzyme to the reaction mixture, the plate was centrifuged at 1000 rpm for 1 min and incubated at 25 °C for 45 min for JAK3 and 90 min for JAK1, JAK2, and Tyk2. The reaction mixture was quenched by the addition of 20 μL of 0.5% TFA containing 0.15 μM of internal standard peptide using a Multidrop Combi reagent dispenser (Thermo Scientific, Waltham, MA, USA). Several wells in column 24 were typically used for the product standard curve. After the quench, the assay plate was centrifuged at 3000 rpm for 3 min and sealed with pierceable aluminum foil (Cat# 06644-001, Agilent) using a PlateLoc (Agilent Technologies). The plates were then transferred on to the RapidFire for the MS analysis. Compound inhibition was assessed by a decrease of the phosphorylated product levels in sample wells compared to the noninhibited enzyme reaction.</div><div class="NLM_table-wrap" id="tbl3a"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Assay Conditions for JAK Family Enzyme Assays<a class="ref internalNav" href="#tbl3a-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char=" " /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">enzyme</th><th class="colsep0 rowsep0" align="center" char=" ">[enzyme], nM</th><th class="colsep0 rowsep0" align="center" char=".">[ATP], μM</th><th class="colsep0 rowsep0" align="center" char=".">[substrate], μM</th><th class="colsep0 rowsep0" align="center" char=".">[IS], nM</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK1-JH1JH2</td><td class="colsep0 rowsep0" align="char" char=" ">8.0</td><td class="colsep0 rowsep0" align="char" char=".">12.5</td><td class="colsep0 rowsep0" align="char" char=".">200</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK2-JH1JH2</td><td class="colsep0 rowsep0" align="char" char=" ">7.0 or 3.6</td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">40</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK3-JH1JH2</td><td class="colsep0 rowsep0" align="char" char=" ">2.0</td><td class="colsep0 rowsep0" align="char" char=".">150</td><td class="colsep0 rowsep0" align="char" char=".">40</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tyk2-JH1JH2</td><td class="colsep0 rowsep0" align="char" char=" ">25 or 14.7</td><td class="colsep0 rowsep0" align="char" char=".">50</td><td class="colsep0 rowsep0" align="char" char=".">200</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl3a-fn1"><div class="footnote" id="tbl3a-fn1"><sup><sup>a</sup></sup><p class="last">Reaction buffer: 50 mM MOPS, pH 7.5 10 mM MgCl<sub>2</sub>, 1 mM EDTA, 2 mM DTT, 0.002% Tween-20; “IS” stands for internal standard peptide; “substrate” stands for peptide.</p></div></div></div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> High-Throughput Mass Spectrometry (HTMS) Method</h5><div class="NLM_p last">The sample analysis on the RapidFire was performed using a mobile phase A1 consisting of water/TFA/FA (100:0.01:0.1, v/v/v) and a mobile phase B1 consisting of ACN/water/TFA/FA (80:20:0.01:0.1, v/v/v). The following run parameters were used: state 1 (aspirate), 250 ms; state 2 (load/wash), 3000 ms; state 3 (elute), 4000 ms; and state 4 (re-equilibrate), 1000 ms with a flow rate of 1.25 mL/min. The samples were aspirated directly from the 384-well assay plate and delivered onto a RF-MS microscale solid-phase C4 extraction cartridge (Type A). The undesired components such as salt, cofactor, detergent, and large protein were washed out, and the retained analytes (substrate, product, and IS) were coeluted directly onto the ABSiex Qtrap 4000 system. The quantification of the peptide (substrate), phospho-peptide (product), and internal standard peptide (IS) was performed by MRM using 562 → 136.0, 589.2 → 215.7, and 953.2 → 158.8 (or 974.2 → 158.8) transitions, respectively.</div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> IL-2 pSTAT5 (JAK1/JAK3), IFNα pSTAT4 (JAK1/TYK2), and GM-CSF pSTAT5 (JAK2/JAK2) Cellular Screening Assays</h4><div class="NLM_p last">The AlphaLISA assay (based on Alpha Technology from PerkinElmer) was performed by first plating freshly thawed PBMCs (Biological Specialty Corporation) in 384-well plates at 30000–100000 cells per well in HBSS (Hanks’ Balanced Salt Solution) containing 0.1% IgG (immunoglobulin G)-free, protease-free BSA (bovine serum albumin) (Jackson ImmunoResearch cat. no. 001-000-161) (for IL-2 and GM-CSF) or DMEM (Dulbecco’s Modified Eagle Medium) containing 10% FBS (fetal bovine serum), and 1000 IU/mL penicillin and 1000 μg/mL streptomycin (for IFNα). The cells were then treated with compounds diluted in DMSO at half-log titrated concentrations, with a highest test concentration of 10 μM and 0.5% final DMSO concentration, for 30 min at 37 °C. Next, the cells were stimulated with IL-2 (5 ng/mL) (R&D Systems cat. no. 202-IL-050), IFNα (4 ng/mL), or GM-CSF (11pg/mL) for 30 min at 37 °C. The cellular reactions were terminated by the addition of lysis buffer (PerkinElmer Cat. No. ALSU-PST5-A10K), and the pSTAT responses were assayed according to the manufacturer’s instructions using EnVision for detection of the time-resolved fluorescence signal. The percentage of pSTAT inhibition was determined at the compound test concentrations, and for each compound, a dose curve was generated, and the IC<sub>50</sub> was calculated. The compound IC<sub>50</sub> was calculated by nonlinear regression of the sigmoidal dose response analysis of the half-log dilution titration curve of the compound concentration versus Alpha signal. The acronym “Alpha” stands for amplified luminescent proximity homogeneous assay; the Alpha signal is a luminescent/fluorescent signal. For the purposes of screening, compounds were evaluated for inhibition in two independent experiments from a single PBMC donor, and the mean IC<sub>50</sub> was determined (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). A study success criteria was utilized such that the IC<sub>50</sub> for a reference compound was within 3-fold of the established IC<sub>50</sub> for each experiment.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> Comparative Cell-Based Activity of Tofacitinib and Compound <b>2</b> in PBMCs</h4><div class="NLM_p last">PBMCs (Biological Specialty) were thawed, washed 1 time in RPMI, and resuspended at 1–1.2 × 10<sup>6</sup> cells/mL in RPMI supplemented with 0.1% IgG-free BSA. Cells were plated at 1 × 10<sup>5</sup> cells/well in a round-bottom plate and were either used immediately (for GM-CSF, IFNα or IL-2 assay) or following overnight stimulation with anti-CD3/CD28 (for IL-12 assay). PBMCs were pretreated with tofacitinib or compound <b>2</b> for 30 min at 37 °C with 5% CO<sub>2</sub> prior to the addition of cytokine (final concentration 16 pg/mL GM-CSF, 4 ng/mL IFNα, 30 ng/mL IL-12, or 5 ng/mL IL-2, previously determined to approximate to EC<sub>80</sub>). To evaluate the activity for each cytokine, a single donor was utilized. In each study, treatment is replicated in biological duplicates or triplicates, and each experiment was replicated 2–5 times. Following a further incubation for 15 (GM-CSF) to 30 min (all other cytokines), the experiment was terminated by transferring the plates to ice for 5 min prior to centrifugation at 1500 rpm for 5 min and decanting the media. Cell pellets were lysed by the addition of 50 or 100 μL of MSD lysis buffer supplemented with protease and phosphatase inhibitor according to the manufacturer’s instructions. Samples were frozen at −80 °C prior to analysis or assayed for pSTAT immediately using single or multiplex assay kits from MSD according to the manufacturer’s instructions.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> MDCK-<i>MDR1</i> Permeability Assay</h4><div class="NLM_p">Permeability measurements were conducted according to the Cyprotex protocol using the MDCK-MDR1 cell line obtained from the NIH (Rockville, MD, USA). Cells between passage numbers 6–30 were seeded onto a Multiscreen plate (Millipore) at a cell density of 3.4 × 10<sup>5</sup> cells/cm<sup>2</sup> and cultured for 3 days before permeability studies were conducted. The cells in this assay form a cohesive sheet of a single cell layer, filling the surface area of the culture dish, also known as a confluent monolayer, and on day four, the test compound was added to the apical side of the membrane; the transport of the compound across the monolayer was monitored over a time period of 60 min.</div><div class="NLM_p">Test compounds were dissolved in DMSO at a concentration of 10 mM. The dosing solutions were prepared by diluting the test compounds with assay buffer, pH 7.4, at a final concentration of 5 μM. For the assessment of the apical to basolateral (“A–B”) permeability, buffer was removed from the apical compartment and replaced with the test compound dosing solution with or without the permeability glycoprotein (P-gp) inhibitor elacridar (2 μM). For the assessment of basolateral to apical (“B–A”) permeability, buffer was removed from the companion plate and replaced with the test compound dosing solution. Incubations were carried out in duplicates at 37 °C in an atmosphere of 5% CO<sub>2</sub> with a relative humidity of 95%. Each assay included the reference markers propranolol (high permeability) and prazosin (P-gp substrate). After incubation for 60 min, apical and basolateral samples were diluted, and the test compounds were quantified by LC/MS/MS using an 8-point calibration in the range 0.0039 to 3 μM with the appropriate dilution of the samples (receiver dilution factor = 1, donor and <i>C</i><sub>0</sub> dilution factor = 10). The permeability coefficient (<i>P</i><sub>app</sub>) for each compound was calculated from the following equation: <i>P</i><sub>app</sub> = (d<i>Q</i>/d<i>t</i>)/(<i>C</i><sub>0</sub> × <i>S</i>), where d<i>Q</i>/d<i>t</i> is the rate of permeation of the drug across the cells, <i>C</i><sub>0</sub> is the donor compartment concentration at time zero, and <i>S</i> is the area of the cell monolayer.</div><div class="NLM_p last">The percent recovery was measured for all incubation conditions. These measurements did not reveal unacceptable compound/plate binding or compound accumulation in the cell monolayer.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> Liver Microsomal Stability</h4><div class="NLM_p last">Test compounds (1 μM) were spiked in a reaction mixture consisting of 100 mM potassium phosphate buffer (pH 7.4), 1 mM MgCl<sub>2</sub>, and 0.5 mg/mL liver microsomes (pooled male CD mice from a reputable source). The reaction mixture was brought to 37 °C, and the reaction was initiated by adding NADPH to bring the mixture to a final concentration of 1 mM. After mixing, 50 μL aliquots were excised from the reaction plate at 0, 5, 10, 20, 40, and 60 min and quenched with methanol. The quenched plates were centrifuged at 2500 rpm for 20 min at 4 °C, and the supernatants were combined in cassettes of up to 8 compounds before LC/MS/MS analysis. The compound half-lives were derived from plots of the ln of the percent of remaining compound over time to determine the intrinsic clearance. The predicted hepatic clearance was derived from the intrinsic clearance value using equations from the well-stirred model,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> where no correction was made for protein binding, and the blood to plasma concentration ratio was assumed to be one. The extraction ratio (ER) was calculated by dividing the predicted hepatic clearance by species blood flow (150 mL/min/kg for mouse).</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> Mouse Pharmacokinetic Studies after 25 mg/kg Oral Dose</h4><div class="NLM_p last">Three nonfasted female C57BL/6 mice were orally administered the test compound at a dose of 25 mg/kg p.o. as a solution in 20% HPβCD at a dose volume of 5 mL/kg. Blood samples were collected at 0.5 and 4 h post-dose via retro-orbital bleed or the dorsal metatarsal vein. Blood samples were collected into tubes containing anticoagulant (Heparin-Na) and placed on wet ice. The plasma fraction was separated by centrifugation and frozen at −20 °C for up to 4 h and −80 °C after 4 h unless analyzed shortly after sample collection. Colon samples were collected at 4 h post-dose. Each animal was terminally anaesthetized by introducing a rising concentration of carbon dioxide, and the blood was removed as much as possible via cardiac puncture. The abdominal cavity was cut open; a 4–6 cm sample of the colon was dissected, cut open on the longitudinal axis; and the solid contents were removed by flushing with 2 mL of ice cold saline. The colon was placed in 5 mL of saline and shaken on a shaker for 5 s. The colon sample was then patted dry, weighed, and homogenized as 1 part tissue (g) to 4 parts HPLC grade water (mL). Concentrations of the compound in plasma and colon homogenate were determined using a qualified liquid chromatography-triple quadrupole mass spectrometry (LC-MS/MS) method.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> Evaluation of Local and Systemic Activity of Compound <b>2</b><i>in Vivo</i></h4><div id="sec5_7_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> Mice</h5><div class="NLM_p last">Female 6–8-week-old C57BL/6 mice were purchased from Taconic farms. Animals were housed five per cage in a pathogen free environment. All the studies were conducted in accordance with approved animal protocols and procedures by the Institutional Animal Care and Use Committee (IACUC).</div></div><div id="sec5_7_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> Treatment with Test Compounds</h5><div class="NLM_p last">Mice were dosed orally with indicated doses of compound <b>2</b> or tofacitinib. Control mice received vehicle (20% HPβCD) in the similar fashion. At indicated times, mice were euthanized, and their blood and colon tissue were collected for measurements of drug levels and <i>ex vivo</i> cytokine stimulation.</div></div><div id="sec5_7_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59"> <i>Ex Vivo</i> Whole Blood Stimulation</h5><div class="NLM_p last">Whole blood from each mouse was diluted 1:1 with sterile HBSS +MgCl<sub>2</sub>/+CaCl<sub>2</sub>. Then, 30 μL of diluted blood from each mouse was aliquoted into 12 individual wells of a U-bottom tissue culture plate according to a predefined plate map. Diluted blood from each animal was treated in triplicate with either IFNα (100 ng/mL) or vehicle (HBSS+MgCl<sub>2</sub>/+CaCl<sub>2</sub>) for 30 min at 37 °C with 5% CO<sub>2</sub>. At the end of the incubation, the plates were immediately transferred to wet ice, and 45 μL of MSD lysis buffer containing protease and phosphatase inhibitors was added to each well. The lysed blood was allowed to incubate on ice for 30 min and was then centrifuged at 1100 rpm for 5 min at 4 °C to pellet any debris. The samples were analyzed for pSTAT4 by MSD according to the manufacturer’s instructions.</div></div><div id="sec5_7_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> Processing of Colon Tissue</h5><div class="NLM_p last">Colon tissue was harvested via excision, and the proximal region was discarded. The following 2 cm section of the proximal colon was opened longitudinally, and the fecal contents were gently pushed and discarded. The resulting tissues were then washed with ice cold PBS, blotted dry, weighed, and saved on dry ice for measurements of drug levels. For cytokine stimulation, excised distal colonic tissue was transferred to a 48-well tissue culture plate containing 150 μL of RPMI-HEPES and challenged with a cocktail of IL-22/IL-6/IFNα (100 ng/mL each) at 37 °C for 1 h. Following incubation, the tissues were freeze fractured according to the manufacturer’s instructions and were solubilized in 1 mL of lysis buffer containing protease and phosphatase inhibitors. Samples were then centrifuged at 13000 <i>g</i> at 4 °C for 10 min, and the total protein was quantitated using a Pierce Coomassie Plus (Bradford) assay kit according to manufacturer’s specifications in supernatants. The pSTAT3 analysis in colon tissue was conducted using a single or multiplex MSD assay according to the manufacturer’s instructions.</div></div><div id="sec5_7_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> Sample Analysis for Serum and Colon Drug Levels</h5><div class="NLM_p last">Concentrations of compound <b>2</b> and tofacitinib in mouse serum and homogenized colon tissues were determined using a qualified liquid chromatography-triple quadrupole mass spectrometry (LC MS/MS) method.</div></div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i62"><a href="/doi/suppl/10.1021/acs.jmedchem.9b01439" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13230" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13230" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.9b01439?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01439</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings of all compounds and cLogP, molecular weight, number of hydrogen bond donors, tPSA, JAK1 IC<sub>50</sub>, JAK2 IC<sub>50</sub>, JAK3IC<sub>50</sub>, Tyk2 IC<sub>50</sub>, and MDCK permeability (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01439/suppl_file/jm9b01439_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Histogram of JAK1 pIC<sub>50</sub>’s, correlation between JAK1 IC<sub>50</sub> and JAK2 IC<sub>50</sub>, correlation between JAK1 IC<sub>50</sub> and JAK3 IC<sub>50</sub>, correlation between JAK1 IC<sub>50</sub> and Tyk2 IC<sub>50</sub>, correlation of cLogP and tPSA to permeability (analogues excluding −CH<sub>2</sub>CONRR and −CH<sub>2</sub>NRCOR subset), and correlation of clogP and tPSA to permeability (−CH<sub>2</sub>CONRR and −CH<sub>2</sub>NRCOR subset) (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01439/suppl_file/jm9b01439_si_002.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01439/suppl_file/jm9b01439_si_001.csv">jm9b01439_si_001.csv (27.33 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01439/suppl_file/jm9b01439_si_002.pdf">jm9b01439_si_002.pdf (524.35 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b01439" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63627" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63627" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kristi A. Leonard</span> - <span class="hlFld-Affiliation affiliation">Janssen
Research and Development, 1400 McKean Road, Spring
House, Pennsylvania 19477, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9398-3354" title="Orcid link">http://orcid.org/0000-0002-9398-3354</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#73383f161c1d120142331a07005d191d195d101c1e"><span class="__cf_email__" data-cfemail="fcb7b09993929d8ecdbc95888fd2969296d29f9391">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lisa A. Madge</span> - <span class="hlFld-Affiliation affiliation">Janssen
Research and Development, 1400 McKean Road, Spring
House, Pennsylvania 19477, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a2eeefc3c6c5c7e2cbd6d18cc8ccc88cc1cdcf"><span class="__cf_email__" data-cfemail="eca0a18d888b89ac85989fc2868286c28f8381">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul J. Krawczuk</span> - <span class="hlFld-Affiliation affiliation">Janssen
Research and Development, 1400 McKean Road, Spring
House, Pennsylvania 19477, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0413-3655" title="Orcid link">http://orcid.org/0000-0003-0413-3655</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aihua Wang</span> - <span class="hlFld-Affiliation affiliation">Janssen
Research and Development, 1400 McKean Road, Spring
House, Pennsylvania 19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin D. Kreutter</span> - <span class="hlFld-Affiliation affiliation">Janssen
Research and Development, 1400 McKean Road, Spring
House, Pennsylvania 19477, United States</span>; 
    <span>Present Address:
                        Present address for K.K.: Nimbus Therapeutics, 130 Prospect St, Suite 301 Cambridge, MA 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Genesis M. Bacani</span> - <span class="hlFld-Affiliation affiliation">Janssen
Research and Development, 3210 Merryfield Row, San
Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenying Chai</span> - <span class="hlFld-Affiliation affiliation">Janssen
Research and Development, 3210 Merryfield Row, San
Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Russell C. Smith</span> - <span class="hlFld-Affiliation affiliation">Janssen
Research and Development, 3210 Merryfield Row, San
Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark S. Tichenor</span> - <span class="hlFld-Affiliation affiliation">Janssen
Research and Development, 3210 Merryfield Row, San
Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael C. Harris</span> - <span class="hlFld-Affiliation affiliation">Janssen
Research and Development, 1400 McKean Road, Spring
House, Pennsylvania 19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ravi Malaviya</span> - <span class="hlFld-Affiliation affiliation">Janssen
Research and Development, 1400 McKean Road, Spring
House, Pennsylvania 19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark Seierstad</span> - <span class="hlFld-Affiliation affiliation">Janssen
Research and Development, 3210 Merryfield Row, San
Diego, California 92121, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6734-4316" title="Orcid link">http://orcid.org/0000-0001-6734-4316</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marguerite E. Johnson</span> - <span class="hlFld-Affiliation affiliation">Janssen
Research and Development, 1400 McKean Road, Spring
House, Pennsylvania 19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jennifer D. Venable</span> - <span class="hlFld-Affiliation affiliation">Janssen
Research and Development, 3210 Merryfield Row, San
Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Suzie Kim</span> - <span class="hlFld-Affiliation affiliation">Janssen
Research and Development, 3210 Merryfield Row, San
Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gavin C. Hirst</span> - <span class="hlFld-Affiliation affiliation">Janssen
Research and Development, 3210 Merryfield Row, San
Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ashok S. Mathur</span> - <span class="hlFld-Affiliation affiliation">Janssen
Research and Development, 1400 McKean Road, Spring
House, Pennsylvania 19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tadimeti S. Rao</span> - <span class="hlFld-Affiliation affiliation">Janssen
Research and Development, 3210 Merryfield Row, San
Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James P. Edwards</span> - <span class="hlFld-Affiliation affiliation">Janssen
Research and Development, 1400 McKean Road, Spring
House, Pennsylvania 19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michele C. Rizzolio</span> - <span class="hlFld-Affiliation affiliation">Janssen
Research and Development, 3210 Merryfield Row, San
Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tatiana Koudriakova</span> - <span class="hlFld-Affiliation affiliation">Janssen
Research and Development, 3210 Merryfield Row, San
Diego, California 92121, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Contributions by K.K. and G.H. were performed while employed at Janssen Research and Development.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ACN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">AE</td><td class="NLM_def"><p class="first last">adverse event</p></td></tr><tr><td class="NLM_term">ANC</td><td class="NLM_def"><p class="first last">absolute neutrophil count</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">Boc</td><td class="NLM_def"><p class="first last"><i>tert</i>-butoxycarbonyl</p></td></tr><tr><td class="NLM_term">BSA</td><td class="NLM_def"><p class="first last">bovine serum albumin</p></td></tr><tr><td class="NLM_term">CD</td><td class="NLM_def"><p class="first last">Crohn’s disease</p></td></tr><tr><td class="NLM_term">cLogP</td><td class="NLM_def"><p class="first last">calculated logarithm of partition coefficient</p></td></tr><tr><td class="NLM_term">DC</td><td class="NLM_def"><p class="first last">dendritic cells</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N,N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DMA</td><td class="NLM_def"><p class="first last">dimethylacetamide</p></td></tr><tr><td class="NLM_term">DMEM</td><td class="NLM_def"><p class="first last">Dulbecco’s modified eagle medium</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last">dimethylformamide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">DTT</td><td class="NLM_def"><p class="first last">dithiothreitol</p></td></tr><tr><td class="NLM_term">EDTA</td><td class="NLM_def"><p class="first last">ethylenediaminetetraacetic acid</p></td></tr><tr><td class="NLM_term">FA</td><td class="NLM_def"><p class="first last">formic acid</p></td></tr><tr><td class="NLM_term">FBS</td><td class="NLM_def"><p class="first last">fetal bovine serum</p></td></tr><tr><td class="NLM_term">GI</td><td class="NLM_def"><p class="first last">gastrointestinal</p></td></tr><tr><td class="NLM_term">GM-CSF</td><td class="NLM_def"><p class="first last">granulocyte monocyte colony stimulating factor</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last"><i>O</i>-(7-azobenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">HBSS</td><td class="NLM_def"><p class="first last">Hanks’ balanced salt solution</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography or high-pressure liquid chromatography</p></td></tr><tr><td class="NLM_term">HPβCD</td><td class="NLM_def"><p class="first last">2-hydroxypropyl-beta-cyclodextrin</p></td></tr><tr><td class="NLM_term">HTMS</td><td class="NLM_def"><p class="first last">high-throughput mass spectrometry</p></td></tr><tr><td class="NLM_term">IBD</td><td class="NLM_def"><p class="first last">inflammatory bowel diseases</p></td></tr><tr><td class="NLM_term">JAK</td><td class="NLM_def"><p class="first last">Janus kinase</p></td></tr><tr><td class="NLM_term">LC-MS</td><td class="NLM_def"><p class="first last">liquid chromatography–mass spectrometry</p></td></tr><tr><td class="NLM_term">MOPS</td><td class="NLM_def"><p class="first last">4-morpholinepropanesulfonic acid</p></td></tr><tr><td class="NLM_term">MS</td><td class="NLM_def"><p class="first last">mass spectrometry</p></td></tr><tr><td class="NLM_term">MsCl</td><td class="NLM_def"><p class="first last">methylsulfonyl (mesyl) chloride</p></td></tr><tr><td class="NLM_term">MW</td><td class="NLM_def"><p class="first last">molecular weight</p></td></tr><tr><td class="NLM_term">NMR</td><td class="NLM_def"><p class="first last">nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">PBMC</td><td class="NLM_def"><p class="first last">peripheral blood mononuclear cell</p></td></tr><tr><td class="NLM_term">P-gp</td><td class="NLM_def"><p class="first last">P-glycoprotein</p></td></tr><tr><td class="NLM_term">PK/PD</td><td class="NLM_def"><p class="first last">pharmacokinetic/pharmacodynamic</p></td></tr><tr><td class="NLM_term">pSTATs</td><td class="NLM_def"><p class="first last">phosphorylated signal transducers and activators of transcription</p></td></tr><tr><td class="NLM_term">PyBrOP</td><td class="NLM_def"><p class="first last">bromotripyrrolidinophosphonium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">RA</td><td class="NLM_def"><p class="first last">rheumatoid arthritis</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">tPSA</td><td class="NLM_def"><p class="first last">topological polar surface area</p></td></tr><tr><td class="NLM_term">UC</td><td class="NLM_def"><p class="first last">ulcerative colitis</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i66">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01012" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01012" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 29 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coskun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salem, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, O. H.</span></span> <span> </span><span class="NLM_article-title">Involvement of Jak/Stat Signaling in the Pathogenesis of Inflammatory Bowel Disease</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2013.06.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1016%2Fj.phrs.2013.06.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=23827161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2ms7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2013&pages=1-8&author=M.+Coskunauthor=M.+Salemauthor=J.+Pedersenauthor=O.+H.+Nielsen&title=Involvement+of+Jak%2FStat+Signaling+in+the+Pathogenesis+of+Inflammatory+Bowel+Disease&doi=10.1016%2Fj.phrs.2013.06.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease</span></div><div class="casAuthors">Coskun, Mehmet; Salem, Mohammad; Pedersen, Jannie; Nielsen, Ole Haagen</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-8</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway constitute the fulcrum in many vital cellular processes, including cell growth, differentiation, proliferation, and regulatory immune functions.  Various cytokines, growth factors, and protein tyrosine kinases communicate through the JAK/STAT pathway and regulate the transcription of numerous genes.  In addn. to their crit. roles in a plethora of key cellular activities, the JAK/STAT signaling pathways also have been implicated in the pathogenesis of several diseases, including inflammatory bowel disease (IBD), esp. since a JAK inhibitor recently has been shown to be effective in the treatment of ulcerative colitis.  The aim of this review is to highlight the recent findings on the regulatory mechanism of JAK/STAT signaling pathways and to reveal the evolving comprehension of their interface which might be of interest for clinicians involved in IBD therapy.  Further, it is described how these signaling pathways have been exploited for the development of promising novel JAK inhibitors with anti-inflammatory effects verified in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5w2NrXEjp4bVg90H21EOLACvtfcHk0lgxRzinZWwvNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2ms7vP&md5=ee07edf3a0fc83840e8c90c178378c98</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2013.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2013.06.007%26sid%3Dliteratum%253Aachs%26aulast%3DCoskun%26aufirst%3DM.%26aulast%3DSalem%26aufirst%3DM.%26aulast%3DPedersen%26aufirst%3DJ.%26aulast%3DNielsen%26aufirst%3DO.%2BH.%26atitle%3DInvolvement%2520of%2520Jak%252FStat%2520Signaling%2520in%2520the%2520Pathogenesis%2520of%2520Inflammatory%2520Bowel%2520Disease%26jtitle%3DPharmacol.%2520Res.%26date%3D2013%26volume%3D76%26spage%3D1%26epage%3D8%26doi%3D10.1016%2Fj.phrs.2013.06.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Danese, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grisham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J. B.</span></span> <span> </span><span class="NLM_article-title">Jak Inhibition Using Tofacitinib for Inflammatory Bowel Disease Treatment: A Hub for Multiple Inflammatory Cytokines</span>. <i>American journal of physiology. Gastrointestinal and liver physiology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>310</i></span>,  <span class="NLM_fpage">G155</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1152/ajpgi.00311.2015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1152%2Fajpgi.00311.2015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=26608188" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=310&publication_year=2016&pages=G155-162&author=S.+Daneseauthor=M.+Grishamauthor=J.+Hodgeauthor=J.+B.+Telliez&title=Jak+Inhibition+Using+Tofacitinib+for+Inflammatory+Bowel+Disease+Treatment%3A+A+Hub+for+Multiple+Inflammatory+Cytokines&doi=10.1152%2Fajpgi.00311.2015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1152%2Fajpgi.00311.2015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpgi.00311.2015%26sid%3Dliteratum%253Aachs%26aulast%3DDanese%26aufirst%3DS.%26aulast%3DGrisham%26aufirst%3DM.%26aulast%3DHodge%26aufirst%3DJ.%26aulast%3DTelliez%26aufirst%3DJ.%2BB.%26atitle%3DJak%2520Inhibition%2520Using%2520Tofacitinib%2520for%2520Inflammatory%2520Bowel%2520Disease%2520Treatment%253A%2520A%2520Hub%2520for%2520Multiple%2520Inflammatory%2520Cytokines%26jtitle%3DAmerican%2520journal%2520of%2520physiology.%2520Gastrointestinal%2520and%2520liver%2520physiology%26date%3D2016%26volume%3D310%26spage%3DG155%26epage%3D162%26doi%3D10.1152%2Fajpgi.00311.2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neurath, M. F.</span></span> <span> </span><span class="NLM_article-title">Cytokines in Inflammatory Bowel Disease</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">342</span>, <span class="refDoi"> DOI: 10.1038/nri3661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1038%2Fnri3661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=24751956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmsFalsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=329-342&author=M.+F.+Neurath&title=Cytokines+in+Inflammatory+Bowel+Disease&doi=10.1038%2Fnri3661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Cytokines in inflammatory bowel disease</span></div><div class="casAuthors">Neurath, Markus F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">329-342</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cytokines have a crucial role in the pathogenesis of inflammatory bowel diseases (IBDs), such as Crohn's disease and ulcerative colitis, where they control multiple aspects of the inflammatory response.  In particular, the imbalance between pro-inflammatory and anti-inflammatory cytokines that occurs in IBD impedes the resoln. of inflammation and instead leads to disease perpetuation and tissue destruction.  Recent studies suggest the existence of a network of regulatory cytokines that has important implications for disease progression.  In this Review, we discuss the role of cytokines produced by innate and adaptive immune cells, as well as their relevance to the future therapy of IBD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphBomEKR1KI7Vg90H21EOLACvtfcHk0lgxRzinZWwvNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmsFalsro%253D&md5=f8ab6ddf3011cbf1a3c54cd7394cd37b</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnri3661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri3661%26sid%3Dliteratum%253Aachs%26aulast%3DNeurath%26aufirst%3DM.%2BF.%26atitle%3DCytokines%2520in%2520Inflammatory%2520Bowel%2520Disease%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2014%26volume%3D14%26spage%3D329%26epage%3D342%26doi%3D10.1038%2Fnri3661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holland, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, L. M.</span></span> <span> </span><span class="NLM_article-title">Jaks and Stats in Immunity, Immunodeficiency, and Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">170</span>, <span class="refDoi"> DOI: 10.1056/NEJMra1202117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1056%2FNEJMra1202117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=23301733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovVyhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2013&pages=161-170&author=J.+J.+O%E2%80%99Sheaauthor=S.+M.+Hollandauthor=L.+M.+Staudt&title=Jaks+and+Stats+in+Immunity%2C+Immunodeficiency%2C+and+Cancer&doi=10.1056%2FNEJMra1202117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">JAKs and STATs in immunity, immunodeficiency, and cancer</span></div><div class="casAuthors">O'Shea, John J.; Holland, Steven M.; Staudt, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">161-170</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review highlights interferon-mediated gene regulation has resulted in a new framework for the study of cell signaling and JAKs STATs in immunity, immunodeficiency, and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqk1n-UgWrlWrVg90H21EOLACvtfcHk0lgkdIvL_nERSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovVyhuw%253D%253D&md5=5d87b67f72b721eb0ca9413adf92a7b9</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1202117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1202117%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DHolland%26aufirst%3DS.%2BM.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DJaks%2520and%2520Stats%2520in%2520Immunity%252C%2520Immunodeficiency%252C%2520and%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D368%26spage%3D161%26epage%3D170%26doi%3D10.1056%2FNEJMra1202117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jostins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weersma, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duerr, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGovern, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philip Schumm, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Essers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitrovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleynen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theatre, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spain, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raychaudhuri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goyette, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achkar, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amininejad, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ananthakrishnan, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baidoo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balschun, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bampton, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brand, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buning, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cichon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Amato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devaney, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubinsky, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellinghaus, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franchimont, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fransen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gearry, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georges, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gieger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haritunians, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsen, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kupcinskas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kugathasan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latiano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laukens, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrance, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansfield, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mowat, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmieri, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponsioen, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potocnik, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prescott, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regueiro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotter, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanderson, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sans, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satsangi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simms, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sventoraityte, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Targan, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremelling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verspaget, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijmenga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkelmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xavier, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeissig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverberg, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annese, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hakonarson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brant, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radford-Smith, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rioux, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadt, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermeire, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J. H</span></span> <span> </span><span class="NLM_article-title">Host-Microbe Interactions Have Shaped the Genetic Architecture of Inflammatory Bowel Disease</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>491</i></span>,  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1038/nature11582</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1038%2Fnature11582" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=23128233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1ajtbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=491&publication_year=2012&pages=119-124&author=L.+Jostinsauthor=S.+Ripkeauthor=R.+K.+Weersmaauthor=R.+H.+Duerrauthor=D.+P.+McGovernauthor=K.+Y.+Huiauthor=J.+C.+Leeauthor=L.+Philip+Schummauthor=Y.+Sharmaauthor=C.+A.+Andersonauthor=J.+Essersauthor=M.+Mitrovicauthor=K.+Ningauthor=I.+Cleynenauthor=E.+Theatreauthor=S.+L.+Spainauthor=S.+Raychaudhuriauthor=P.+Goyetteauthor=Z.+Weiauthor=C.+Abrahamauthor=J.-P.+Achkarauthor=T.+Ahmadauthor=L.+Amininejadauthor=A.+N.+Ananthakrishnanauthor=V.+Andersenauthor=J.+M.+Andrewsauthor=L.+Baidooauthor=T.+Balschunauthor=P.+A.+Bamptonauthor=A.+Bittonauthor=G.+Boucherauthor=S.+Brandauthor=C.+Buningauthor=A.+Cohainauthor=S.+Cichonauthor=M.+D%E2%80%99Amatoauthor=D.+De+Jongauthor=K.+L.+Devaneyauthor=M.+Dubinskyauthor=C.+Edwardsauthor=D.+Ellinghausauthor=L.+R.+Fergusonauthor=D.+Franchimontauthor=K.+Fransenauthor=R.+Gearryauthor=M.+Georgesauthor=C.+Giegerauthor=J.+Glasauthor=T.+Harituniansauthor=A.+Hartauthor=C.+Hawkeyauthor=M.+Hedlauthor=X.+Huauthor=T.+H.+Karlsenauthor=L.+Kupcinskasauthor=S.+Kugathasanauthor=A.+Latianoauthor=D.+Laukensauthor=I.+C.+Lawranceauthor=C.+W.+Leesauthor=E.+Louisauthor=G.+Mahyauthor=J.+Mansfieldauthor=A.+R.+Morganauthor=C.+Mowatauthor=W.+Newmanauthor=O.+Palmieriauthor=C.+Y.+Ponsioenauthor=U.+Potocnikauthor=N.+J.+Prescottauthor=M.+Regueiroauthor=J.+I.+Rotterauthor=R.+K.+Russellauthor=J.+D.+Sandersonauthor=M.+Sansauthor=J.+Satsangiauthor=S.+Schreiberauthor=L.+A.+Simmsauthor=J.+Sventoraityteauthor=S.+R.+Targanauthor=K.+D.+Taylorauthor=M.+Tremellingauthor=H.+W.+Verspagetauthor=M.+De+Vosauthor=C.+Wijmengaauthor=D.+C.+Wilsonauthor=J.+Winkelmannauthor=R.+J.+Xavierauthor=S.+Zeissigauthor=B.+Zhangauthor=C.+K.+Zhangauthor=H.+Zhaoauthor=M.+S.+Silverbergauthor=V.+Anneseauthor=H.+Hakonarsonauthor=S.+R.+Brantauthor=G.+Radford-Smithauthor=C.+G.+Mathewauthor=J.+D.+Riouxauthor=E.+E.+Schadtauthor=M.+J.+Dalyauthor=A.+Frankeauthor=M.+Parkesauthor=S.+Vermeireauthor=J.+C.+Barrettauthor=J.+H+Cho&title=Host-Microbe+Interactions+Have+Shaped+the+Genetic+Architecture+of+Inflammatory+Bowel+Disease&doi=10.1038%2Fnature11582"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease</span></div><div class="casAuthors">Jostins, Luke; Ripke, Stephan; Weersma, Rinse K.; Duerr, Richard H.; McGovern, Dermot P.; Hui, Ken Y.; Lee, James C.; Philip Schumm, L.; Sharma, Yashoda; Anderson, Carl A.; Essers, Jonah; Mitrovic, Mitja; Ning, Kaida; Cleynen, Isabelle; Theatre, Emilie; Spain, Sarah L.; Raychaudhuri, Soumya; Goyette, Philippe; Wei, Zhi; Abraham, Clara; Achkar, Jean-Paul; Ahmad, Tariq; Amininejad, Leila; Ananthakrishnan, Ashwin N.; Andersen, Vibeke; Andrews, Jane M.; Baidoo, Leonard; Balschun, Tobias; Bampton, Peter A.; Bitton, Alain; Boucher, Gabrielle; Brand, Stephan; Buening, Carsten; Cohain, Ariella; Cichon, Sven; D'Amato, Mauro; De Jong, Dirk; Devaney, Kathy L.; Dubinsky, Marla; Edwards, Cathryn; Ellinghaus, David; Ferguson, Lynnette R.; Franchimont, Denis; Fransen, Karin; Gearry, Richard; Georges, Michel; Gieger, Christian; Glas, Juergen; Haritunians, Talin; Hart, Ailsa; Hawkey, Chris; Hedl, Matija; Hu, Xinli; Karlsen, Tom H.; Kupcinskas, Limas; Kugathasan, Subra; Latiano, Anna; Laukens, Debby; Lawrance, Ian C.; Lees, Charlie W.; Louis, Edouard; Mahy, Gillian; Mansfield, John; Morgan, Angharad R.; Mowat, Craig; Newman, William; Palmieri, Orazio; Ponsioen, Cyriel Y.; Potocnik, Uros; Prescott, Natalie J.; Regueiro, Miguel; Rotter, Jerome I.; Russell, Richard K.; Sanderson, Jeremy D.; Sans, Miquel; Satsangi, Jack; Schreiber, Stefan; Simms, Lisa A.; Sventoraityte, Jurgita; Targan, Stephan R.; Taylor, Kent D.; Tremelling, Mark; Verspaget, Hein W.; De Vos, Martine; Wijmenga, Cisca; Wilson, David C.; Winkelmann, Juliane; Xavier, Ramnik J.; Zeissig, Sebastian; Zhang, Bin; Zhang, Clarence K.; Zhao, Hongyu; Silverberg, Mark S.; Annese, Vito; Hakonarson, Hakon; Brant, Steven R.; Radford-Smith, Graham; Mathew, Christopher G.; Rioux, John D.; Schadt, Eric E.; Daly, Mark J.; Franke, Andre; Parkes, Miles; Vermeire, Severine; Barrett, Jeffrey C.; Cho, Judy H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">491</span>
        (<span class="NLM_cas:issue">7422</span>),
    <span class="NLM_cas:pages">119-124</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Crohn's disease and ulcerative colitis, the two common forms of inflammatory bowel disease (IBD), affect over 2.5 million people of European ancestry, with rising prevalence in other populations.  Genome-wide assocn. studies and subsequent meta-analyses of these two diseases as sep. phenotypes have implicated previously unsuspected mechanisms, such as autophagy, in their pathogenesis and showed that some IBD loci are shared with other inflammatory diseases.  Here we expand on the knowledge of relevant pathways by undertaking a meta-anal. of Crohn's disease and ulcerative colitis genome-wide assocn. scans, followed by extensive validation of significant findings, with a combined total of more than 75,000 cases and controls.  We identify 71 new assocns., for a total of 163 IBD loci, that meet genome-wide significance thresholds.  Most loci contribute to both phenotypes, and both directional (consistently favoring one allele over the course of human history) and balancing (favoring the retention of both alleles within populations) selection effects are evident.  Many IBD loci are also implicated in other immune-mediated disorders, most notably with ankylosing spondylitis and psoriasis.  We also observe considerable overlap between susceptibility loci for IBD and mycobacterial infection.  Gene co-expression network anal. emphasizes this relationship, with pathways shared between host responses to mycobacteria and those predisposing to IBD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHFW8T01tr1LVg90H21EOLACvtfcHk0lg5GiVNM0BD5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1ajtbzP&md5=c12c310a78520076fb66584d21c9e366</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnature11582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11582%26sid%3Dliteratum%253Aachs%26aulast%3DJostins%26aufirst%3DL.%26aulast%3DRipke%26aufirst%3DS.%26aulast%3DWeersma%26aufirst%3DR.%2BK.%26aulast%3DDuerr%26aufirst%3DR.%2BH.%26aulast%3DMcGovern%26aufirst%3DD.%2BP.%26aulast%3DHui%26aufirst%3DK.%2BY.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DPhilip%2BSchumm%26aufirst%3DL.%26aulast%3DSharma%26aufirst%3DY.%26aulast%3DAnderson%26aufirst%3DC.%2BA.%26aulast%3DEssers%26aufirst%3DJ.%26aulast%3DMitrovic%26aufirst%3DM.%26aulast%3DNing%26aufirst%3DK.%26aulast%3DCleynen%26aufirst%3DI.%26aulast%3DTheatre%26aufirst%3DE.%26aulast%3DSpain%26aufirst%3DS.%2BL.%26aulast%3DRaychaudhuri%26aufirst%3DS.%26aulast%3DGoyette%26aufirst%3DP.%26aulast%3DWei%26aufirst%3DZ.%26aulast%3DAbraham%26aufirst%3DC.%26aulast%3DAchkar%26aufirst%3DJ.-P.%26aulast%3DAhmad%26aufirst%3DT.%26aulast%3DAmininejad%26aufirst%3DL.%26aulast%3DAnanthakrishnan%26aufirst%3DA.%2BN.%26aulast%3DAndersen%26aufirst%3DV.%26aulast%3DAndrews%26aufirst%3DJ.%2BM.%26aulast%3DBaidoo%26aufirst%3DL.%26aulast%3DBalschun%26aufirst%3DT.%26aulast%3DBampton%26aufirst%3DP.%2BA.%26aulast%3DBitton%26aufirst%3DA.%26aulast%3DBoucher%26aufirst%3DG.%26aulast%3DBrand%26aufirst%3DS.%26aulast%3DBuning%26aufirst%3DC.%26aulast%3DCohain%26aufirst%3DA.%26aulast%3DCichon%26aufirst%3DS.%26aulast%3DD%25E2%2580%2599Amato%26aufirst%3DM.%26aulast%3DDe%2BJong%26aufirst%3DD.%26aulast%3DDevaney%26aufirst%3DK.%2BL.%26aulast%3DDubinsky%26aufirst%3DM.%26aulast%3DEdwards%26aufirst%3DC.%26aulast%3DEllinghaus%26aufirst%3DD.%26aulast%3DFerguson%26aufirst%3DL.%2BR.%26aulast%3DFranchimont%26aufirst%3DD.%26aulast%3DFransen%26aufirst%3DK.%26aulast%3DGearry%26aufirst%3DR.%26aulast%3DGeorges%26aufirst%3DM.%26aulast%3DGieger%26aufirst%3DC.%26aulast%3DGlas%26aufirst%3DJ.%26aulast%3DHaritunians%26aufirst%3DT.%26aulast%3DHart%26aufirst%3DA.%26aulast%3DHawkey%26aufirst%3DC.%26aulast%3DHedl%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DKarlsen%26aufirst%3DT.%2BH.%26aulast%3DKupcinskas%26aufirst%3DL.%26aulast%3DKugathasan%26aufirst%3DS.%26aulast%3DLatiano%26aufirst%3DA.%26aulast%3DLaukens%26aufirst%3DD.%26aulast%3DLawrance%26aufirst%3DI.%2BC.%26aulast%3DLees%26aufirst%3DC.%2BW.%26aulast%3DLouis%26aufirst%3DE.%26aulast%3DMahy%26aufirst%3DG.%26aulast%3DMansfield%26aufirst%3DJ.%26aulast%3DMorgan%26aufirst%3DA.%2BR.%26aulast%3DMowat%26aufirst%3DC.%26aulast%3DNewman%26aufirst%3DW.%26aulast%3DPalmieri%26aufirst%3DO.%26aulast%3DPonsioen%26aufirst%3DC.%2BY.%26aulast%3DPotocnik%26aufirst%3DU.%26aulast%3DPrescott%26aufirst%3DN.%2BJ.%26aulast%3DRegueiro%26aufirst%3DM.%26aulast%3DRotter%26aufirst%3DJ.%2BI.%26aulast%3DRussell%26aufirst%3DR.%2BK.%26aulast%3DSanderson%26aufirst%3DJ.%2BD.%26aulast%3DSans%26aufirst%3DM.%26aulast%3DSatsangi%26aufirst%3DJ.%26aulast%3DSchreiber%26aufirst%3DS.%26aulast%3DSimms%26aufirst%3DL.%2BA.%26aulast%3DSventoraityte%26aufirst%3DJ.%26aulast%3DTargan%26aufirst%3DS.%2BR.%26aulast%3DTaylor%26aufirst%3DK.%2BD.%26aulast%3DTremelling%26aufirst%3DM.%26aulast%3DVerspaget%26aufirst%3DH.%2BW.%26aulast%3DDe%2BVos%26aufirst%3DM.%26aulast%3DWijmenga%26aufirst%3DC.%26aulast%3DWilson%26aufirst%3DD.%2BC.%26aulast%3DWinkelmann%26aufirst%3DJ.%26aulast%3DXavier%26aufirst%3DR.%2BJ.%26aulast%3DZeissig%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DC.%2BK.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DSilverberg%26aufirst%3DM.%2BS.%26aulast%3DAnnese%26aufirst%3DV.%26aulast%3DHakonarson%26aufirst%3DH.%26aulast%3DBrant%26aufirst%3DS.%2BR.%26aulast%3DRadford-Smith%26aufirst%3DG.%26aulast%3DMathew%26aufirst%3DC.%2BG.%26aulast%3DRioux%26aufirst%3DJ.%2BD.%26aulast%3DSchadt%26aufirst%3DE.%2BE.%26aulast%3DDaly%26aufirst%3DM.%2BJ.%26aulast%3DFranke%26aufirst%3DA.%26aulast%3DParkes%26aufirst%3DM.%26aulast%3DVermeire%26aufirst%3DS.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DCho%26aufirst%3DJ.%2BH%26atitle%3DHost-Microbe%2520Interactions%2520Have%2520Shaped%2520the%2520Genetic%2520Architecture%2520of%2520Inflammatory%2520Bowel%2520Disease%26jtitle%3DNature%26date%3D2012%26volume%3D491%26spage%3D119%26epage%3D124%26doi%3D10.1038%2Fnature11582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boland, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandborn, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. T.</span></span> <span> </span><span class="NLM_article-title">Update on Janus Kinase Antagonists in Inflammatory Bowel Disease</span>. <i>Gastroenterology clinics of North America</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">603</span>– <span class="NLM_lpage">617</span>, <span class="refDoi"> DOI: 10.1016/j.gtc.2014.05.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1016%2Fj.gtc.2014.05.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=25110261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A280%3ADC%252BC2M7jsl2rug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2014&pages=603-617&author=B.+S.+Bolandauthor=W.+J.+Sandbornauthor=J.+T.+Chang&title=Update+on+Janus+Kinase+Antagonists+in+Inflammatory+Bowel+Disease&doi=10.1016%2Fj.gtc.2014.05.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Update on Janus kinase antagonists in inflammatory bowel disease</span></div><div class="casAuthors">Boland Brigid S; Sandborn William J; Chang John T</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology clinics of North America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">603-17</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Janus kinase (JAK) inhibitors have emerged as a novel orally administered small-molecule therapy for the treatment of ulcerative colitis and possibly Crohn disease.  These molecules are designed to selectively target the activity of specific JAKs and to offer a targeted mechanism of action without risk of immunogenicity.  Based on data from clinical trials in rheumatoid arthritis and phase 2 studies in inflammatory bowel disease, tofacitinib and other JAK inhibitors are likely to become a new form of medical therapy for the treatment of inflammatory bowel disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSVKdNIYzs50ny-c-E1v-fmfW6udTcc2eaFnLQBcKwHI7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M7jsl2rug%253D%253D&md5=8814b4d1e5ae091533bdbeec71829843</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.gtc.2014.05.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gtc.2014.05.011%26sid%3Dliteratum%253Aachs%26aulast%3DBoland%26aufirst%3DB.%2BS.%26aulast%3DSandborn%26aufirst%3DW.%2BJ.%26aulast%3DChang%26aufirst%3DJ.%2BT.%26atitle%3DUpdate%2520on%2520Janus%2520Kinase%2520Antagonists%2520in%2520Inflammatory%2520Bowel%2520Disease%26jtitle%3DGastroenterology%2520clinics%2520of%2520North%2520America%26date%3D2014%26volume%3D43%26spage%3D603%26epage%3D617%26doi%3D10.1016%2Fj.gtc.2014.05.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sandborn, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sands, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Haens, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermeire, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danese, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panés, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feagan, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinisch, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niezychowski, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawendy, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodworth, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healey, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, C.</span></span> <span> </span><span class="NLM_article-title">767 Efficacy and Safety of Oral Tofacitinib as Induction Therapy in Patients with Moderate to Severe Ulcerative Colitis: Results from Two Phase 3 Randomized Controlled Trials</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">S157</span>, <span class="refDoi"> DOI: 10.1016/S0016-5085(16)30622-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1016%2FS0016-5085%2816%2930622-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2016&pages=S157&author=W.+Sandbornauthor=B.+E.+Sandsauthor=G.+R.+D%E2%80%99Haensauthor=S.+Vermeireauthor=S.+Schreiberauthor=S.+Daneseauthor=J.+Pan%C3%A9sauthor=B.+G.+Feaganauthor=W.+Reinischauthor=W.+Niezychowskiauthor=G.+Friedmanauthor=N.+Lawendyauthor=D.+Yuauthor=D.+A.+Woodworthauthor=A.+Mukherjeeauthor=P.+J.+Healeyauthor=H.+Zhangauthor=C.+Su&title=767+Efficacy+and+Safety+of+Oral+Tofacitinib+as+Induction+Therapy+in+Patients+with+Moderate+to+Severe+Ulcerative+Colitis%3A+Results+from+Two+Phase+3+Randomized+Controlled+Trials&doi=10.1016%2FS0016-5085%2816%2930622-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS0016-5085%2816%2930622-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0016-5085%252816%252930622-9%26sid%3Dliteratum%253Aachs%26aulast%3DSandborn%26aufirst%3DW.%26aulast%3DSands%26aufirst%3DB.%2BE.%26aulast%3DD%25E2%2580%2599Haens%26aufirst%3DG.%2BR.%26aulast%3DVermeire%26aufirst%3DS.%26aulast%3DSchreiber%26aufirst%3DS.%26aulast%3DDanese%26aufirst%3DS.%26aulast%3DPan%25C3%25A9s%26aufirst%3DJ.%26aulast%3DFeagan%26aufirst%3DB.%2BG.%26aulast%3DReinisch%26aufirst%3DW.%26aulast%3DNiezychowski%26aufirst%3DW.%26aulast%3DFriedman%26aufirst%3DG.%26aulast%3DLawendy%26aufirst%3DN.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DWoodworth%26aufirst%3DD.%2BA.%26aulast%3DMukherjee%26aufirst%3DA.%26aulast%3DHealey%26aufirst%3DP.%2BJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DSu%26aufirst%3DC.%26atitle%3D767%2520Efficacy%2520and%2520Safety%2520of%2520Oral%2520Tofacitinib%2520as%2520Induction%2520Therapy%2520in%2520Patients%2520with%2520Moderate%2520to%2520Severe%2520Ulcerative%2520Colitis%253A%2520Results%2520from%2520Two%2520Phase%25203%2520Randomized%2520Controlled%2520Trials%26jtitle%3DGastroenterology%26date%3D2016%26volume%3D150%26spage%3DS157%26doi%3D10.1016%2FS0016-5085%2816%2930622-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sandborn, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vranic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niezychowski, W.</span></span> <span> </span><span class="NLM_article-title">Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">616</span>– <span class="NLM_lpage">624</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1112168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1056%2FNEJMoa1112168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=22894574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Chu77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=616-624&author=W.+J.+Sandbornauthor=S.+Ghoshauthor=J.+Panesauthor=I.+Vranicauthor=C.+Suauthor=S.+Rousellauthor=W.+Niezychowski&title=Tofacitinib%2C+an+Oral+Janus+Kinase+Inhibitor%2C+in+Active+Ulcerative+Colitis&doi=10.1056%2FNEJMoa1112168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis</span></div><div class="casAuthors">Sandborn, William J.; Ghosh, Subrata; Panes, Julian; Vranic, Ivana; Su, Chinyu; Rousell, Samantha; Niezychowski, Wojciech</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">616-624</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Ulcerative colitis is a chronic inflammatory disease of the colon for which current treatments are not universally effective.  One addnl. treatment may be tofacitinib (CP-690,550), an oral inhibitor of Janus kinases 1, 2, and 3 with in vitro functional specificity for kinases 1 and 3 over kinase 2, which is expected to block signaling involving gamma chain-contg. cytokines including interleukins 2, 4, 7, 9, 15, and 21.  These cytokines are integral to lymphocyte activation, function, and proliferation.  Methods: In a double-blind, placebo-controlled, phase 2 trial, we evaluated the efficacy of tofacitinib in 194 adults with moderately to severely active ulcerative colitis.  Patients were randomly assigned to receive tofacitinib at a dose of 0.5 mg, 3 mg, 10 mg, or 15 mg or placebo twice daily for 8 wk.  The primary outcome was a clin. response at 8 wk, defined as an abs. decrease from baseline in the score on the Mayo scoring system for assessment of ulcerative colitis activity (possible score, 0 to 12, with higher scores indicating more severe disease) of 3 or more and a relative decrease from baseline of 30% or more with an accompanying decrease in the rectal bleeding subscore of 1 point or more or an abs. rectal bleeding subscore of 0 or 1.  Results: The primary outcome, clin. response at 8 wk, occurred in 32%, 48%, 61%, and 78% of patients receiving tofacitinib at a dose of 0.5 mg (P = 0.39), 3 mg (P = 0.55), 10 mg (P = 0.10), and 15 mg (P<0.001), resp., as compared with 42% of patients receiving placebo.  Clin. remission (defined as a Mayo score ≤2, with no subscore >1) at 8 wk occurred in 13%, 33%, 48%, and 41% of patients receiving tofacitinib at a dose of 0.5 mg (P = 0.76), 3 mg (P = 0.01), 10 mg (P<0.001), and 15 mg (P<0.001), resp., as compared with 10% of patients receiving placebo.  There was a dose-dependent increase in both low-d. and high-d. lipoprotein cholesterol.  Three patients treated with tofacitinib had an abs. neutrophil count of less than 1500.  Conclusions: Patients with moderately to severely active ulcerative colitis treated with tofacitinib were more likely to have clin. response and remission than those receiving placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ_Al47Ev_6rVg90H21EOLACvtfcHk0lj4QOod6pJJRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Chu77K&md5=1ae8898c6de9bd24113b1f0a8e7fbed8</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1112168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1112168%26sid%3Dliteratum%253Aachs%26aulast%3DSandborn%26aufirst%3DW.%2BJ.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DPanes%26aufirst%3DJ.%26aulast%3DVranic%26aufirst%3DI.%26aulast%3DSu%26aufirst%3DC.%26aulast%3DRousell%26aufirst%3DS.%26aulast%3DNiezychowski%26aufirst%3DW.%26atitle%3DTofacitinib%252C%2520an%2520Oral%2520Janus%2520Kinase%2520Inhibitor%252C%2520in%2520Active%2520Ulcerative%2520Colitis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D616%26epage%3D624%26doi%3D10.1056%2FNEJMoa1112168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sandborn, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vranic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niezychowski, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Study, A. I.</span></span> <span> </span><span class="NLM_article-title">A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Crohn’s Disease</span>. <i>Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1485</span>– <span class="NLM_lpage">1493</span>, <span class="refDoi"> DOI: 10.1016/j.cgh.2014.01.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1016%2Fj.cgh.2014.01.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=24480677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A280%3ADC%252BC2cvgsFygtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=1485-1493&author=W.+J.+Sandbornauthor=S.+Ghoshauthor=J.+Panesauthor=I.+Vranicauthor=W.+Wangauthor=W.+Niezychowskiauthor=A.+I.+Study&title=A+Phase+2+Study+of+Tofacitinib%2C+an+Oral+Janus+Kinase+Inhibitor%2C+in+Patients+with+Crohn%E2%80%99s+Disease&doi=10.1016%2Fj.cgh.2014.01.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease</span></div><div class="casAuthors">Sandborn William J; Ghosh Subrata; Panes Julian; Vranic Ivana; Wang Wenjin; Niezychowski Wojciech</div><div class="citationInfo"><span class="NLM_cas:title">Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1485-93.e2</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND & AIMS:  Tofacitinib, an orally administered Janus kinase inhibitor, blocks signaling through γ-chain-containing cytokines (interleukins 2, 4, 7, 9, 15, and 21).  We performed a phase 2 trial to measure its efficacy in patients with moderate-to-severe active Crohn's disease.  METHODS:  Patients (N = 139; age, ≥18 y) with moderate-to-severe active Crohn's disease were assigned randomly to groups given 1 mg (n = 36), 5 mg (n = 34), or 15 mg (n = 35) tofacitinib or placebo (n = 34), twice daily for 4 weeks, at 48 centers in 12 countries.  The primary end point was the proportion of clinical responders at week 4 (decrease from baseline in the Crohn's Disease Activity Index score of ≥70 points [Response-70]).  Secondary end points included clinical remission (Crohn's Disease Activity Index score of <150 points) at week 4.  RESULTS:  A clinical response was observed in 36% (P = .467), 58% (P = .466), and 46% (P ≥ .999) of patients given the 1-, 5-, and 15-mg doses of tofacitinib, compared with 47% of patients given placebo.  Clinical remission was observed in 31% (P = .417), 24% (P = .776), and 14% (P = .540) of patients given the 1-, 5-, and 15-mg doses of tofacitinib, compared with 21% of patients given placebo.  The 15-mg dose of tofacitinib reduced levels of C-reactive protein and fecal calprotectin from baseline.  Adverse and serious adverse events were similar among groups.  Dose-dependent increases in low- and high-density lipoprotein cholesterol were observed in patients given the 5- or 15-mg doses of tofacitinib.  CONCLUSIONS:  There were no significant differences in the percentage of patients with moderate-to-severe active Crohn's disease who achieved clinical responses (Response-70) or clinical remission after 4 weeks' administration of tofacitinib (1, 5, or 15 mg) or placebo twice daily.  However, a large percentage of patients given placebo achieved Response-70 or remission.  Reductions in C-reactive protein and fecal calprotectin levels among patients given the 15-mg dose of tofacitinib indicate its biologic activity.  ClinicalTrials.gov number: NCT00615199.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQXZWWuvyNAp2LFM_lbR1VmfW6udTcc2eZDhgmGLTlwfbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cvgsFygtw%253D%253D&md5=b1dffa1b3a6f78760025787651d32e80</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.cgh.2014.01.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cgh.2014.01.029%26sid%3Dliteratum%253Aachs%26aulast%3DSandborn%26aufirst%3DW.%2BJ.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DPanes%26aufirst%3DJ.%26aulast%3DVranic%26aufirst%3DI.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DNiezychowski%26aufirst%3DW.%26aulast%3DStudy%26aufirst%3DA.%2BI.%26atitle%3DA%2520Phase%25202%2520Study%2520of%2520Tofacitinib%252C%2520an%2520Oral%2520Janus%2520Kinase%2520Inhibitor%252C%2520in%2520Patients%2520with%2520Crohn%25E2%2580%2599s%2520Disease%26jtitle%3DClinical%2520gastroenterology%2520and%2520hepatology%253A%2520the%2520official%2520clinical%2520practice%2520journal%2520of%2520the%2520American%2520Gastroenterological%2520Association%26date%3D2014%26volume%3D12%26spage%3D1485%26epage%3D1493%26doi%3D10.1016%2Fj.cgh.2014.01.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menet, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Lommen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geney, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanc, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smits, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouannigot, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deprez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Aar, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clement-Lacroix, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepescheux, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galien, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vayssiere, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelles, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christophe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brys, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhring, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciesielski, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Rompaey, L.</span></span> <span> </span><span class="NLM_article-title">Triazolopyridines as Selective Jak1 Inhibitors: From Hit Identification to Glpg0634</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">9323</span>– <span class="NLM_lpage">9342</span>, <span class="refDoi"> DOI: 10.1021/jm501262q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501262q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGls7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=9323-9342&author=C.+J.+Menetauthor=S.+R.+Fletcherauthor=G.+Van+Lommenauthor=R.+Geneyauthor=J.+Blancauthor=K.+Smitsauthor=N.+Jouannigotauthor=P.+Deprezauthor=E.+M.+van+der%0AAarauthor=P.+Clement-Lacroixauthor=L.+Lepescheuxauthor=R.+Galienauthor=B.+Vayssiereauthor=L.+Nellesauthor=T.+Christopheauthor=R.+Brysauthor=M.+Uhringauthor=F.+Ciesielskiauthor=L.+Van+Rompaey&title=Triazolopyridines+as+Selective+Jak1+Inhibitors%3A+From+Hit+Identification+to+Glpg0634&doi=10.1021%2Fjm501262q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634</span></div><div class="casAuthors">Menet, Christel J.; Fletcher, Stephen R.; Van Lommen, Guy; Geney, Raphael; Blanc, Javier; Smits, Koen; Jouannigot, Nolwenn; Deprez, Pierre; van der Aar, Ellen M.; Clement-Lacroix, Philippe; Lepescheux, Lien; Galien, Rene; Vayssiere, Beatrice; Nelles, Luc; Christophe, Thierry; Brys, Reginald; Uhring, Muriel; Ciesielski, Fabrice; Van Rompaey, Luc</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9323-9342</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Janus kinases (JAK1, JAK2, JAK3, and TYK2) are involved in the signaling of multiple cytokines important in cellular function.  Blockade of the JAK-STAT pathway with a small mol. has been shown to provide therapeutic immunomodulation.  Having identified JAK1 as a possible new target for arthritis at Galapagos, the compd. library was screened against JAK1, resulting in the identification of a triazolopyridine-based series of inhibitors represented by I.  Optimization within this chem. series led to identification of II (GLPG0634, filgotinib), a selective JAK1 inhibitor currently in phase 2B development for RA and phase 2A development for Crohn's disease (CD).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBHELw4zQ5QLVg90H21EOLACvtfcHk0lhnu6qOc-SLYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGls7nN&md5=756f687dc30e6fd34004deb672fe8b23</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm501262q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501262q%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%26aulast%3DFletcher%26aufirst%3DS.%2BR.%26aulast%3DVan%2BLommen%26aufirst%3DG.%26aulast%3DGeney%26aufirst%3DR.%26aulast%3DBlanc%26aufirst%3DJ.%26aulast%3DSmits%26aufirst%3DK.%26aulast%3DJouannigot%26aufirst%3DN.%26aulast%3DDeprez%26aufirst%3DP.%26aulast%3Dvan%2Bder%2BAar%26aufirst%3DE.%2BM.%26aulast%3DClement-Lacroix%26aufirst%3DP.%26aulast%3DLepescheux%26aufirst%3DL.%26aulast%3DGalien%26aufirst%3DR.%26aulast%3DVayssiere%26aufirst%3DB.%26aulast%3DNelles%26aufirst%3DL.%26aulast%3DChristophe%26aufirst%3DT.%26aulast%3DBrys%26aufirst%3DR.%26aulast%3DUhring%26aufirst%3DM.%26aulast%3DCiesielski%26aufirst%3DF.%26aulast%3DVan%2BRompaey%26aufirst%3DL.%26atitle%3DTriazolopyridines%2520as%2520Selective%2520Jak1%2520Inhibitors%253A%2520From%2520Hit%2520Identification%2520to%2520Glpg0634%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D9323%26epage%3D9342%26doi%3D10.1021%2Fjm501262q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloom, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breedveld, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coombs, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruben, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnaswami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgos-Vargas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zerbini, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwillich, S. H.</span></span> <span> </span><span class="NLM_article-title">The Safety and Efficacy of a Jak Inhibitor in Patients with Active Rheumatoid Arthritis: Results of a Double-Blind, Placebo-Controlled Phase Iia Trial of Three Dosage Levels of Cp-690,550 Versus Placebo</span>. <i>Arthritis Rheum.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1895</span>– <span class="NLM_lpage">1905</span>, <span class="refDoi"> DOI: 10.1002/art.24567</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1002%2Fart.24567" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=19565475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptlKktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=1895-1905&author=J.+M.+Kremerauthor=B.+J.+Bloomauthor=F.+C.+Breedveldauthor=J.+H.+Coombsauthor=M.+P.+Fletcherauthor=D.+Grubenauthor=S.+Krishnaswamiauthor=R.+Burgos-Vargasauthor=B.+Wilkinsonauthor=C.+A.+Zerbiniauthor=S.+H.+Zwillich&title=The+Safety+and+Efficacy+of+a+Jak+Inhibitor+in+Patients+with+Active+Rheumatoid+Arthritis%3A+Results+of+a+Double-Blind%2C+Placebo-Controlled+Phase+Iia+Trial+of+Three+Dosage+Levels+of+Cp-690%2C550+Versus+Placebo&doi=10.1002%2Fart.24567"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo</span></div><div class="casAuthors">Kremer, Joel M.; Bloom, Bradley J.; Breedveld, Ferdinand C.; Coombs, John H.; Fletcher, Mark P.; Gruben, David; Krishnaswami, Sriram; Burgos-Vargas, Ruben; Wilkinson, Bethanie; Zerbini, Cristiano A. F.; Zwillich, Samuel H.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1895-1905</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">To det. the efficacy, safety, and tolerability of 3 different dosages of CP-690,550, a potent, orally active JAK inhibitor, in patients with active rheumatoid arthritis (RA) in whom methotrexate, etanercept, infliximab, or adalimumab caused an inadequate or toxic response.  Patients (n = 264) were randomized equally to receive placebo, 5 mg of CP-690,550,15 mg of CP-690,550, or 30 mg of CP-690,550 twice daily for 6 wk, and were followed up for an addnl. 6 wk after treatment.  The primary efficacy end point was the American College of Rheumatol. 20% improvement criteria (ACR20) response rate at 6 wk.  By week 6, the ACR20 response rates were 70.5%, 81.2%, and 76.8% in the 5 mg, 15 mg, and 30 mg twice daily groups, resp., compared with 29.2% in the placebo group (P < 0.001).  Improvements in disease activity in CP-690,550-treated patients compared with placebo were seen in all treatment groups as early as week 1.  ACR50 and ACR70 response rates significantly improved in all treatment groups by week 4.  The most common adverse events reported were headache and nausea.  The infection rate in both the 15 mg twice daily group and the 30 mg twice daily group was 30.4% (vs. 26.2% in the placebo group).  No opportunistic infections or deaths occurred.  Increases in mean low-d. lipoprotein cholesterol and high-d. lipoprotein cholesterol levels, and increases in mean serum creatinine level (0.04-0.06 mg/dL) were seen in all CP-690,550 treatment arms.  Our findings indicate that CP-690,550 is efficacious in the treatment of RA, resulting in rapid, statistically significant, and clin. meaningful redns. in the signs and symptoms of RA.  Further studies of CP-690,550 in RA are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBhxBhh_mG7rVg90H21EOLACvtfcHk0lhnu6qOc-SLYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptlKktLg%253D&md5=ab5fb34e43d8643871560c67bbbca07d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fart.24567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.24567%26sid%3Dliteratum%253Aachs%26aulast%3DKremer%26aufirst%3DJ.%2BM.%26aulast%3DBloom%26aufirst%3DB.%2BJ.%26aulast%3DBreedveld%26aufirst%3DF.%2BC.%26aulast%3DCoombs%26aufirst%3DJ.%2BH.%26aulast%3DFletcher%26aufirst%3DM.%2BP.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DBurgos-Vargas%26aufirst%3DR.%26aulast%3DWilkinson%26aufirst%3DB.%26aulast%3DZerbini%26aufirst%3DC.%2BA.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26atitle%3DThe%2520Safety%2520and%2520Efficacy%2520of%2520a%2520Jak%2520Inhibitor%2520in%2520Patients%2520with%2520Active%2520Rheumatoid%2520Arthritis%253A%2520Results%2520of%2520a%2520Double-Blind%252C%2520Placebo-Controlled%2520Phase%2520Iia%2520Trial%2520of%2520Three%2520Dosage%2520Levels%2520of%2520Cp-690%252C550%2520Versus%2520Placebo%26jtitle%3DArthritis%2520Rheum.%26date%3D2009%26volume%3D60%26spage%3D1895%26epage%3D1905%26doi%3D10.1002%2Fart.24567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, O. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidelin, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ainsworth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coskun, M.</span></span> <span> </span><span class="NLM_article-title">Will Novel Oral Formulations Change the Management of Inflammatory Bowel Disease?</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">718</span>, <span class="refDoi"> DOI: 10.1517/13543784.2016.1165204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1517%2F13543784.2016.1165204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=26967267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvFGqs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2016&pages=709-718&author=O.+H.+Nielsenauthor=J.+B.+Seidelinauthor=M.+Ainsworthauthor=M.+Coskun&title=Will+Novel+Oral+Formulations+Change+the+Management+of+Inflammatory+Bowel+Disease%3F&doi=10.1517%2F13543784.2016.1165204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Will novel oral formulations change the management of inflammatory bowel disease?</span></div><div class="casAuthors">Nielsen, Ole Haagen; Seidelin, Jakob Benedict; Ainsworth, Mark; Coskun, Mehmet</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">709-718</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The traditional management of inflammatory bowel disease (IBD) with sulphasalazine/5-aminosalicylic acid, glucocorticoids and immunomodulators (i.e., thiopurines and methotrexate) was nearly two decades ago extended with i.v. or s.c. administered biologics (i.e., tumor necrosis factor inhibitors and later gut-selective integrin antagonists).  However, recently, orally administered treatments with simple, well-characterized, and stable structures consisting of either small mols. or anti-sense therapy have been devised.  This review discusses the current approaches with promising new oral drugs with distinct modes of action, including: the Janus kinase inhibitors (i.e., tofacitinib, filgotinib and peficitinib); the immunomodulatory drug (laquinimod); a small α4 antagonist (AJM300); agonists for sphingosine-phosphate receptors (i.e., ozanimod, APD334, and amiselimod), as well as anti-sense therapy (mongersen) targeting SMAD7, drugs which directly target intracellular pathways of relevance for intestinal inflammation.  A new avenue using easily administered oral therapies for the management of IBD is being introduced.  While their place in the clin. armamentarium remains to be proven, it is likely that many of these drugs will find their place in the treatment algorithm of IBD in the next few years.  Thus, we will face times in which IBD therapy will be based on significantly more tablets than prescribed today.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp53hEx6x0XvbVg90H21EOLACvtfcHk0ljEsyqo4x2jSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvFGqs7Y%253D&md5=35fb0a1717d67eff029d7e5f51354cce</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1517%2F13543784.2016.1165204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2016.1165204%26sid%3Dliteratum%253Aachs%26aulast%3DNielsen%26aufirst%3DO.%2BH.%26aulast%3DSeidelin%26aufirst%3DJ.%2BB.%26aulast%3DAinsworth%26aufirst%3DM.%26aulast%3DCoskun%26aufirst%3DM.%26atitle%3DWill%2520Novel%2520Oral%2520Formulations%2520Change%2520the%2520Management%2520of%2520Inflammatory%2520Bowel%2520Disease%253F%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2016%26volume%3D25%26spage%3D709%26epage%3D718%26doi%3D10.1517%2F13543784.2016.1165204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">USFDA</span>. <span> </span><span class="NLM_article-title">FDA Approves Boxed Warning About
Increased Risk
of Blood Clots and Death with Higher Dose of Arthritis and Ulcerative
Colitis Medicine Tofacitinib (Xeljanz, Xeljanz Xr)</span>. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and" class="extLink">https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=USFDA.+FDA+Approves+Boxed+Warning+About%0AIncreased+Risk%0Aof+Blood+Clots+and+Death+with+Higher+Dose+of+Arthritis+and+Ulcerative%0AColitis+Medicine+Tofacitinib+%28Xeljanz%2C+Xeljanz+Xr%29.+https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-safety-and-availability%2Ffda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DFDA%2520Approves%2520Boxed%2520Warning%2520About%250AIncreased%2520Risk%250Aof%2520Blood%2520Clots%2520and%2520Death%2520with%2520Higher%2520Dose%2520of%2520Arthritis%2520and%2520Ulcerative%250AColitis%2520Medicine%2520Tofacitinib%2520%2528Xeljanz%252C%2520Xeljanz%2520Xr%2529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">USFDA</span>. <span> </span><span class="NLM_article-title">Upadacitinib Prescribing Information</span>. <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=USFDA.+Upadacitinib+Prescribing+Information.+https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F211675s000lbl.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DUpadacitinib%2520Prescribing%2520Information" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Filipski, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varma, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kattan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambler, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goosen, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, K. O.</span></span> <span> </span><span class="NLM_article-title">Intestinal Targeting of Drugs: Rational Design Approaches and Challenges</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">776</span>– <span class="NLM_lpage">802</span>, <span class="refDoi"> DOI: 10.2174/1568026611313070002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.2174%2F1568026611313070002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=23578023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpsVaqt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=776-802&author=K.+J.+Filipskiauthor=M.+V.+Varmaauthor=A.+F.+El-Kattanauthor=C.+M.+Amblerauthor=R.+B.+Ruggeriauthor=T.+C.+Goosenauthor=K.+O.+Cameron&title=Intestinal+Targeting+of+Drugs%3A+Rational+Design+Approaches+and+Challenges&doi=10.2174%2F1568026611313070002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinal targeting of drugs: rational design approaches and challenges</span></div><div class="casAuthors">Filipski, Kevin J.; Varma, Manthena V.; El-Kattan, Ayman F.; Ambler, Catherine M.; Ruggeri, Roger B.; Goosen, Theunis C.; Cameron, Kimberly O.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">776-802</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Targeting drugs to the gastrointestinal tract has been and continues to be an active area of research.  Guttargeting is an effective means of increasing the local concn. of active substance at the desired site of action while minimizing concns. elsewhere in the body that could lead to unwanted side-effects.  Several approaches to intestinal targeting exist.  Physicochem. property manipulation can drive mols. to large, polar, low absorption space or alternatively to lipophilic, high clearance space in order to minimize systemic exposure.  Design of compds. that are substrates for transporters within the gastrointestinal tract, either uptake or efflux, or at the hepato-biliary interface, may help to increase intestinal concn.  Prodrug strategies have been shown to be effective particularly for colon targeting, and several different technol. formulation approaches are currently being researched.  This review provides examples of various approaches to intestinal targeting, and discusses challenges and areas in need of future scientific advances.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn5CowmF-p-LVg90H21EOLACvtfcHk0ljEsyqo4x2jSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpsVaqt7w%253D&md5=b950400c76b8d955ebd39e6cad4a20aa</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.2174%2F1568026611313070002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026611313070002%26sid%3Dliteratum%253Aachs%26aulast%3DFilipski%26aufirst%3DK.%2BJ.%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DEl-Kattan%26aufirst%3DA.%2BF.%26aulast%3DAmbler%26aufirst%3DC.%2BM.%26aulast%3DRuggeri%26aufirst%3DR.%2BB.%26aulast%3DGoosen%26aufirst%3DT.%2BC.%26aulast%3DCameron%26aufirst%3DK.%2BO.%26atitle%3DIntestinal%2520Targeting%2520of%2520Drugs%253A%2520Rational%2520Design%2520Approaches%2520and%2520Challenges%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D776%26epage%3D802%26doi%3D10.2174%2F1568026611313070002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menees, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maneerattannaporn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chey, W. D.</span></span> <span> </span><span class="NLM_article-title">The Efficacy and Safety of Rifaximin for the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis</span>. <i>Am. J. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.1038/ajg.2011.355</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1038%2Fajg.2011.355" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=22045120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADC%252BC38XkslOmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2012&pages=28-35&author=S.+B.+Meneesauthor=M.+Maneerattannapornauthor=H.+M.+Kimauthor=W.+D.+Chey&title=The+Efficacy+and+Safety+of+Rifaximin+for+the+Irritable+Bowel+Syndrome%3A+A+Systematic+Review+and+Meta-Analysis&doi=10.1038%2Fajg.2011.355"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The Efficacy and Safety of Rifaximin for the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis</span></div><div class="casAuthors">Menees, Stacy B.; Maneerattannaporn, Monthira; Kim, Hyungjin Myra; Chey, William D.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-35</span>CODEN:
                <span class="NLM_cas:coden">AJGAAR</span>;
        ISSN:<span class="NLM_cas:issn">0002-9270</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">OBJECTIVES: Irritable bowel syndrome (IBS) affects 10-15% of the population, and treatment options are limited.  Rifaximin is a minimally absorbed antibiotic that has shown efficacy in IBS patients.  The objective of our study was to perform a meta-anal. and systematic review of available randomized, placebo controlled trials evaluating the efficacy and tolerability of rifaximin in patients with IBS.  METHODS: We performed a systematic literature search of multiple online electronic databases regardless of language.  Inclusion criteria entailed randomized, placebo controlled trials and IBS defined by accepted symptom-based criteria.  Meta-anal. was conducted to evaluate the summary odds ratios (ORs) and 95% confidence intervals (CIs) of combined studies for the primary and secondary outcomes using a random-effects model based on the DerSimonian and Laird method to reflect both within- and between study variability.  We assessed heterogeneity using χ2 test and the inconsistency index statistic (I2).  Significant heterogeneity was defined as I2 ≥25%.  Meta-regression was performed using generalized linear mixed-effects model and study as random effects to est. the summary OR adjusting for covariate differences across studies and treatment group.  Publication bias was assessed by funnel plot anal.  RESULTS: Systematic review identified 13,700 citations.  Eighteen were deemed to be potentially relevant, of which five articles met eligibility.  Meta-anal. found rifaximin to be more efficacious than placebo for global IBS symptom improvement (OR=1.57; 95% CI=1.22, 2.01; therapeutic gain=9.8%; no. needed to treat (NNT)=10.2), with mild heterogeneity (P=0.25, I2=26%).  For the key secondary outcome of bloating, raw data were available for four studies.  Rifaximin was significantly more likely to improve bloating than placebo (OR=1.55; 95% CI=1.23-1.96; therapeutic gain=9.9%; NNT=10.1), with no significant heterogeneity (P=0.27, I2=23%).  We found that studies with older patients and more females demonstrated higher response rates, which was consistent regardless of treatment group.  In addn., studies with higher cumulative dose tended to report a higher response rate.  Of the covariates evaluated, we found age to be most predictive of response, with a correlation coeff. of 0.97 between aggregate response rate and mean age in the placebo groups.  Although studies with higher cumulative dose tended to show increased response rates, this was also seen consistently in both the treated and placebo groups.  Adverse effects were similar among patients receiving rifaximin or placebo in all studies.  The most common adverse events (AEs) (≤10%) with rifaximin were headache, upper respiratory infection, nausea, nasopharygitis, diarrhea, and abdominal pain.  Serious AEs were rare (<1%) and similar with rifaximin and placebo.  CONCLUSIONS: Rifaximin proved more effective than placebo for global symptoms and bloating in IBS patients.  The modest therapeutic gain was similar to that yielded by other currently available therapies for IBS.  AEs were similar between rifaximin and placebo.  Am J Gastroenterol 2012; 107:28-35; doi:10.1038/ajg.2011.355; published online 1 Nov. 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBt5S9T_Bj2LVg90H21EOLACvtfcHk0lhB6y2uFOrx8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkslOmsg%253D%253D&md5=b74dd80328ed42f815c5152144f0df52</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fajg.2011.355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fajg.2011.355%26sid%3Dliteratum%253Aachs%26aulast%3DMenees%26aufirst%3DS.%2BB.%26aulast%3DManeerattannaporn%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DH.%2BM.%26aulast%3DChey%26aufirst%3DW.%2BD.%26atitle%3DThe%2520Efficacy%2520and%2520Safety%2520of%2520Rifaximin%2520for%2520the%2520Irritable%2520Bowel%2520Syndrome%253A%2520A%2520Systematic%2520Review%2520and%2520Meta-Analysis%26jtitle%3DAm.%2520J.%2520Gastroenterol.%26date%3D2012%26volume%3D107%26spage%3D28%26epage%3D35%26doi%3D10.1038%2Fajg.2011.355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez-Roque, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouras, E. P.</span></span> <span> </span><span class="NLM_article-title">Linaclotide, Novel Therapy for the Treatment of Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome</span>. <i>Adv. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">211</span>, <span class="refDoi"> DOI: 10.1007/s12325-013-0012-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1007%2Fs12325-013-0012-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=23436110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksFegsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2013&pages=203-211&author=M.+I.+Vazquez-Roqueauthor=E.+P.+Bouras&title=Linaclotide%2C+Novel+Therapy+for+the+Treatment+of+Chronic+Idiopathic+Constipation+and+Constipation-Predominant+Irritable+Bowel+Syndrome&doi=10.1007%2Fs12325-013-0012-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Linaclotide, Novel Therapy for the Treatment of Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome</span></div><div class="casAuthors">Vazquez-Roque, Maria I.; Bouras, Ernest P.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">203-211</span>CODEN:
                <span class="NLM_cas:coden">ADTHE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-238X</span>.
    
            (<span class="NLM_cas:orgname">Springer Healthcare Ltd.</span>)
        </div><div class="casAbstract">A review.  Chronic constipation (CC) and irritable bowel syndrome with constipation (IBS-C) are common gastrointestinal (GI) disorders.  Current treatment options, either prescription or nonprescription medications, have limited efficacy in a subset of patients.  There is significant demand for more efficacious medications for the treatment of CC and IBS-C.  Linaclotide, a secretagogue, has a novel mechanism of action designed to treat patients with CC and IBS-C.  It has a low oral bioavailability with negligible systemic side effects, and it acts locally in the intestinal lumen.  In several clin. trials, in health and disease, linaclotide has demonstrated durable efficacy and safety in CC and IBS-C.  Linaclotide received approval by the Federal Drug Administration in August 2012 to treat chronic idiopathic constipation and IBS-C.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogNjGesknmN7Vg90H21EOLACvtfcHk0lhB6y2uFOrx8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksFegsLg%253D&md5=33bc79f667f537b2594f171db26501e5</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2Fs12325-013-0012-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12325-013-0012-9%26sid%3Dliteratum%253Aachs%26aulast%3DVazquez-Roque%26aufirst%3DM.%2BI.%26aulast%3DBouras%26aufirst%3DE.%2BP.%26atitle%3DLinaclotide%252C%2520Novel%2520Therapy%2520for%2520the%2520Treatment%2520of%2520Chronic%2520Idiopathic%2520Constipation%2520and%2520Constipation-Predominant%2520Irritable%2520Bowel%2520Syndrome%26jtitle%3DAdv.%2520Ther.%26date%3D2013%26volume%3D30%26spage%3D203%26epage%3D211%26doi%3D10.1007%2Fs12325-013-0012-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowtle, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryden, R.</span></span> <span> </span><span class="NLM_article-title">Disposition of Vancomycin in Healthy Volunteers from Oral Solution and Semi-Solid Matrix Capsules</span>. <i>Journal of clinical pharmacy and therapeutics</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2710.1976.tb00415.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1111%2Fj.1365-2710.1976.tb00415.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=3449561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADyaL2sXkvVekt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1987&pages=27-31&author=R.+A.+Lucasauthor=W.+J.+Bowtleauthor=R.+Ryden&title=Disposition+of+Vancomycin+in+Healthy+Volunteers+from+Oral+Solution+and+Semi-Solid+Matrix+Capsules&doi=10.1111%2Fj.1365-2710.1976.tb00415.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Disposition of vancomycin in healthy volunteers from oral solution and semi-solid matrix capsules</span></div><div class="casAuthors">Lucas, R. A.; Bowtle, W. J.; Ryden, R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacy and Therapeutics</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-31</span>CODEN:
                <span class="NLM_cas:coden">JCPTED</span>;
        ISSN:<span class="NLM_cas:issn">0269-4727</span>.
    </div><div class="casAbstract">Gastrointestinal availability of vancomycin from oral soln. and semi-solid matrix capsules was detd. in volunteers.  The capsule produced fecal, plasma and urine levels of the antibiotic which are similar to those obtained with the soln., and offers a viable, convenient oral dosage form.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjM31rDkBVBrVg90H21EOLACvtfcHk0lj8mTPz5qfVUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXkvVekt7k%253D&md5=53c0ee15682856c500f73962c95f7b9f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2710.1976.tb00415.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2710.1976.tb00415.x%26sid%3Dliteratum%253Aachs%26aulast%3DLucas%26aufirst%3DR.%2BA.%26aulast%3DBowtle%26aufirst%3DW.%2BJ.%26aulast%3DRyden%26aufirst%3DR.%26atitle%3DDisposition%2520of%2520Vancomycin%2520in%2520Healthy%2520Volunteers%2520from%2520Oral%2520Solution%2520and%2520Semi-Solid%2520Matrix%2520Capsules%26jtitle%3DJournal%2520of%2520clinical%2520pharmacy%2520and%2520therapeutics%26date%3D1987%26volume%3D12%26spage%3D27%26epage%3D31%26doi%3D10.1111%2Fj.1365-2710.1976.tb00415.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pastan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottesman, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovelace, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutherford, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willingham, M. C.</span></span> <span> </span><span class="NLM_article-title">A Retrovirus Carrying an Mdr1 Cdna Confers Multidrug Resistance and Polarized Expression of P-Glycoprotein in Mdck Cells</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">4486</span>– <span class="NLM_lpage">4490</span>, <span class="refDoi"> DOI: 10.1073/pnas.85.12.4486</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1073%2Fpnas.85.12.4486" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=2898143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADyaL1cXkvVOnsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=1988&pages=4486-4490&author=I.+Pastanauthor=M.+M.+Gottesmanauthor=K.+Uedaauthor=E.+Lovelaceauthor=A.+V.+Rutherfordauthor=M.+C.+Willingham&title=A+Retrovirus+Carrying+an+Mdr1+Cdna+Confers+Multidrug+Resistance+and+Polarized+Expression+of+P-Glycoprotein+in+Mdck+Cells&doi=10.1073%2Fpnas.85.12.4486"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells</span></div><div class="casAuthors">Pastan, Ira; Gottesman, Michael M.; Ueda, Kazumitsu; Lovelace, Elizabeth; Rutherford, Angelina V.; Willingham, Mark C.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4486-90</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">A full-length cDNA for the human multidrug resistance gene 1 (MDR1) has been inserted into a retroviral vector contg. a murine Harvey sarcoma virus from which the viral oncogene was deleted.  Ecotropic and amphotropic virus was produced after transfection of this vector into ψ-2 and PA-12 packaging cell lines.  This virus conferred the full phenotype of multidrug resistance on mouse and human cell lines.  Viral titers of up to 2 × 105 drug-resistant colonies per mL were obsd.  Infected cells became resistant to colchicine, vinblastine, doxorubicin, VP16 (etoposide), and puromycin, but not cisplatin, indicating that the presence of the human MDR1 gene is sufficient to cause multidrug resistance.  When the dog kidney cell line MDCK was infected with the MDR1 virus, P-glycoprotein was expressed in a polarized manner on the upper surface of the cells, showing that the cloned cDNA also encodes information for polarized expression of P-glycoprotein.  The MDR1 virus should be useful for introducing this drug resistance gene into a variety of cell types for biol. expts. in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC3cSVZ7zWEbVg90H21EOLACvtfcHk0lj8mTPz5qfVUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXkvVOnsLw%253D&md5=78e8299b8a21cde221dbb3116dd89288</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1073%2Fpnas.85.12.4486&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.85.12.4486%26sid%3Dliteratum%253Aachs%26aulast%3DPastan%26aufirst%3DI.%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26aulast%3DUeda%26aufirst%3DK.%26aulast%3DLovelace%26aufirst%3DE.%26aulast%3DRutherford%26aufirst%3DA.%2BV.%26aulast%3DWillingham%26aufirst%3DM.%2BC.%26atitle%3DA%2520Retrovirus%2520Carrying%2520an%2520Mdr1%2520Cdna%2520Confers%2520Multidrug%2520Resistance%2520and%2520Polarized%2520Expression%2520of%2520P-Glycoprotein%2520in%2520Mdck%2520Cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1988%26volume%3D85%26spage%3D4486%26epage%3D4490%26doi%3D10.1073%2Fpnas.85.12.4486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Irvine, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolan, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selick, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grove, J. R.</span></span> <span> </span><span class="NLM_article-title">Mdck (Madin-Darby Canine Kidney) Cells: A Tool for Membrane Permeability Screening</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1021/js9803205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1021%2Fjs9803205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=9874698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADyaK1cXns1ylurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=1999&pages=28-33&author=J.+D.+Irvineauthor=L.+Takahashiauthor=K.+Lockhartauthor=J.+Cheongauthor=J.+W.+Tolanauthor=H.+E.+Selickauthor=J.+R.+Grove&title=Mdck+%28Madin-Darby+Canine+Kidney%29+Cells%3A+A+Tool+for+Membrane+Permeability+Screening&doi=10.1021%2Fjs9803205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening</span></div><div class="casAuthors">Irvine, Jennifer D.; Takahashi, Lori; Lockhart, Karen; Cheong, Jonathan; Tolan, John W.; Selick, H. E.; Grove, J. Russell</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-33</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The goal of this work was to investigate the use of MDCK (Madin-Darby canine kidney) cells as a possible tool for assessing the membrane permeability properties of early drug discovery compds.  Apparent permeability (Papp) values of 55 compds. with known human absorption values were detd. using MDCK cell monolayers.  For comparison, Papp values of the same compds. were also detd. using Caco-2 cells, a well-characterized in vitro model of intestinal drug absorption.  Monolayers were grown on 0.4-μm Transwell-COL membrane culture inserts. MDCK cells were seeded at high d. and cultured for 3 days, and Caco-2 cells were cultured under std. conditions for 21 to 25 days.  Compds. were tested using 100 μM donor solns. in transport medium (pH 7.4) contg. 1% DMSO.  The Papp values in MDCK cells correlated well with those in Caco-2 cells (r2 = 0.79). Spearman's rank correlation coeff. for MDCK Papp and human absorption was 0.58 compared with 0.54 for Caco-2 Papp and human absorption.  These results indicate that MDCK cells may be a useful tool for rapid membrane permeability screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolDvo0FQMg7bVg90H21EOLACvtfcHk0liu94LOnlCnmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXns1ylurk%253D&md5=ea421117433fa4067578476edde9444e</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjs9803205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjs9803205%26sid%3Dliteratum%253Aachs%26aulast%3DIrvine%26aufirst%3DJ.%2BD.%26aulast%3DTakahashi%26aufirst%3DL.%26aulast%3DLockhart%26aufirst%3DK.%26aulast%3DCheong%26aufirst%3DJ.%26aulast%3DTolan%26aufirst%3DJ.%2BW.%26aulast%3DSelick%26aufirst%3DH.%2BE.%26aulast%3DGrove%26aufirst%3DJ.%2BR.%26atitle%3DMdck%2520%2528Madin-Darby%2520Canine%2520Kidney%2529%2520Cells%253A%2520A%2520Tool%2520for%2520Membrane%2520Permeability%2520Screening%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D1999%26volume%3D88%26spage%3D28%26epage%3D33%26doi%3D10.1021%2Fjs9803205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thiel-Demby, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St John Williams, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellens, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayrton, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polli, J. W.</span></span> <span> </span><span class="NLM_article-title">Biopharmaceutics Classification System: Validation and Learnings of an in Vitro Permeability Assay</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1021/mp800122b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp800122b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWgt7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=11-18&author=V.+E.+Thiel-Dembyauthor=J.+E.+Humphreysauthor=L.+A.+St+John+Williamsauthor=H.+M.+Ellensauthor=N.+Shahauthor=A.+D.+Ayrtonauthor=J.+W.+Polli&title=Biopharmaceutics+Classification+System%3A+Validation+and+Learnings+of+an+in+Vitro+Permeability+Assay&doi=10.1021%2Fmp800122b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Biopharmaceutics Classification System: Validation and Learnings of an in Vitro Permeability Assay</span></div><div class="casAuthors">Thiel-Demby, Victoria E.; Humphreys, Joan E.; St. John Williams, Lisa A.; Ellens, Harma M.; Shah, Nipa; Ayrton, Andrew D.; Polli, Joseph W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-18</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Biopharmaceutics Classification System (BCS) is the scientific basis for classifying drugs based on their aq. soly. and intestinal permeability that supports in vivo bioavailability and bioequivalence waivers for immediate-release solid dosage form drugs.  One requirement of the BCS is that the permeability method must be validated.  In order to accommodate the variety of in vitro/in situ permeability models, the BCS Guidance gives a general framework for the validation requirements, necessitating implemented exptl. details to be selected by the applicant lab.  The objective of this work was to define the parameters for a cell based in vitro permeability method (e.g., cell type, pH, transport direction, time, and concn.) and validate the method to support formal BCS classification of drugs.  Twenty ref. drugs were selected and permeability values detd. using the Madin-Darby canine kidney type II cell line heterologously expressing the human P-glycoprotein transporter (MDCKII-MDR1).  A rank order relationship was established between the in vitro permeability value and human intestinal absorption values.  This relationship was as predicted and validates the MDCKII-MDR1 permeability method as defined by the BCS Guidance.  The final validated in vitro permeability method employs the MDCKII-MDR1 cell line incubated with the Pgp inhibitor GF120918.  It is a unidirectional apical-to-basolateral transport assay performed at apical pH values of 5.5 and 7.4 and a basolateral pH of 7.4.  Four ref. stds. (metoprolol, pindolol, labetalol and ranitidine) dosed and analyzed as a single cassette are included in each expt.  A strategy on selection of drug concns. and on how to deal with problematic compds. (i.e., those suffering from poor mass balance) is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZBvEmiKWNBLVg90H21EOLACvtfcHk0liu94LOnlCnmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWgt7vN&md5=b630091c50b109c4a4e9e902583f5b38</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fmp800122b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp800122b%26sid%3Dliteratum%253Aachs%26aulast%3DThiel-Demby%26aufirst%3DV.%2BE.%26aulast%3DHumphreys%26aufirst%3DJ.%2BE.%26aulast%3DSt%2BJohn%2BWilliams%26aufirst%3DL.%2BA.%26aulast%3DEllens%26aufirst%3DH.%2BM.%26aulast%3DShah%26aufirst%3DN.%26aulast%3DAyrton%26aufirst%3DA.%2BD.%26aulast%3DPolli%26aufirst%3DJ.%2BW.%26atitle%3DBiopharmaceutics%2520Classification%2520System%253A%2520Validation%2520and%2520Learnings%2520of%2520an%2520in%2520Vitro%2520Permeability%2520Assay%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2009%26volume%3D6%26spage%3D11%26epage%3D18%26doi%3D10.1021%2Fmp800122b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurley, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bull, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarty, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crackett, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVoss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragovich, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellwood, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaines, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gradl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribling, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harstad, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenny, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehler, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bir Kohli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labadie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liimatta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendonca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narukulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeve, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savage, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ubhayakar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Abbema, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliagas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avitabile-Woo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulagowski, J. J.</span></span> <span> </span><span class="NLM_article-title">Identification of C-2 Hydroxyethyl Imidazopyrrolopyridines as Potent Jak1 Inhibitors with Favorable Physicochemical Properties and High Selectivity over Jak2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4764</span>– <span class="NLM_lpage">4785</span>, <span class="refDoi"> DOI: 10.1021/jm4004895</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4004895" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsVWit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4764-4785&author=M.+Zakauthor=C.+A.+Hurleyauthor=S.+I.+Wardauthor=P.+Bergeronauthor=K.+Barrettauthor=M.+Balazsauthor=W.+S.+Blairauthor=R.+Bullauthor=P.+Chakravartyauthor=C.+Changauthor=P.+Crackettauthor=G.+Deshmukhauthor=J.+DeVossauthor=P.+S.+Dragovichauthor=C.+Eigenbrotauthor=C.+Ellwoodauthor=S.+Gainesauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=S.+Gradlauthor=P.+Griblingauthor=C.+Hammanauthor=E.+Harstadauthor=P.+Hewittauthor=A.+Johnsonauthor=T.+Johnsonauthor=J.+R.+Kennyauthor=M.+F.+Koehlerauthor=P.+Bir+Kohliauthor=S.+Labadieauthor=W.+P.+Leeauthor=J.+Liaoauthor=M.+Liimattaauthor=R.+Mendoncaauthor=R.+Narukullaauthor=R.+Pulkauthor=A.+Reeveauthor=S.+Savageauthor=S.+Shiaauthor=M.+Steffekauthor=S.+Ubhayakarauthor=A.+van+Abbemaauthor=I.+Aliagasauthor=B.+Avitabile-Wooauthor=Y.+Xiaoauthor=J.+Yangauthor=J.+J.+Kulagowski&title=Identification+of+C-2+Hydroxyethyl+Imidazopyrrolopyridines+as+Potent+Jak1+Inhibitors+with+Favorable+Physicochemical+Properties+and+High+Selectivity+over+Jak2&doi=10.1021%2Fjm4004895"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of C-2 Hydroxyethyl Imidazopyrrolopyridines as Potent JAK1 Inhibitors with Favorable Physicochemical Properties and High Selectivity over JAK2</span></div><div class="casAuthors">Zak, Mark; Hurley, Christopher A.; Ward, Stuart I.; Bergeron, Philippe; Barrett, Kathy; Balazs, Mercedesz; Blair, Wade S.; Bull, Richard; Chakravarty, Paroma; Chang, Christine; Crackett, Peter; Deshmukh, Gauri; DeVoss, Jason; Dragovich, Peter S.; Eigenbrot, Charles; Ellwood, Charles; Gaines, Simon; Ghilardi, Nico; Gibbons, Paul; Gradl, Stefan; Gribling, Peter; Hamman, Chris; Harstad, Eric; Hewitt, Peter; Johnson, Adam; Johnson, Tony; Kenny, Jane R.; Koehler, Michael F. T.; Bir Kohli, Pawan; Labadie, Sharada; Lee, Wyne P.; Liao, Jiangpeng; Liimatta, Marya; Mendonca, Rohan; Narukulla, Raman; Pulk, Rebecca; Reeve, Austin; Savage, Scott; Shia, Steven; Steffek, Micah; Ubhayakar, Savita; van Abbema, Anne; Aliagas, Ignacio; Avitabile-Woo, Barbara; Xiao, Yisong; Yang, Jing; Kulagowski, Janusz J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4764-4785</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein we report on the structure-based discovery of a C-2 hydroxyethyl moiety which provided consistently high levels of selectivity for JAK1 over JAK2 to the imidazopyrrolopyridine series of JAK1 inhibitors.  X-ray structures of a C-2 hydroxyethyl analog in complex with both JAK1 and JAK2 revealed differential ligand/protein interactions between the two isoforms and offered an explanation for the obsd. selectivity.  Anal. of historical data from related mols. was used to develop a set of physicochem. compd. design parameters to impart desirable properties such as acceptable membrane permeability, potent whole blood activity, and a high degree of metabolic stability.  This work culminated in the identification of a highly JAK1 selective compd. (31) exhibiting favorable oral bioavailability across a range of preclin. species and robust efficacy in a rat CIA model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP0DlLtJCYq7Vg90H21EOLACvtfcHk0lhV0_ywV_FWJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsVWit74%253D&md5=0b0d1950adebf325cc434344f57ca139</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm4004895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4004895%26sid%3Dliteratum%253Aachs%26aulast%3DZak%26aufirst%3DM.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DWard%26aufirst%3DS.%2BI.%26aulast%3DBergeron%26aufirst%3DP.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DBull%26aufirst%3DR.%26aulast%3DChakravarty%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DCrackett%26aufirst%3DP.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DEllwood%26aufirst%3DC.%26aulast%3DGaines%26aufirst%3DS.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DGradl%26aufirst%3DS.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHamman%26aufirst%3DC.%26aulast%3DHarstad%26aufirst%3DE.%26aulast%3DHewitt%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DKoehler%26aufirst%3DM.%2BF.%26aulast%3DBir%2BKohli%26aufirst%3DP.%26aulast%3DLabadie%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DMendonca%26aufirst%3DR.%26aulast%3DNarukulla%26aufirst%3DR.%26aulast%3DPulk%26aufirst%3DR.%26aulast%3DReeve%26aufirst%3DA.%26aulast%3DSavage%26aufirst%3DS.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DSteffek%26aufirst%3DM.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3Dvan%2BAbbema%26aufirst%3DA.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DAvitabile-Woo%26aufirst%3DB.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26atitle%3DIdentification%2520of%2520C-2%2520Hydroxyethyl%2520Imidazopyrrolopyridines%2520as%2520Potent%2520Jak1%2520Inhibitors%2520with%2520Favorable%2520Physicochemical%2520Properties%2520and%2520High%2520Selectivity%2520over%2520Jak2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4764%26epage%3D4785%26doi%3D10.1021%2Fjm4004895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominy, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feeney, P. J.</span></span> <span> </span><span class="NLM_article-title">Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/S0169-409X(00)00129-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1016%2FS0169-409X%2800%2900129-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=11259830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitVOhs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2001&pages=3-26&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+Computational+Approaches+to+Estimate+Solubility+and+Permeability+in+Drug+Discovery+and+Development+Settings&doi=10.1016%2FS0169-409X%2800%2900129-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-26</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is greater than 500 and the calcd. Log P (CLogP) is greater than 5 (or MlogP >4.15).  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYDqa02g16urVg90H21EOLACvtfcHk0lhV0_ywV_FWJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitVOhs7o%253D&md5=c60bb89da68f051c0ee7ac4c0468a0e4</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2800%2900129-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252800%252900129-0%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520Computational%2520Approaches%2520to%2520Estimate%2520Solubility%2520and%2520Permeability%2520in%2520Drug%2520Discovery%2520and%2520Development%2520Settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2001%26volume%3D46%26spage%3D3%26epage%3D26%26doi%3D10.1016%2FS0169-409X%2800%2900129-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paolini, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapland, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Hoorn, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span> <span> </span><span class="NLM_article-title">Global Mapping of Pharmacological Space</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">805</span>– <span class="NLM_lpage">815</span>, <span class="refDoi"> DOI: 10.1038/nbt1228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1038%2Fnbt1228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=16841068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFansb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=805-815&author=G.+V.+Paoliniauthor=R.+H.+Shaplandauthor=W.+P.+van+Hoornauthor=J.+S.+Masonauthor=A.+L.+Hopkins&title=Global+Mapping+of+Pharmacological+Space&doi=10.1038%2Fnbt1228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Global mapping of pharmacological space</span></div><div class="casAuthors">Paolini, Gaia V.; Shapland, Richard H. B.; van Hoorn, Willem P.; Mason, Jonathan S.; Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">805-815</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We present the global mapping of pharmacol. space by the integration of several vast sources of medicinal chem. structure-activity relationships (SAR) data.  Our comprehensive mapping of pharmacol. space enables us to identify confidently the human targets for which chem. tools and drugs have been discovered to date.  The integration of SAR data from diverse sources by unique canonical chem. structure, protein sequence and disease indication enables the construction of a ligand-target matrix to explore the global relationships between chem. structure and biol. targets.  Using the data matrix, we are able to catalog the links between proteins in chem. space as a polypharmacol. interaction network.  We demonstrate that probabilistic models can be used to predict pharmacol. from a large knowledge base.  The relationships between proteins, chem. structures and drug-like properties provide a framework for developing a probabilistic approach to drug discovery that can be exploited to increase research productivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV_CE47zZq8LVg90H21EOLACvtfcHk0liHJsT0oHesCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFansb8%253D&md5=f559b34692cc903a1b503deb07030c5d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnbt1228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1228%26sid%3Dliteratum%253Aachs%26aulast%3DPaolini%26aufirst%3DG.%2BV.%26aulast%3DShapland%26aufirst%3DR.%2BH.%26aulast%3Dvan%2BHoorn%26aufirst%3DW.%2BP.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DGlobal%2520Mapping%2520of%2520Pharmacological%2520Space%26jtitle%3DNat.%2520Biotechnol.%26date%3D2006%26volume%3D24%26spage%3D805%26epage%3D815%26doi%3D10.1038%2Fnbt1228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, M. A.</span></span> <span> </span><span class="NLM_article-title">Chemistry: Chemical Con Artists Foil Drug Discovery</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>513</i></span>,  <span class="NLM_fpage">481</span>– <span class="NLM_lpage">483</span>, <span class="refDoi"> DOI: 10.1038/513481a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1038%2F513481a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=25254460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1WjsL7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=513&publication_year=2014&pages=481-483&author=J.+Baellauthor=M.+A.+Walters&title=Chemistry%3A+Chemical+Con+Artists+Foil+Drug+Discovery&doi=10.1038%2F513481a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Chemistry: Chemical con artists foil drug discovery</span></div><div class="casAuthors">Baell, Jonathan; Walters, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">513</span>
        (<span class="NLM_cas:issue">7519</span>),
    <span class="NLM_cas:pages">481-483</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Naivety about promiscuous, assay-duping mols. is polluting the literature and wasting resources, warn Jonathan Baell and Michael A. Walters.  Academic drug discoverers must be more vigilant.  Mols. that show the strongest activity in screening might not be the best starting points for drugs.  PAINS hits should almost always be ignored.  Even trained medicinal chemists have to be careful until they become experienced in screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJFYQ0B4VVoLVg90H21EOLACvtfcHk0liHJsT0oHesCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1WjsL7M&md5=f5788d81d006460c688e4b78e6200503</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2F513481a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F513481a%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%26aulast%3DWalters%26aufirst%3DM.%2BA.%26atitle%3DChemistry%253A%2520Chemical%2520Con%2520Artists%2520Foil%2520Drug%2520Discovery%26jtitle%3DNature%26date%3D2014%26volume%3D513%26spage%3D481%26epage%3D483%26doi%3D10.1038%2F513481a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hack, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rassokhin, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buyck, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seierstad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skalkin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ten Holte, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirzadegan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrafiotis, D. K.</span></span> <span> </span><span class="NLM_article-title">Library Enhancement through the Wisdom of Crowds</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">3275</span>– <span class="NLM_lpage">3286</span>, <span class="refDoi"> DOI: 10.1021/ci200446y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci200446y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyhtbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2011&pages=3275-3286&author=M.+D.+Hackauthor=D.+N.+Rassokhinauthor=C.+Buyckauthor=M.+Seierstadauthor=A.+Skalkinauthor=P.+ten+Holteauthor=T.+K.+Jonesauthor=T.+Mirzadeganauthor=D.+K.+Agrafiotis&title=Library+Enhancement+through+the+Wisdom+of+Crowds&doi=10.1021%2Fci200446y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Library Enhancement through the Wisdom of Crowds</span></div><div class="casAuthors">Hack, Michael D.; Rassokhin, Dmitrii N.; Buyck, Christophe; Seierstad, Mark; Skalkin, Andrew; ten Holte, Peter; Jones, Todd K.; Mirzadegan, Taraneh; Agrafiotis, Dimitris K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3275-3286</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We present a novel approach for enhancing the diversity of a chem. library rooted on the theory of the wisdom of crowds.  Our approach was motivated by a desire to tap into the collective experience of our global medicinal chem. community and involved four basic steps: (1) Candidate compds. for acquisition were screened using various structural and property filters in order to eliminate clearly nondrug-like matter. (2) The remaining compds. were clustered together with our inhouse collection using a novel fingerprint-based clustering algorithm that emphasizes common substructures and works with millions of mols. (3) Clusters populated exclusively by external compds. were identified as "diversity holes", and representative members of these clusters were presented to our global medicinal chem. community, who were asked to specify which ones they liked, disliked, or were indifferent to using a simple point-and-click interface. (4) The resulting votes were used to rank the clusters from most to least desirable, and to prioritize which ones should be targeted for acquisition.  Anal. of the voting results reveals interesting voter behaviors and distinct preferences for certain mol. property ranges that are fully consistent with lead-like profiles established through systematic anal. of large historical databases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAlOmFi56CvLVg90H21EOLACvtfcHk0ljEsD8A42BNPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyhtbrM&md5=c6544962d51835903246e7a691069e11</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fci200446y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci200446y%26sid%3Dliteratum%253Aachs%26aulast%3DHack%26aufirst%3DM.%2BD.%26aulast%3DRassokhin%26aufirst%3DD.%2BN.%26aulast%3DBuyck%26aufirst%3DC.%26aulast%3DSeierstad%26aufirst%3DM.%26aulast%3DSkalkin%26aufirst%3DA.%26aulast%3Dten%2BHolte%26aufirst%3DP.%26aulast%3DJones%26aufirst%3DT.%2BK.%26aulast%3DMirzadegan%26aufirst%3DT.%26aulast%3DAgrafiotis%26aufirst%3DD.%2BK.%26atitle%3DLibrary%2520Enhancement%2520through%2520the%2520Wisdom%2520of%2520Crowds%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2011%26volume%3D51%26spage%3D3275%26epage%3D3286%26doi%3D10.1021%2Fci200446y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Houston, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galetin, A.</span></span> <span> </span><span class="NLM_article-title">Methods for Predicting in Vivo Pharmacokinetics Using Data from in Vitro Assays</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">940</span>– <span class="NLM_lpage">951</span>, <span class="refDoi"> DOI: 10.2174/138920008786485164</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.2174%2F138920008786485164" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=18991591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivF2nsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=940-951&author=J.+B.+Houstonauthor=A.+Galetin&title=Methods+for+Predicting+in+Vivo+Pharmacokinetics+Using+Data+from+in+Vitro+Assays&doi=10.2174%2F138920008786485164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Methods for predicting in vivo pharmacokinetics using data from in vitro assays</span></div><div class="casAuthors">Houston, J. Brian; Galetin, Aleksandra</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">940-951</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Strategies for optimizing in vivo predictions from in vitro data on metabolic stability and CYP inhibition are discussed.  Potential pitfalls and areas of inaccuracy are highlighted together with recommendations for best practice.  The use of both hepatic microsomes and isolated hepatocytes for the assessment of metabolic stability is discussed in terms of scaling from the in vitro system up to whole liver.  The importance of integrating metabolic stability data together with other drug pharmacokinetic characteristics (e.g., protein binding and red blood cell uptake) as well as blood flow are presented within the context of different liver models.  The assessment of CYP inhibition potential requires in vitro data on the inhibitor potency either in the form of Ki (for reversible inhibition) or Kl and kinact (for time-dependent inhibition).  The integration of these in vitro parameters together with other pharmacokinetic information is essential for the in vivo prediction.  While a qual. assessment may be made from the I/Ki ratio, a no. of addnl. victim drug and enzyme-related parameters are required for quant. prediction.  Of particular importance is the parameter fmCYP (the fraction of the metabolic clearance of the victim drug that is catalyzed by the enzyme subject to the inhibition).  Impact of other victim drug properties (e.g., fractional importance of the intestine) and enzyme properties (e.g., kdeg for time-dependent inhibition) on the drug-drug interaction prediction is discussed.  In addn., mechanisms by which false negatives and false positives may result from in vitro strategies are summarized.  Finally perspectives for future application and improvements in these predictions strategies are outlined.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5SQoxJv6217Vg90H21EOLACvtfcHk0ljEsD8A42BNPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivF2nsbY%253D&md5=8ec402521f33f7704edc184f7cab9a35</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.2174%2F138920008786485164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920008786485164%26sid%3Dliteratum%253Aachs%26aulast%3DHouston%26aufirst%3DJ.%2BB.%26aulast%3DGaletin%26aufirst%3DA.%26atitle%3DMethods%2520for%2520Predicting%2520in%2520Vivo%2520Pharmacokinetics%2520Using%2520Data%2520from%2520in%2520Vitro%2520Assays%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2008%26volume%3D9%26spage%3D940%26epage%3D951%26doi%3D10.2174%2F138920008786485164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="ref28_1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koudriakova, T.</span>; <span class="NLM_string-name">Kreutter, K. D.</span>; <span class="NLM_string-name">Leonard, K.</span>; <span class="NLM_string-name">Rizzolio, M. C.</span>; <span class="NLM_string-name">Smith, R. C.</span>; <span class="NLM_string-name">Tichenor, M. S.</span>; <span class="NLM_string-name">Wang, A.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Inhibitors of the JAK Family of Kinases</span>. <span class="NLM_patent">US2018/0170931A1</span>, June 21, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=T.+Koudriakova&author=K.+D.+Kreutter&author=K.+Leonard&author=M.+C.+Rizzolio&author=R.+C.+Smith&author=M.+S.+Tichenor&author=A.+Wang&title=Small+Molecule+Inhibitors+of+the+JAK+Family+of+Kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=ref28_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKoudriakova%26aufirst%3DT.%26atitle%3DSmall%2520Molecule%2520Inhibitors%2520of%2520the%2520JAK%2520Family%2520of%2520Kinases%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="ref29_1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bacani, G. M.</span>; <span class="NLM_string-name">Chai, W.</span>; <span class="NLM_string-name">Koudriakova, T.</span>; <span class="NLM_string-name">Krawczuk, P. J.</span>; <span class="NLM_string-name">Kreutter, K. D.</span>; <span class="NLM_string-name">Leonard, K.</span>; <span class="NLM_string-name">Rizzolio, M. C.</span>; <span class="NLM_string-name">Seierstad, M.</span>; <span class="NLM_string-name">Smith, R. C.</span>; <span class="NLM_string-name">Tichenor, M. S.</span>; <span class="NLM_string-name">Venable, J. D.</span>; <span class="NLM_string-name">Wang, A.</span></span> <span> </span><span class="NLM_article-title">Imidazopyrrolopyridine as inhibitors of the jak family of kinases</span>. <span class="NLM_patent">WO2018/112382A1</span>, June 21, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=G.+M.+Bacani&author=W.+Chai&author=T.+Koudriakova&author=P.+J.+Krawczuk&author=K.+D.+Kreutter&author=K.+Leonard&author=M.+C.+Rizzolio&author=M.+Seierstad&author=R.+C.+Smith&author=M.+S.+Tichenor&author=J.+D.+Venable&author=A.+Wang&title=Imidazopyrrolopyridine+as+inhibitors+of+the+jak+family+of+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=ref29_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBacani%26aufirst%3DG.%2BM.%26atitle%3DImidazopyrrolopyridine%2520as%2520inhibitors%2520of%2520the%2520jak%2520family%2520of%2520kinases%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['ref28_1'],'ref29':['ref29_1']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 2 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiamin  Zheng</span>, <span class="hlFld-ContribAuthor ">Jun  Wu</span>, <span class="hlFld-ContribAuthor ">Xiao  Ding</span>, <span class="hlFld-ContribAuthor ">Hong C.  Shen</span>, <span class="hlFld-ContribAuthor ">Ge  Zou</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): Kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>38 </em>, 127862. <a href="https://doi.org/10.1016/j.bmcl.2021.127862" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.127862</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.127862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.127862%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSmall%252Bmolecule%252Bapproaches%252Bto%252Btreat%252Bautoimmune%252Band%252Binflammatory%252Bdiseases%252B%252528Part%252BI%252529%25253A%252BKinase%252Binhibitors%26aulast%3DZheng%26aufirst%3DJiamin%26date%3D2021%26volume%3D38%26spage%3D127862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cristian  Hernandez-Rocha</span>, <span class="hlFld-ContribAuthor ">Niels  Vande Casteele</span>. </span><span class="cited-content_cbyCitation_article-title">JAK inhibitors: current position in treatment strategies for use in inflammatory bowel disease. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Pharmacology</span><span> <strong>2020,</strong> <em>55 </em>, 99-109. <a href="https://doi.org/10.1016/j.coph.2020.10.010" title="DOI URL">https://doi.org/10.1016/j.coph.2020.10.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.coph.2020.10.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.coph.2020.10.010%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Pharmacology%26atitle%3DJAK%252Binhibitors%25253A%252Bcurrent%252Bposition%252Bin%252Btreatment%252Bstrategies%252Bfor%252Buse%252Bin%252Binflammatory%252Bbowel%252Bdisease%26aulast%3DHernandez-Rocha%26aufirst%3DCristian%26date%3D2020%26volume%3D55%26spage%3D99%26epage%3D109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/medium/jm9b01439_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01439&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/medium/jm9b01439_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Enzyme potency (JAK1, JAK2, JAK3, and Tyk2), intrinsic permeability in MDCK-<i>MDR1</i> permeability assay, and systemic exposure at 0.5 h after oral dosing in mouse of Compound <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01439&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/medium/jm9b01439_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Analogues of compound <b>1</b> synthesized to evaluate a range of physicochemical properties through substitution at the C2-position of the imidazole. See <a class="ref internalNav" href="#notes1" aria-label="Supporting Information">Supporting Information</a> for details.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01439&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/medium/jm9b01439_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Range of properties of analogues from <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, including cLogP, tPSA, H-bond donors, and MW, that create a diverse set of physicochemical properties.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01439&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/medium/jm9b01439_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Correlation between instrinsic permeability (measured by MDCK-<i>MDR1</i> (A → B (+P-gp inhibitor))) and clogP and tPSA (logarithmic scale used on <i>y</i>-axis) of compounds with −CH<sub>2</sub>CONRR and −CH<sub>2</sub>NRCOR substituents at the C2-position of the imidazole.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01439&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/medium/jm9b01439_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. A comparison of mouse plasma exposure at 0.5 h following oral dosing to intrinsic permeability (MDCK-<i>MDR1</i> A → B (+P-gp inhibitor)) (logarithmic scale used on <i>y</i>-axis).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01439&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/medium/jm9b01439_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>2</b>–<b>7</b> and <b>9</b>–<b>11</b> (Containing the −CH<sub>2</sub>CONRR Linker)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01439&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) DIPEA, DMA, 80 °C; (b) Pd/C, 1 atm H<sub>2</sub> (via H-Cube), THF/MeOH (1:1), 80 °C; (c) EtOH, 90 °C; (d) (1) R<sub>1</sub>R<sub>2</sub>NH, DMA, 125 °C, (2) 3 M KOH in water, dioxane, 80 °C; (e) (1) 1 M NaOH in water, MeOH/THF (1:1), (2) R<sub>1</sub>R<sub>2</sub>NH, PyBrOP, DIPEA, DMF.</p></p></figure><figure data-id="sch2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/medium/jm9b01439_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compound <b>8</b> (with the −CH<sub>2</sub>NHCOR Linker)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01439&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Na<sub>2</sub>S<sub>2</sub>O<sub>4</sub>, DMSO/MeOH/water, 100 °C; (b) 3 M KOH in water, dioxane, 80 °C; (c) 4 M HCl in dioxane, DCM; (d) HATU, DIPEA, DCM.</p></p></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/medium/jm9b01439_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Comparative activity of compound <b>2</b> and tofacitinib in mouse whole blood post-oral dose. Mice were dosed orally with compound <b>2</b> and tofacitinib at 25 mg/kg. Control mice received equal volume of 20% of 2-hydroxypropyl-β-cyclodextrin (HPβCD) in the similar fashion. After 0.5 h, the animals were sacrificed, and their blood was collected and stimulated with IFNα as described in <a class="ref internalNav" href="#sec5" aria-label="Methods">Methods</a>. pSTAT4 levels were measured following 30 min of stimulation and expressed as a percentage of the IFNα-induced pSTAT4 response observed relative to the vehicle-treated group. Data are presented as mean ± SEM; <i>N</i> = 4 mice/group. Statistics are derived from ANOVA analysis of pSTAT4 raw relative luminescent values (RLU) and are applicable to data presented as percent inhibition. ** = <i>P</i> < 0.001 vs cytokine simulated vehicle. <sup>##</sup> = <i>P</i> < 0.001 vs unstimulated vehicle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01439&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/medium/jm9b01439_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Dose response of compound 2 effect on basal and IL-22/IL-6/IFNα-induced pSTAT3 in mouse colon explants. Mice were dosed orally with compound <b>2</b> or tofacitinib at indicated doses. Control mice received equal volumes of 20% HPβCD (Veh) in the similar fashion. At 4 h post-dose, animals were sacrificed, and colon tissue was harvested as detailed in <a class="ref internalNav" href="#sec5" aria-label="Methods">Methods</a>. (A) pSTAT3 levels were measured in the proximal colon explants following <i>ex vivo</i> stimulation with the IL-22/IL-6/IFNα cytokine cocktail for 1 h. Control explants (no stimulation) were treated with media alone. Data are presented as mean ± SEM; <i>N</i> = 5 mice/group. ** = <i>p</i> < 0.01; **** = <i>p</i> < 0.00001; ns = not significant. (B) Colonic tissue levels of compound <b>2</b> from all mice dosed 0.5–25 mg/kg were measured by the liquid chromatography-triple quadrupole mass spectrometry (LC MS/MS) method and corresponding inhibition of IL-22/IL-6/IFNα responses for each explant plotted.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-6/acs.jmedchem.9b01439/20200323/images/large/jm9b01439_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01439&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i66">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58100" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58100" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 29 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coskun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salem, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, O. H.</span></span> <span> </span><span class="NLM_article-title">Involvement of Jak/Stat Signaling in the Pathogenesis of Inflammatory Bowel Disease</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2013.06.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1016%2Fj.phrs.2013.06.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=23827161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2ms7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2013&pages=1-8&author=M.+Coskunauthor=M.+Salemauthor=J.+Pedersenauthor=O.+H.+Nielsen&title=Involvement+of+Jak%2FStat+Signaling+in+the+Pathogenesis+of+Inflammatory+Bowel+Disease&doi=10.1016%2Fj.phrs.2013.06.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease</span></div><div class="casAuthors">Coskun, Mehmet; Salem, Mohammad; Pedersen, Jannie; Nielsen, Ole Haagen</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-8</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway constitute the fulcrum in many vital cellular processes, including cell growth, differentiation, proliferation, and regulatory immune functions.  Various cytokines, growth factors, and protein tyrosine kinases communicate through the JAK/STAT pathway and regulate the transcription of numerous genes.  In addn. to their crit. roles in a plethora of key cellular activities, the JAK/STAT signaling pathways also have been implicated in the pathogenesis of several diseases, including inflammatory bowel disease (IBD), esp. since a JAK inhibitor recently has been shown to be effective in the treatment of ulcerative colitis.  The aim of this review is to highlight the recent findings on the regulatory mechanism of JAK/STAT signaling pathways and to reveal the evolving comprehension of their interface which might be of interest for clinicians involved in IBD therapy.  Further, it is described how these signaling pathways have been exploited for the development of promising novel JAK inhibitors with anti-inflammatory effects verified in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5w2NrXEjp4bVg90H21EOLACvtfcHk0li0S4SsNsaJmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2ms7vP&md5=ee07edf3a0fc83840e8c90c178378c98</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2013.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2013.06.007%26sid%3Dliteratum%253Aachs%26aulast%3DCoskun%26aufirst%3DM.%26aulast%3DSalem%26aufirst%3DM.%26aulast%3DPedersen%26aufirst%3DJ.%26aulast%3DNielsen%26aufirst%3DO.%2BH.%26atitle%3DInvolvement%2520of%2520Jak%252FStat%2520Signaling%2520in%2520the%2520Pathogenesis%2520of%2520Inflammatory%2520Bowel%2520Disease%26jtitle%3DPharmacol.%2520Res.%26date%3D2013%26volume%3D76%26spage%3D1%26epage%3D8%26doi%3D10.1016%2Fj.phrs.2013.06.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Danese, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grisham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J. B.</span></span> <span> </span><span class="NLM_article-title">Jak Inhibition Using Tofacitinib for Inflammatory Bowel Disease Treatment: A Hub for Multiple Inflammatory Cytokines</span>. <i>American journal of physiology. Gastrointestinal and liver physiology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>310</i></span>,  <span class="NLM_fpage">G155</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1152/ajpgi.00311.2015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1152%2Fajpgi.00311.2015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=26608188" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=310&publication_year=2016&pages=G155-162&author=S.+Daneseauthor=M.+Grishamauthor=J.+Hodgeauthor=J.+B.+Telliez&title=Jak+Inhibition+Using+Tofacitinib+for+Inflammatory+Bowel+Disease+Treatment%3A+A+Hub+for+Multiple+Inflammatory+Cytokines&doi=10.1152%2Fajpgi.00311.2015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1152%2Fajpgi.00311.2015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpgi.00311.2015%26sid%3Dliteratum%253Aachs%26aulast%3DDanese%26aufirst%3DS.%26aulast%3DGrisham%26aufirst%3DM.%26aulast%3DHodge%26aufirst%3DJ.%26aulast%3DTelliez%26aufirst%3DJ.%2BB.%26atitle%3DJak%2520Inhibition%2520Using%2520Tofacitinib%2520for%2520Inflammatory%2520Bowel%2520Disease%2520Treatment%253A%2520A%2520Hub%2520for%2520Multiple%2520Inflammatory%2520Cytokines%26jtitle%3DAmerican%2520journal%2520of%2520physiology.%2520Gastrointestinal%2520and%2520liver%2520physiology%26date%3D2016%26volume%3D310%26spage%3DG155%26epage%3D162%26doi%3D10.1152%2Fajpgi.00311.2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neurath, M. F.</span></span> <span> </span><span class="NLM_article-title">Cytokines in Inflammatory Bowel Disease</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">342</span>, <span class="refDoi"> DOI: 10.1038/nri3661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1038%2Fnri3661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=24751956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmsFalsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=329-342&author=M.+F.+Neurath&title=Cytokines+in+Inflammatory+Bowel+Disease&doi=10.1038%2Fnri3661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Cytokines in inflammatory bowel disease</span></div><div class="casAuthors">Neurath, Markus F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">329-342</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cytokines have a crucial role in the pathogenesis of inflammatory bowel diseases (IBDs), such as Crohn's disease and ulcerative colitis, where they control multiple aspects of the inflammatory response.  In particular, the imbalance between pro-inflammatory and anti-inflammatory cytokines that occurs in IBD impedes the resoln. of inflammation and instead leads to disease perpetuation and tissue destruction.  Recent studies suggest the existence of a network of regulatory cytokines that has important implications for disease progression.  In this Review, we discuss the role of cytokines produced by innate and adaptive immune cells, as well as their relevance to the future therapy of IBD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphBomEKR1KI7Vg90H21EOLACvtfcHk0lgpft_a2QKZAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmsFalsro%253D&md5=f8ab6ddf3011cbf1a3c54cd7394cd37b</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnri3661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri3661%26sid%3Dliteratum%253Aachs%26aulast%3DNeurath%26aufirst%3DM.%2BF.%26atitle%3DCytokines%2520in%2520Inflammatory%2520Bowel%2520Disease%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2014%26volume%3D14%26spage%3D329%26epage%3D342%26doi%3D10.1038%2Fnri3661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holland, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, L. M.</span></span> <span> </span><span class="NLM_article-title">Jaks and Stats in Immunity, Immunodeficiency, and Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">170</span>, <span class="refDoi"> DOI: 10.1056/NEJMra1202117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1056%2FNEJMra1202117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=23301733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovVyhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2013&pages=161-170&author=J.+J.+O%E2%80%99Sheaauthor=S.+M.+Hollandauthor=L.+M.+Staudt&title=Jaks+and+Stats+in+Immunity%2C+Immunodeficiency%2C+and+Cancer&doi=10.1056%2FNEJMra1202117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">JAKs and STATs in immunity, immunodeficiency, and cancer</span></div><div class="casAuthors">O'Shea, John J.; Holland, Steven M.; Staudt, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">161-170</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review highlights interferon-mediated gene regulation has resulted in a new framework for the study of cell signaling and JAKs STATs in immunity, immunodeficiency, and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqk1n-UgWrlWrVg90H21EOLACvtfcHk0lgpft_a2QKZAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovVyhuw%253D%253D&md5=5d87b67f72b721eb0ca9413adf92a7b9</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1202117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1202117%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DHolland%26aufirst%3DS.%2BM.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DJaks%2520and%2520Stats%2520in%2520Immunity%252C%2520Immunodeficiency%252C%2520and%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D368%26spage%3D161%26epage%3D170%26doi%3D10.1056%2FNEJMra1202117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jostins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weersma, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duerr, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGovern, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philip Schumm, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Essers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitrovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleynen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theatre, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spain, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raychaudhuri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goyette, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achkar, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amininejad, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ananthakrishnan, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baidoo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balschun, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bampton, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brand, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buning, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cichon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Amato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devaney, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubinsky, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellinghaus, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franchimont, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fransen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gearry, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georges, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gieger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haritunians, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsen, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kupcinskas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kugathasan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latiano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laukens, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrance, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansfield, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mowat, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmieri, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponsioen, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potocnik, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prescott, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regueiro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotter, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanderson, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sans, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satsangi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simms, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sventoraityte, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Targan, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremelling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verspaget, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijmenga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkelmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xavier, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeissig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverberg, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annese, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hakonarson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brant, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radford-Smith, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rioux, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadt, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermeire, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J. H</span></span> <span> </span><span class="NLM_article-title">Host-Microbe Interactions Have Shaped the Genetic Architecture of Inflammatory Bowel Disease</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>491</i></span>,  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1038/nature11582</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1038%2Fnature11582" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=23128233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1ajtbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=491&publication_year=2012&pages=119-124&author=L.+Jostinsauthor=S.+Ripkeauthor=R.+K.+Weersmaauthor=R.+H.+Duerrauthor=D.+P.+McGovernauthor=K.+Y.+Huiauthor=J.+C.+Leeauthor=L.+Philip+Schummauthor=Y.+Sharmaauthor=C.+A.+Andersonauthor=J.+Essersauthor=M.+Mitrovicauthor=K.+Ningauthor=I.+Cleynenauthor=E.+Theatreauthor=S.+L.+Spainauthor=S.+Raychaudhuriauthor=P.+Goyetteauthor=Z.+Weiauthor=C.+Abrahamauthor=J.-P.+Achkarauthor=T.+Ahmadauthor=L.+Amininejadauthor=A.+N.+Ananthakrishnanauthor=V.+Andersenauthor=J.+M.+Andrewsauthor=L.+Baidooauthor=T.+Balschunauthor=P.+A.+Bamptonauthor=A.+Bittonauthor=G.+Boucherauthor=S.+Brandauthor=C.+Buningauthor=A.+Cohainauthor=S.+Cichonauthor=M.+D%E2%80%99Amatoauthor=D.+De+Jongauthor=K.+L.+Devaneyauthor=M.+Dubinskyauthor=C.+Edwardsauthor=D.+Ellinghausauthor=L.+R.+Fergusonauthor=D.+Franchimontauthor=K.+Fransenauthor=R.+Gearryauthor=M.+Georgesauthor=C.+Giegerauthor=J.+Glasauthor=T.+Harituniansauthor=A.+Hartauthor=C.+Hawkeyauthor=M.+Hedlauthor=X.+Huauthor=T.+H.+Karlsenauthor=L.+Kupcinskasauthor=S.+Kugathasanauthor=A.+Latianoauthor=D.+Laukensauthor=I.+C.+Lawranceauthor=C.+W.+Leesauthor=E.+Louisauthor=G.+Mahyauthor=J.+Mansfieldauthor=A.+R.+Morganauthor=C.+Mowatauthor=W.+Newmanauthor=O.+Palmieriauthor=C.+Y.+Ponsioenauthor=U.+Potocnikauthor=N.+J.+Prescottauthor=M.+Regueiroauthor=J.+I.+Rotterauthor=R.+K.+Russellauthor=J.+D.+Sandersonauthor=M.+Sansauthor=J.+Satsangiauthor=S.+Schreiberauthor=L.+A.+Simmsauthor=J.+Sventoraityteauthor=S.+R.+Targanauthor=K.+D.+Taylorauthor=M.+Tremellingauthor=H.+W.+Verspagetauthor=M.+De+Vosauthor=C.+Wijmengaauthor=D.+C.+Wilsonauthor=J.+Winkelmannauthor=R.+J.+Xavierauthor=S.+Zeissigauthor=B.+Zhangauthor=C.+K.+Zhangauthor=H.+Zhaoauthor=M.+S.+Silverbergauthor=V.+Anneseauthor=H.+Hakonarsonauthor=S.+R.+Brantauthor=G.+Radford-Smithauthor=C.+G.+Mathewauthor=J.+D.+Riouxauthor=E.+E.+Schadtauthor=M.+J.+Dalyauthor=A.+Frankeauthor=M.+Parkesauthor=S.+Vermeireauthor=J.+C.+Barrettauthor=J.+H+Cho&title=Host-Microbe+Interactions+Have+Shaped+the+Genetic+Architecture+of+Inflammatory+Bowel+Disease&doi=10.1038%2Fnature11582"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease</span></div><div class="casAuthors">Jostins, Luke; Ripke, Stephan; Weersma, Rinse K.; Duerr, Richard H.; McGovern, Dermot P.; Hui, Ken Y.; Lee, James C.; Philip Schumm, L.; Sharma, Yashoda; Anderson, Carl A.; Essers, Jonah; Mitrovic, Mitja; Ning, Kaida; Cleynen, Isabelle; Theatre, Emilie; Spain, Sarah L.; Raychaudhuri, Soumya; Goyette, Philippe; Wei, Zhi; Abraham, Clara; Achkar, Jean-Paul; Ahmad, Tariq; Amininejad, Leila; Ananthakrishnan, Ashwin N.; Andersen, Vibeke; Andrews, Jane M.; Baidoo, Leonard; Balschun, Tobias; Bampton, Peter A.; Bitton, Alain; Boucher, Gabrielle; Brand, Stephan; Buening, Carsten; Cohain, Ariella; Cichon, Sven; D'Amato, Mauro; De Jong, Dirk; Devaney, Kathy L.; Dubinsky, Marla; Edwards, Cathryn; Ellinghaus, David; Ferguson, Lynnette R.; Franchimont, Denis; Fransen, Karin; Gearry, Richard; Georges, Michel; Gieger, Christian; Glas, Juergen; Haritunians, Talin; Hart, Ailsa; Hawkey, Chris; Hedl, Matija; Hu, Xinli; Karlsen, Tom H.; Kupcinskas, Limas; Kugathasan, Subra; Latiano, Anna; Laukens, Debby; Lawrance, Ian C.; Lees, Charlie W.; Louis, Edouard; Mahy, Gillian; Mansfield, John; Morgan, Angharad R.; Mowat, Craig; Newman, William; Palmieri, Orazio; Ponsioen, Cyriel Y.; Potocnik, Uros; Prescott, Natalie J.; Regueiro, Miguel; Rotter, Jerome I.; Russell, Richard K.; Sanderson, Jeremy D.; Sans, Miquel; Satsangi, Jack; Schreiber, Stefan; Simms, Lisa A.; Sventoraityte, Jurgita; Targan, Stephan R.; Taylor, Kent D.; Tremelling, Mark; Verspaget, Hein W.; De Vos, Martine; Wijmenga, Cisca; Wilson, David C.; Winkelmann, Juliane; Xavier, Ramnik J.; Zeissig, Sebastian; Zhang, Bin; Zhang, Clarence K.; Zhao, Hongyu; Silverberg, Mark S.; Annese, Vito; Hakonarson, Hakon; Brant, Steven R.; Radford-Smith, Graham; Mathew, Christopher G.; Rioux, John D.; Schadt, Eric E.; Daly, Mark J.; Franke, Andre; Parkes, Miles; Vermeire, Severine; Barrett, Jeffrey C.; Cho, Judy H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">491</span>
        (<span class="NLM_cas:issue">7422</span>),
    <span class="NLM_cas:pages">119-124</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Crohn's disease and ulcerative colitis, the two common forms of inflammatory bowel disease (IBD), affect over 2.5 million people of European ancestry, with rising prevalence in other populations.  Genome-wide assocn. studies and subsequent meta-analyses of these two diseases as sep. phenotypes have implicated previously unsuspected mechanisms, such as autophagy, in their pathogenesis and showed that some IBD loci are shared with other inflammatory diseases.  Here we expand on the knowledge of relevant pathways by undertaking a meta-anal. of Crohn's disease and ulcerative colitis genome-wide assocn. scans, followed by extensive validation of significant findings, with a combined total of more than 75,000 cases and controls.  We identify 71 new assocns., for a total of 163 IBD loci, that meet genome-wide significance thresholds.  Most loci contribute to both phenotypes, and both directional (consistently favoring one allele over the course of human history) and balancing (favoring the retention of both alleles within populations) selection effects are evident.  Many IBD loci are also implicated in other immune-mediated disorders, most notably with ankylosing spondylitis and psoriasis.  We also observe considerable overlap between susceptibility loci for IBD and mycobacterial infection.  Gene co-expression network anal. emphasizes this relationship, with pathways shared between host responses to mycobacteria and those predisposing to IBD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHFW8T01tr1LVg90H21EOLACvtfcHk0lhhot3VmhF54Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1ajtbzP&md5=c12c310a78520076fb66584d21c9e366</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnature11582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11582%26sid%3Dliteratum%253Aachs%26aulast%3DJostins%26aufirst%3DL.%26aulast%3DRipke%26aufirst%3DS.%26aulast%3DWeersma%26aufirst%3DR.%2BK.%26aulast%3DDuerr%26aufirst%3DR.%2BH.%26aulast%3DMcGovern%26aufirst%3DD.%2BP.%26aulast%3DHui%26aufirst%3DK.%2BY.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DPhilip%2BSchumm%26aufirst%3DL.%26aulast%3DSharma%26aufirst%3DY.%26aulast%3DAnderson%26aufirst%3DC.%2BA.%26aulast%3DEssers%26aufirst%3DJ.%26aulast%3DMitrovic%26aufirst%3DM.%26aulast%3DNing%26aufirst%3DK.%26aulast%3DCleynen%26aufirst%3DI.%26aulast%3DTheatre%26aufirst%3DE.%26aulast%3DSpain%26aufirst%3DS.%2BL.%26aulast%3DRaychaudhuri%26aufirst%3DS.%26aulast%3DGoyette%26aufirst%3DP.%26aulast%3DWei%26aufirst%3DZ.%26aulast%3DAbraham%26aufirst%3DC.%26aulast%3DAchkar%26aufirst%3DJ.-P.%26aulast%3DAhmad%26aufirst%3DT.%26aulast%3DAmininejad%26aufirst%3DL.%26aulast%3DAnanthakrishnan%26aufirst%3DA.%2BN.%26aulast%3DAndersen%26aufirst%3DV.%26aulast%3DAndrews%26aufirst%3DJ.%2BM.%26aulast%3DBaidoo%26aufirst%3DL.%26aulast%3DBalschun%26aufirst%3DT.%26aulast%3DBampton%26aufirst%3DP.%2BA.%26aulast%3DBitton%26aufirst%3DA.%26aulast%3DBoucher%26aufirst%3DG.%26aulast%3DBrand%26aufirst%3DS.%26aulast%3DBuning%26aufirst%3DC.%26aulast%3DCohain%26aufirst%3DA.%26aulast%3DCichon%26aufirst%3DS.%26aulast%3DD%25E2%2580%2599Amato%26aufirst%3DM.%26aulast%3DDe%2BJong%26aufirst%3DD.%26aulast%3DDevaney%26aufirst%3DK.%2BL.%26aulast%3DDubinsky%26aufirst%3DM.%26aulast%3DEdwards%26aufirst%3DC.%26aulast%3DEllinghaus%26aufirst%3DD.%26aulast%3DFerguson%26aufirst%3DL.%2BR.%26aulast%3DFranchimont%26aufirst%3DD.%26aulast%3DFransen%26aufirst%3DK.%26aulast%3DGearry%26aufirst%3DR.%26aulast%3DGeorges%26aufirst%3DM.%26aulast%3DGieger%26aufirst%3DC.%26aulast%3DGlas%26aufirst%3DJ.%26aulast%3DHaritunians%26aufirst%3DT.%26aulast%3DHart%26aufirst%3DA.%26aulast%3DHawkey%26aufirst%3DC.%26aulast%3DHedl%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DKarlsen%26aufirst%3DT.%2BH.%26aulast%3DKupcinskas%26aufirst%3DL.%26aulast%3DKugathasan%26aufirst%3DS.%26aulast%3DLatiano%26aufirst%3DA.%26aulast%3DLaukens%26aufirst%3DD.%26aulast%3DLawrance%26aufirst%3DI.%2BC.%26aulast%3DLees%26aufirst%3DC.%2BW.%26aulast%3DLouis%26aufirst%3DE.%26aulast%3DMahy%26aufirst%3DG.%26aulast%3DMansfield%26aufirst%3DJ.%26aulast%3DMorgan%26aufirst%3DA.%2BR.%26aulast%3DMowat%26aufirst%3DC.%26aulast%3DNewman%26aufirst%3DW.%26aulast%3DPalmieri%26aufirst%3DO.%26aulast%3DPonsioen%26aufirst%3DC.%2BY.%26aulast%3DPotocnik%26aufirst%3DU.%26aulast%3DPrescott%26aufirst%3DN.%2BJ.%26aulast%3DRegueiro%26aufirst%3DM.%26aulast%3DRotter%26aufirst%3DJ.%2BI.%26aulast%3DRussell%26aufirst%3DR.%2BK.%26aulast%3DSanderson%26aufirst%3DJ.%2BD.%26aulast%3DSans%26aufirst%3DM.%26aulast%3DSatsangi%26aufirst%3DJ.%26aulast%3DSchreiber%26aufirst%3DS.%26aulast%3DSimms%26aufirst%3DL.%2BA.%26aulast%3DSventoraityte%26aufirst%3DJ.%26aulast%3DTargan%26aufirst%3DS.%2BR.%26aulast%3DTaylor%26aufirst%3DK.%2BD.%26aulast%3DTremelling%26aufirst%3DM.%26aulast%3DVerspaget%26aufirst%3DH.%2BW.%26aulast%3DDe%2BVos%26aufirst%3DM.%26aulast%3DWijmenga%26aufirst%3DC.%26aulast%3DWilson%26aufirst%3DD.%2BC.%26aulast%3DWinkelmann%26aufirst%3DJ.%26aulast%3DXavier%26aufirst%3DR.%2BJ.%26aulast%3DZeissig%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DC.%2BK.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DSilverberg%26aufirst%3DM.%2BS.%26aulast%3DAnnese%26aufirst%3DV.%26aulast%3DHakonarson%26aufirst%3DH.%26aulast%3DBrant%26aufirst%3DS.%2BR.%26aulast%3DRadford-Smith%26aufirst%3DG.%26aulast%3DMathew%26aufirst%3DC.%2BG.%26aulast%3DRioux%26aufirst%3DJ.%2BD.%26aulast%3DSchadt%26aufirst%3DE.%2BE.%26aulast%3DDaly%26aufirst%3DM.%2BJ.%26aulast%3DFranke%26aufirst%3DA.%26aulast%3DParkes%26aufirst%3DM.%26aulast%3DVermeire%26aufirst%3DS.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DCho%26aufirst%3DJ.%2BH%26atitle%3DHost-Microbe%2520Interactions%2520Have%2520Shaped%2520the%2520Genetic%2520Architecture%2520of%2520Inflammatory%2520Bowel%2520Disease%26jtitle%3DNature%26date%3D2012%26volume%3D491%26spage%3D119%26epage%3D124%26doi%3D10.1038%2Fnature11582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boland, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandborn, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. T.</span></span> <span> </span><span class="NLM_article-title">Update on Janus Kinase Antagonists in Inflammatory Bowel Disease</span>. <i>Gastroenterology clinics of North America</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">603</span>– <span class="NLM_lpage">617</span>, <span class="refDoi"> DOI: 10.1016/j.gtc.2014.05.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1016%2Fj.gtc.2014.05.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=25110261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A280%3ADC%252BC2M7jsl2rug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2014&pages=603-617&author=B.+S.+Bolandauthor=W.+J.+Sandbornauthor=J.+T.+Chang&title=Update+on+Janus+Kinase+Antagonists+in+Inflammatory+Bowel+Disease&doi=10.1016%2Fj.gtc.2014.05.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Update on Janus kinase antagonists in inflammatory bowel disease</span></div><div class="casAuthors">Boland Brigid S; Sandborn William J; Chang John T</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology clinics of North America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">603-17</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Janus kinase (JAK) inhibitors have emerged as a novel orally administered small-molecule therapy for the treatment of ulcerative colitis and possibly Crohn disease.  These molecules are designed to selectively target the activity of specific JAKs and to offer a targeted mechanism of action without risk of immunogenicity.  Based on data from clinical trials in rheumatoid arthritis and phase 2 studies in inflammatory bowel disease, tofacitinib and other JAK inhibitors are likely to become a new form of medical therapy for the treatment of inflammatory bowel disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSVKdNIYzs50ny-c-E1v-fmfW6udTcc2eaHud3c5ofzrLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M7jsl2rug%253D%253D&md5=8814b4d1e5ae091533bdbeec71829843</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.gtc.2014.05.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gtc.2014.05.011%26sid%3Dliteratum%253Aachs%26aulast%3DBoland%26aufirst%3DB.%2BS.%26aulast%3DSandborn%26aufirst%3DW.%2BJ.%26aulast%3DChang%26aufirst%3DJ.%2BT.%26atitle%3DUpdate%2520on%2520Janus%2520Kinase%2520Antagonists%2520in%2520Inflammatory%2520Bowel%2520Disease%26jtitle%3DGastroenterology%2520clinics%2520of%2520North%2520America%26date%3D2014%26volume%3D43%26spage%3D603%26epage%3D617%26doi%3D10.1016%2Fj.gtc.2014.05.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sandborn, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sands, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Haens, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermeire, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danese, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panés, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feagan, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinisch, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niezychowski, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawendy, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodworth, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healey, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, C.</span></span> <span> </span><span class="NLM_article-title">767 Efficacy and Safety of Oral Tofacitinib as Induction Therapy in Patients with Moderate to Severe Ulcerative Colitis: Results from Two Phase 3 Randomized Controlled Trials</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">S157</span>, <span class="refDoi"> DOI: 10.1016/S0016-5085(16)30622-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1016%2FS0016-5085%2816%2930622-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2016&pages=S157&author=W.+Sandbornauthor=B.+E.+Sandsauthor=G.+R.+D%E2%80%99Haensauthor=S.+Vermeireauthor=S.+Schreiberauthor=S.+Daneseauthor=J.+Pan%C3%A9sauthor=B.+G.+Feaganauthor=W.+Reinischauthor=W.+Niezychowskiauthor=G.+Friedmanauthor=N.+Lawendyauthor=D.+Yuauthor=D.+A.+Woodworthauthor=A.+Mukherjeeauthor=P.+J.+Healeyauthor=H.+Zhangauthor=C.+Su&title=767+Efficacy+and+Safety+of+Oral+Tofacitinib+as+Induction+Therapy+in+Patients+with+Moderate+to+Severe+Ulcerative+Colitis%3A+Results+from+Two+Phase+3+Randomized+Controlled+Trials&doi=10.1016%2FS0016-5085%2816%2930622-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS0016-5085%2816%2930622-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0016-5085%252816%252930622-9%26sid%3Dliteratum%253Aachs%26aulast%3DSandborn%26aufirst%3DW.%26aulast%3DSands%26aufirst%3DB.%2BE.%26aulast%3DD%25E2%2580%2599Haens%26aufirst%3DG.%2BR.%26aulast%3DVermeire%26aufirst%3DS.%26aulast%3DSchreiber%26aufirst%3DS.%26aulast%3DDanese%26aufirst%3DS.%26aulast%3DPan%25C3%25A9s%26aufirst%3DJ.%26aulast%3DFeagan%26aufirst%3DB.%2BG.%26aulast%3DReinisch%26aufirst%3DW.%26aulast%3DNiezychowski%26aufirst%3DW.%26aulast%3DFriedman%26aufirst%3DG.%26aulast%3DLawendy%26aufirst%3DN.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DWoodworth%26aufirst%3DD.%2BA.%26aulast%3DMukherjee%26aufirst%3DA.%26aulast%3DHealey%26aufirst%3DP.%2BJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DSu%26aufirst%3DC.%26atitle%3D767%2520Efficacy%2520and%2520Safety%2520of%2520Oral%2520Tofacitinib%2520as%2520Induction%2520Therapy%2520in%2520Patients%2520with%2520Moderate%2520to%2520Severe%2520Ulcerative%2520Colitis%253A%2520Results%2520from%2520Two%2520Phase%25203%2520Randomized%2520Controlled%2520Trials%26jtitle%3DGastroenterology%26date%3D2016%26volume%3D150%26spage%3DS157%26doi%3D10.1016%2FS0016-5085%2816%2930622-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sandborn, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vranic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niezychowski, W.</span></span> <span> </span><span class="NLM_article-title">Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">616</span>– <span class="NLM_lpage">624</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1112168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1056%2FNEJMoa1112168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=22894574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Chu77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=616-624&author=W.+J.+Sandbornauthor=S.+Ghoshauthor=J.+Panesauthor=I.+Vranicauthor=C.+Suauthor=S.+Rousellauthor=W.+Niezychowski&title=Tofacitinib%2C+an+Oral+Janus+Kinase+Inhibitor%2C+in+Active+Ulcerative+Colitis&doi=10.1056%2FNEJMoa1112168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis</span></div><div class="casAuthors">Sandborn, William J.; Ghosh, Subrata; Panes, Julian; Vranic, Ivana; Su, Chinyu; Rousell, Samantha; Niezychowski, Wojciech</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">616-624</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Ulcerative colitis is a chronic inflammatory disease of the colon for which current treatments are not universally effective.  One addnl. treatment may be tofacitinib (CP-690,550), an oral inhibitor of Janus kinases 1, 2, and 3 with in vitro functional specificity for kinases 1 and 3 over kinase 2, which is expected to block signaling involving gamma chain-contg. cytokines including interleukins 2, 4, 7, 9, 15, and 21.  These cytokines are integral to lymphocyte activation, function, and proliferation.  Methods: In a double-blind, placebo-controlled, phase 2 trial, we evaluated the efficacy of tofacitinib in 194 adults with moderately to severely active ulcerative colitis.  Patients were randomly assigned to receive tofacitinib at a dose of 0.5 mg, 3 mg, 10 mg, or 15 mg or placebo twice daily for 8 wk.  The primary outcome was a clin. response at 8 wk, defined as an abs. decrease from baseline in the score on the Mayo scoring system for assessment of ulcerative colitis activity (possible score, 0 to 12, with higher scores indicating more severe disease) of 3 or more and a relative decrease from baseline of 30% or more with an accompanying decrease in the rectal bleeding subscore of 1 point or more or an abs. rectal bleeding subscore of 0 or 1.  Results: The primary outcome, clin. response at 8 wk, occurred in 32%, 48%, 61%, and 78% of patients receiving tofacitinib at a dose of 0.5 mg (P = 0.39), 3 mg (P = 0.55), 10 mg (P = 0.10), and 15 mg (P<0.001), resp., as compared with 42% of patients receiving placebo.  Clin. remission (defined as a Mayo score ≤2, with no subscore >1) at 8 wk occurred in 13%, 33%, 48%, and 41% of patients receiving tofacitinib at a dose of 0.5 mg (P = 0.76), 3 mg (P = 0.01), 10 mg (P<0.001), and 15 mg (P<0.001), resp., as compared with 10% of patients receiving placebo.  There was a dose-dependent increase in both low-d. and high-d. lipoprotein cholesterol.  Three patients treated with tofacitinib had an abs. neutrophil count of less than 1500.  Conclusions: Patients with moderately to severely active ulcerative colitis treated with tofacitinib were more likely to have clin. response and remission than those receiving placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ_Al47Ev_6rVg90H21EOLACvtfcHk0lilMLHUfK_thA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Chu77K&md5=1ae8898c6de9bd24113b1f0a8e7fbed8</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1112168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1112168%26sid%3Dliteratum%253Aachs%26aulast%3DSandborn%26aufirst%3DW.%2BJ.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DPanes%26aufirst%3DJ.%26aulast%3DVranic%26aufirst%3DI.%26aulast%3DSu%26aufirst%3DC.%26aulast%3DRousell%26aufirst%3DS.%26aulast%3DNiezychowski%26aufirst%3DW.%26atitle%3DTofacitinib%252C%2520an%2520Oral%2520Janus%2520Kinase%2520Inhibitor%252C%2520in%2520Active%2520Ulcerative%2520Colitis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D616%26epage%3D624%26doi%3D10.1056%2FNEJMoa1112168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sandborn, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vranic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niezychowski, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Study, A. I.</span></span> <span> </span><span class="NLM_article-title">A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Crohn’s Disease</span>. <i>Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1485</span>– <span class="NLM_lpage">1493</span>, <span class="refDoi"> DOI: 10.1016/j.cgh.2014.01.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1016%2Fj.cgh.2014.01.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=24480677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A280%3ADC%252BC2cvgsFygtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=1485-1493&author=W.+J.+Sandbornauthor=S.+Ghoshauthor=J.+Panesauthor=I.+Vranicauthor=W.+Wangauthor=W.+Niezychowskiauthor=A.+I.+Study&title=A+Phase+2+Study+of+Tofacitinib%2C+an+Oral+Janus+Kinase+Inhibitor%2C+in+Patients+with+Crohn%E2%80%99s+Disease&doi=10.1016%2Fj.cgh.2014.01.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease</span></div><div class="casAuthors">Sandborn William J; Ghosh Subrata; Panes Julian; Vranic Ivana; Wang Wenjin; Niezychowski Wojciech</div><div class="citationInfo"><span class="NLM_cas:title">Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1485-93.e2</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND & AIMS:  Tofacitinib, an orally administered Janus kinase inhibitor, blocks signaling through γ-chain-containing cytokines (interleukins 2, 4, 7, 9, 15, and 21).  We performed a phase 2 trial to measure its efficacy in patients with moderate-to-severe active Crohn's disease.  METHODS:  Patients (N = 139; age, ≥18 y) with moderate-to-severe active Crohn's disease were assigned randomly to groups given 1 mg (n = 36), 5 mg (n = 34), or 15 mg (n = 35) tofacitinib or placebo (n = 34), twice daily for 4 weeks, at 48 centers in 12 countries.  The primary end point was the proportion of clinical responders at week 4 (decrease from baseline in the Crohn's Disease Activity Index score of ≥70 points [Response-70]).  Secondary end points included clinical remission (Crohn's Disease Activity Index score of <150 points) at week 4.  RESULTS:  A clinical response was observed in 36% (P = .467), 58% (P = .466), and 46% (P ≥ .999) of patients given the 1-, 5-, and 15-mg doses of tofacitinib, compared with 47% of patients given placebo.  Clinical remission was observed in 31% (P = .417), 24% (P = .776), and 14% (P = .540) of patients given the 1-, 5-, and 15-mg doses of tofacitinib, compared with 21% of patients given placebo.  The 15-mg dose of tofacitinib reduced levels of C-reactive protein and fecal calprotectin from baseline.  Adverse and serious adverse events were similar among groups.  Dose-dependent increases in low- and high-density lipoprotein cholesterol were observed in patients given the 5- or 15-mg doses of tofacitinib.  CONCLUSIONS:  There were no significant differences in the percentage of patients with moderate-to-severe active Crohn's disease who achieved clinical responses (Response-70) or clinical remission after 4 weeks' administration of tofacitinib (1, 5, or 15 mg) or placebo twice daily.  However, a large percentage of patients given placebo achieved Response-70 or remission.  Reductions in C-reactive protein and fecal calprotectin levels among patients given the 15-mg dose of tofacitinib indicate its biologic activity.  ClinicalTrials.gov number: NCT00615199.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQXZWWuvyNAp2LFM_lbR1VmfW6udTcc2eaGPP3SQZwY7rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cvgsFygtw%253D%253D&md5=b1dffa1b3a6f78760025787651d32e80</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.cgh.2014.01.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cgh.2014.01.029%26sid%3Dliteratum%253Aachs%26aulast%3DSandborn%26aufirst%3DW.%2BJ.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DPanes%26aufirst%3DJ.%26aulast%3DVranic%26aufirst%3DI.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DNiezychowski%26aufirst%3DW.%26aulast%3DStudy%26aufirst%3DA.%2BI.%26atitle%3DA%2520Phase%25202%2520Study%2520of%2520Tofacitinib%252C%2520an%2520Oral%2520Janus%2520Kinase%2520Inhibitor%252C%2520in%2520Patients%2520with%2520Crohn%25E2%2580%2599s%2520Disease%26jtitle%3DClinical%2520gastroenterology%2520and%2520hepatology%253A%2520the%2520official%2520clinical%2520practice%2520journal%2520of%2520the%2520American%2520Gastroenterological%2520Association%26date%3D2014%26volume%3D12%26spage%3D1485%26epage%3D1493%26doi%3D10.1016%2Fj.cgh.2014.01.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menet, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Lommen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geney, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanc, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smits, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouannigot, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deprez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Aar, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clement-Lacroix, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepescheux, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galien, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vayssiere, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelles, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christophe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brys, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhring, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciesielski, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Rompaey, L.</span></span> <span> </span><span class="NLM_article-title">Triazolopyridines as Selective Jak1 Inhibitors: From Hit Identification to Glpg0634</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">9323</span>– <span class="NLM_lpage">9342</span>, <span class="refDoi"> DOI: 10.1021/jm501262q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501262q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGls7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=9323-9342&author=C.+J.+Menetauthor=S.+R.+Fletcherauthor=G.+Van+Lommenauthor=R.+Geneyauthor=J.+Blancauthor=K.+Smitsauthor=N.+Jouannigotauthor=P.+Deprezauthor=E.+M.+van+der%0AAarauthor=P.+Clement-Lacroixauthor=L.+Lepescheuxauthor=R.+Galienauthor=B.+Vayssiereauthor=L.+Nellesauthor=T.+Christopheauthor=R.+Brysauthor=M.+Uhringauthor=F.+Ciesielskiauthor=L.+Van+Rompaey&title=Triazolopyridines+as+Selective+Jak1+Inhibitors%3A+From+Hit+Identification+to+Glpg0634&doi=10.1021%2Fjm501262q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634</span></div><div class="casAuthors">Menet, Christel J.; Fletcher, Stephen R.; Van Lommen, Guy; Geney, Raphael; Blanc, Javier; Smits, Koen; Jouannigot, Nolwenn; Deprez, Pierre; van der Aar, Ellen M.; Clement-Lacroix, Philippe; Lepescheux, Lien; Galien, Rene; Vayssiere, Beatrice; Nelles, Luc; Christophe, Thierry; Brys, Reginald; Uhring, Muriel; Ciesielski, Fabrice; Van Rompaey, Luc</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9323-9342</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Janus kinases (JAK1, JAK2, JAK3, and TYK2) are involved in the signaling of multiple cytokines important in cellular function.  Blockade of the JAK-STAT pathway with a small mol. has been shown to provide therapeutic immunomodulation.  Having identified JAK1 as a possible new target for arthritis at Galapagos, the compd. library was screened against JAK1, resulting in the identification of a triazolopyridine-based series of inhibitors represented by I.  Optimization within this chem. series led to identification of II (GLPG0634, filgotinib), a selective JAK1 inhibitor currently in phase 2B development for RA and phase 2A development for Crohn's disease (CD).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBHELw4zQ5QLVg90H21EOLACvtfcHk0lifssWHFMq2og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGls7nN&md5=756f687dc30e6fd34004deb672fe8b23</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm501262q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501262q%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%26aulast%3DFletcher%26aufirst%3DS.%2BR.%26aulast%3DVan%2BLommen%26aufirst%3DG.%26aulast%3DGeney%26aufirst%3DR.%26aulast%3DBlanc%26aufirst%3DJ.%26aulast%3DSmits%26aufirst%3DK.%26aulast%3DJouannigot%26aufirst%3DN.%26aulast%3DDeprez%26aufirst%3DP.%26aulast%3Dvan%2Bder%2BAar%26aufirst%3DE.%2BM.%26aulast%3DClement-Lacroix%26aufirst%3DP.%26aulast%3DLepescheux%26aufirst%3DL.%26aulast%3DGalien%26aufirst%3DR.%26aulast%3DVayssiere%26aufirst%3DB.%26aulast%3DNelles%26aufirst%3DL.%26aulast%3DChristophe%26aufirst%3DT.%26aulast%3DBrys%26aufirst%3DR.%26aulast%3DUhring%26aufirst%3DM.%26aulast%3DCiesielski%26aufirst%3DF.%26aulast%3DVan%2BRompaey%26aufirst%3DL.%26atitle%3DTriazolopyridines%2520as%2520Selective%2520Jak1%2520Inhibitors%253A%2520From%2520Hit%2520Identification%2520to%2520Glpg0634%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D9323%26epage%3D9342%26doi%3D10.1021%2Fjm501262q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloom, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breedveld, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coombs, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruben, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnaswami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgos-Vargas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zerbini, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwillich, S. H.</span></span> <span> </span><span class="NLM_article-title">The Safety and Efficacy of a Jak Inhibitor in Patients with Active Rheumatoid Arthritis: Results of a Double-Blind, Placebo-Controlled Phase Iia Trial of Three Dosage Levels of Cp-690,550 Versus Placebo</span>. <i>Arthritis Rheum.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1895</span>– <span class="NLM_lpage">1905</span>, <span class="refDoi"> DOI: 10.1002/art.24567</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1002%2Fart.24567" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=19565475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptlKktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=1895-1905&author=J.+M.+Kremerauthor=B.+J.+Bloomauthor=F.+C.+Breedveldauthor=J.+H.+Coombsauthor=M.+P.+Fletcherauthor=D.+Grubenauthor=S.+Krishnaswamiauthor=R.+Burgos-Vargasauthor=B.+Wilkinsonauthor=C.+A.+Zerbiniauthor=S.+H.+Zwillich&title=The+Safety+and+Efficacy+of+a+Jak+Inhibitor+in+Patients+with+Active+Rheumatoid+Arthritis%3A+Results+of+a+Double-Blind%2C+Placebo-Controlled+Phase+Iia+Trial+of+Three+Dosage+Levels+of+Cp-690%2C550+Versus+Placebo&doi=10.1002%2Fart.24567"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo</span></div><div class="casAuthors">Kremer, Joel M.; Bloom, Bradley J.; Breedveld, Ferdinand C.; Coombs, John H.; Fletcher, Mark P.; Gruben, David; Krishnaswami, Sriram; Burgos-Vargas, Ruben; Wilkinson, Bethanie; Zerbini, Cristiano A. F.; Zwillich, Samuel H.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1895-1905</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">To det. the efficacy, safety, and tolerability of 3 different dosages of CP-690,550, a potent, orally active JAK inhibitor, in patients with active rheumatoid arthritis (RA) in whom methotrexate, etanercept, infliximab, or adalimumab caused an inadequate or toxic response.  Patients (n = 264) were randomized equally to receive placebo, 5 mg of CP-690,550,15 mg of CP-690,550, or 30 mg of CP-690,550 twice daily for 6 wk, and were followed up for an addnl. 6 wk after treatment.  The primary efficacy end point was the American College of Rheumatol. 20% improvement criteria (ACR20) response rate at 6 wk.  By week 6, the ACR20 response rates were 70.5%, 81.2%, and 76.8% in the 5 mg, 15 mg, and 30 mg twice daily groups, resp., compared with 29.2% in the placebo group (P < 0.001).  Improvements in disease activity in CP-690,550-treated patients compared with placebo were seen in all treatment groups as early as week 1.  ACR50 and ACR70 response rates significantly improved in all treatment groups by week 4.  The most common adverse events reported were headache and nausea.  The infection rate in both the 15 mg twice daily group and the 30 mg twice daily group was 30.4% (vs. 26.2% in the placebo group).  No opportunistic infections or deaths occurred.  Increases in mean low-d. lipoprotein cholesterol and high-d. lipoprotein cholesterol levels, and increases in mean serum creatinine level (0.04-0.06 mg/dL) were seen in all CP-690,550 treatment arms.  Our findings indicate that CP-690,550 is efficacious in the treatment of RA, resulting in rapid, statistically significant, and clin. meaningful redns. in the signs and symptoms of RA.  Further studies of CP-690,550 in RA are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBhxBhh_mG7rVg90H21EOLACvtfcHk0lgRQ0uJqbphjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptlKktLg%253D&md5=ab5fb34e43d8643871560c67bbbca07d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fart.24567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.24567%26sid%3Dliteratum%253Aachs%26aulast%3DKremer%26aufirst%3DJ.%2BM.%26aulast%3DBloom%26aufirst%3DB.%2BJ.%26aulast%3DBreedveld%26aufirst%3DF.%2BC.%26aulast%3DCoombs%26aufirst%3DJ.%2BH.%26aulast%3DFletcher%26aufirst%3DM.%2BP.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DBurgos-Vargas%26aufirst%3DR.%26aulast%3DWilkinson%26aufirst%3DB.%26aulast%3DZerbini%26aufirst%3DC.%2BA.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26atitle%3DThe%2520Safety%2520and%2520Efficacy%2520of%2520a%2520Jak%2520Inhibitor%2520in%2520Patients%2520with%2520Active%2520Rheumatoid%2520Arthritis%253A%2520Results%2520of%2520a%2520Double-Blind%252C%2520Placebo-Controlled%2520Phase%2520Iia%2520Trial%2520of%2520Three%2520Dosage%2520Levels%2520of%2520Cp-690%252C550%2520Versus%2520Placebo%26jtitle%3DArthritis%2520Rheum.%26date%3D2009%26volume%3D60%26spage%3D1895%26epage%3D1905%26doi%3D10.1002%2Fart.24567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, O. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidelin, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ainsworth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coskun, M.</span></span> <span> </span><span class="NLM_article-title">Will Novel Oral Formulations Change the Management of Inflammatory Bowel Disease?</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">718</span>, <span class="refDoi"> DOI: 10.1517/13543784.2016.1165204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1517%2F13543784.2016.1165204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=26967267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvFGqs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2016&pages=709-718&author=O.+H.+Nielsenauthor=J.+B.+Seidelinauthor=M.+Ainsworthauthor=M.+Coskun&title=Will+Novel+Oral+Formulations+Change+the+Management+of+Inflammatory+Bowel+Disease%3F&doi=10.1517%2F13543784.2016.1165204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Will novel oral formulations change the management of inflammatory bowel disease?</span></div><div class="casAuthors">Nielsen, Ole Haagen; Seidelin, Jakob Benedict; Ainsworth, Mark; Coskun, Mehmet</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">709-718</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The traditional management of inflammatory bowel disease (IBD) with sulphasalazine/5-aminosalicylic acid, glucocorticoids and immunomodulators (i.e., thiopurines and methotrexate) was nearly two decades ago extended with i.v. or s.c. administered biologics (i.e., tumor necrosis factor inhibitors and later gut-selective integrin antagonists).  However, recently, orally administered treatments with simple, well-characterized, and stable structures consisting of either small mols. or anti-sense therapy have been devised.  This review discusses the current approaches with promising new oral drugs with distinct modes of action, including: the Janus kinase inhibitors (i.e., tofacitinib, filgotinib and peficitinib); the immunomodulatory drug (laquinimod); a small α4 antagonist (AJM300); agonists for sphingosine-phosphate receptors (i.e., ozanimod, APD334, and amiselimod), as well as anti-sense therapy (mongersen) targeting SMAD7, drugs which directly target intracellular pathways of relevance for intestinal inflammation.  A new avenue using easily administered oral therapies for the management of IBD is being introduced.  While their place in the clin. armamentarium remains to be proven, it is likely that many of these drugs will find their place in the treatment algorithm of IBD in the next few years.  Thus, we will face times in which IBD therapy will be based on significantly more tablets than prescribed today.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp53hEx6x0XvbVg90H21EOLACvtfcHk0lgRQ0uJqbphjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvFGqs7Y%253D&md5=35fb0a1717d67eff029d7e5f51354cce</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1517%2F13543784.2016.1165204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2016.1165204%26sid%3Dliteratum%253Aachs%26aulast%3DNielsen%26aufirst%3DO.%2BH.%26aulast%3DSeidelin%26aufirst%3DJ.%2BB.%26aulast%3DAinsworth%26aufirst%3DM.%26aulast%3DCoskun%26aufirst%3DM.%26atitle%3DWill%2520Novel%2520Oral%2520Formulations%2520Change%2520the%2520Management%2520of%2520Inflammatory%2520Bowel%2520Disease%253F%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2016%26volume%3D25%26spage%3D709%26epage%3D718%26doi%3D10.1517%2F13543784.2016.1165204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">USFDA</span>. <span> </span><span class="NLM_article-title">FDA Approves Boxed Warning About
Increased Risk
of Blood Clots and Death with Higher Dose of Arthritis and Ulcerative
Colitis Medicine Tofacitinib (Xeljanz, Xeljanz Xr)</span>. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and" class="extLink">https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=USFDA.+FDA+Approves+Boxed+Warning+About%0AIncreased+Risk%0Aof+Blood+Clots+and+Death+with+Higher+Dose+of+Arthritis+and+Ulcerative%0AColitis+Medicine+Tofacitinib+%28Xeljanz%2C+Xeljanz+Xr%29.+https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-safety-and-availability%2Ffda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DFDA%2520Approves%2520Boxed%2520Warning%2520About%250AIncreased%2520Risk%250Aof%2520Blood%2520Clots%2520and%2520Death%2520with%2520Higher%2520Dose%2520of%2520Arthritis%2520and%2520Ulcerative%250AColitis%2520Medicine%2520Tofacitinib%2520%2528Xeljanz%252C%2520Xeljanz%2520Xr%2529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">USFDA</span>. <span> </span><span class="NLM_article-title">Upadacitinib Prescribing Information</span>. <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=USFDA.+Upadacitinib+Prescribing+Information.+https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F211675s000lbl.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DUpadacitinib%2520Prescribing%2520Information" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Filipski, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varma, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kattan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambler, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goosen, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, K. O.</span></span> <span> </span><span class="NLM_article-title">Intestinal Targeting of Drugs: Rational Design Approaches and Challenges</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">776</span>– <span class="NLM_lpage">802</span>, <span class="refDoi"> DOI: 10.2174/1568026611313070002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.2174%2F1568026611313070002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=23578023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpsVaqt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=776-802&author=K.+J.+Filipskiauthor=M.+V.+Varmaauthor=A.+F.+El-Kattanauthor=C.+M.+Amblerauthor=R.+B.+Ruggeriauthor=T.+C.+Goosenauthor=K.+O.+Cameron&title=Intestinal+Targeting+of+Drugs%3A+Rational+Design+Approaches+and+Challenges&doi=10.2174%2F1568026611313070002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinal targeting of drugs: rational design approaches and challenges</span></div><div class="casAuthors">Filipski, Kevin J.; Varma, Manthena V.; El-Kattan, Ayman F.; Ambler, Catherine M.; Ruggeri, Roger B.; Goosen, Theunis C.; Cameron, Kimberly O.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">776-802</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Targeting drugs to the gastrointestinal tract has been and continues to be an active area of research.  Guttargeting is an effective means of increasing the local concn. of active substance at the desired site of action while minimizing concns. elsewhere in the body that could lead to unwanted side-effects.  Several approaches to intestinal targeting exist.  Physicochem. property manipulation can drive mols. to large, polar, low absorption space or alternatively to lipophilic, high clearance space in order to minimize systemic exposure.  Design of compds. that are substrates for transporters within the gastrointestinal tract, either uptake or efflux, or at the hepato-biliary interface, may help to increase intestinal concn.  Prodrug strategies have been shown to be effective particularly for colon targeting, and several different technol. formulation approaches are currently being researched.  This review provides examples of various approaches to intestinal targeting, and discusses challenges and areas in need of future scientific advances.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn5CowmF-p-LVg90H21EOLACvtfcHk0lgS3EM9jmFdLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpsVaqt7w%253D&md5=b950400c76b8d955ebd39e6cad4a20aa</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.2174%2F1568026611313070002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026611313070002%26sid%3Dliteratum%253Aachs%26aulast%3DFilipski%26aufirst%3DK.%2BJ.%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DEl-Kattan%26aufirst%3DA.%2BF.%26aulast%3DAmbler%26aufirst%3DC.%2BM.%26aulast%3DRuggeri%26aufirst%3DR.%2BB.%26aulast%3DGoosen%26aufirst%3DT.%2BC.%26aulast%3DCameron%26aufirst%3DK.%2BO.%26atitle%3DIntestinal%2520Targeting%2520of%2520Drugs%253A%2520Rational%2520Design%2520Approaches%2520and%2520Challenges%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D776%26epage%3D802%26doi%3D10.2174%2F1568026611313070002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menees, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maneerattannaporn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chey, W. D.</span></span> <span> </span><span class="NLM_article-title">The Efficacy and Safety of Rifaximin for the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis</span>. <i>Am. J. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.1038/ajg.2011.355</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1038%2Fajg.2011.355" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=22045120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADC%252BC38XkslOmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2012&pages=28-35&author=S.+B.+Meneesauthor=M.+Maneerattannapornauthor=H.+M.+Kimauthor=W.+D.+Chey&title=The+Efficacy+and+Safety+of+Rifaximin+for+the+Irritable+Bowel+Syndrome%3A+A+Systematic+Review+and+Meta-Analysis&doi=10.1038%2Fajg.2011.355"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The Efficacy and Safety of Rifaximin for the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis</span></div><div class="casAuthors">Menees, Stacy B.; Maneerattannaporn, Monthira; Kim, Hyungjin Myra; Chey, William D.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-35</span>CODEN:
                <span class="NLM_cas:coden">AJGAAR</span>;
        ISSN:<span class="NLM_cas:issn">0002-9270</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">OBJECTIVES: Irritable bowel syndrome (IBS) affects 10-15% of the population, and treatment options are limited.  Rifaximin is a minimally absorbed antibiotic that has shown efficacy in IBS patients.  The objective of our study was to perform a meta-anal. and systematic review of available randomized, placebo controlled trials evaluating the efficacy and tolerability of rifaximin in patients with IBS.  METHODS: We performed a systematic literature search of multiple online electronic databases regardless of language.  Inclusion criteria entailed randomized, placebo controlled trials and IBS defined by accepted symptom-based criteria.  Meta-anal. was conducted to evaluate the summary odds ratios (ORs) and 95% confidence intervals (CIs) of combined studies for the primary and secondary outcomes using a random-effects model based on the DerSimonian and Laird method to reflect both within- and between study variability.  We assessed heterogeneity using χ2 test and the inconsistency index statistic (I2).  Significant heterogeneity was defined as I2 ≥25%.  Meta-regression was performed using generalized linear mixed-effects model and study as random effects to est. the summary OR adjusting for covariate differences across studies and treatment group.  Publication bias was assessed by funnel plot anal.  RESULTS: Systematic review identified 13,700 citations.  Eighteen were deemed to be potentially relevant, of which five articles met eligibility.  Meta-anal. found rifaximin to be more efficacious than placebo for global IBS symptom improvement (OR=1.57; 95% CI=1.22, 2.01; therapeutic gain=9.8%; no. needed to treat (NNT)=10.2), with mild heterogeneity (P=0.25, I2=26%).  For the key secondary outcome of bloating, raw data were available for four studies.  Rifaximin was significantly more likely to improve bloating than placebo (OR=1.55; 95% CI=1.23-1.96; therapeutic gain=9.9%; NNT=10.1), with no significant heterogeneity (P=0.27, I2=23%).  We found that studies with older patients and more females demonstrated higher response rates, which was consistent regardless of treatment group.  In addn., studies with higher cumulative dose tended to report a higher response rate.  Of the covariates evaluated, we found age to be most predictive of response, with a correlation coeff. of 0.97 between aggregate response rate and mean age in the placebo groups.  Although studies with higher cumulative dose tended to show increased response rates, this was also seen consistently in both the treated and placebo groups.  Adverse effects were similar among patients receiving rifaximin or placebo in all studies.  The most common adverse events (AEs) (≤10%) with rifaximin were headache, upper respiratory infection, nausea, nasopharygitis, diarrhea, and abdominal pain.  Serious AEs were rare (<1%) and similar with rifaximin and placebo.  CONCLUSIONS: Rifaximin proved more effective than placebo for global symptoms and bloating in IBS patients.  The modest therapeutic gain was similar to that yielded by other currently available therapies for IBS.  AEs were similar between rifaximin and placebo.  Am J Gastroenterol 2012; 107:28-35; doi:10.1038/ajg.2011.355; published online 1 Nov. 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBt5S9T_Bj2LVg90H21EOLACvtfcHk0lgnAqms1YU4Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkslOmsg%253D%253D&md5=b74dd80328ed42f815c5152144f0df52</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fajg.2011.355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fajg.2011.355%26sid%3Dliteratum%253Aachs%26aulast%3DMenees%26aufirst%3DS.%2BB.%26aulast%3DManeerattannaporn%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DH.%2BM.%26aulast%3DChey%26aufirst%3DW.%2BD.%26atitle%3DThe%2520Efficacy%2520and%2520Safety%2520of%2520Rifaximin%2520for%2520the%2520Irritable%2520Bowel%2520Syndrome%253A%2520A%2520Systematic%2520Review%2520and%2520Meta-Analysis%26jtitle%3DAm.%2520J.%2520Gastroenterol.%26date%3D2012%26volume%3D107%26spage%3D28%26epage%3D35%26doi%3D10.1038%2Fajg.2011.355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez-Roque, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouras, E. P.</span></span> <span> </span><span class="NLM_article-title">Linaclotide, Novel Therapy for the Treatment of Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome</span>. <i>Adv. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">211</span>, <span class="refDoi"> DOI: 10.1007/s12325-013-0012-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1007%2Fs12325-013-0012-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=23436110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksFegsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2013&pages=203-211&author=M.+I.+Vazquez-Roqueauthor=E.+P.+Bouras&title=Linaclotide%2C+Novel+Therapy+for+the+Treatment+of+Chronic+Idiopathic+Constipation+and+Constipation-Predominant+Irritable+Bowel+Syndrome&doi=10.1007%2Fs12325-013-0012-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Linaclotide, Novel Therapy for the Treatment of Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome</span></div><div class="casAuthors">Vazquez-Roque, Maria I.; Bouras, Ernest P.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">203-211</span>CODEN:
                <span class="NLM_cas:coden">ADTHE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-238X</span>.
    
            (<span class="NLM_cas:orgname">Springer Healthcare Ltd.</span>)
        </div><div class="casAbstract">A review.  Chronic constipation (CC) and irritable bowel syndrome with constipation (IBS-C) are common gastrointestinal (GI) disorders.  Current treatment options, either prescription or nonprescription medications, have limited efficacy in a subset of patients.  There is significant demand for more efficacious medications for the treatment of CC and IBS-C.  Linaclotide, a secretagogue, has a novel mechanism of action designed to treat patients with CC and IBS-C.  It has a low oral bioavailability with negligible systemic side effects, and it acts locally in the intestinal lumen.  In several clin. trials, in health and disease, linaclotide has demonstrated durable efficacy and safety in CC and IBS-C.  Linaclotide received approval by the Federal Drug Administration in August 2012 to treat chronic idiopathic constipation and IBS-C.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogNjGesknmN7Vg90H21EOLACvtfcHk0lgnAqms1YU4Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksFegsLg%253D&md5=33bc79f667f537b2594f171db26501e5</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2Fs12325-013-0012-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12325-013-0012-9%26sid%3Dliteratum%253Aachs%26aulast%3DVazquez-Roque%26aufirst%3DM.%2BI.%26aulast%3DBouras%26aufirst%3DE.%2BP.%26atitle%3DLinaclotide%252C%2520Novel%2520Therapy%2520for%2520the%2520Treatment%2520of%2520Chronic%2520Idiopathic%2520Constipation%2520and%2520Constipation-Predominant%2520Irritable%2520Bowel%2520Syndrome%26jtitle%3DAdv.%2520Ther.%26date%3D2013%26volume%3D30%26spage%3D203%26epage%3D211%26doi%3D10.1007%2Fs12325-013-0012-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowtle, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryden, R.</span></span> <span> </span><span class="NLM_article-title">Disposition of Vancomycin in Healthy Volunteers from Oral Solution and Semi-Solid Matrix Capsules</span>. <i>Journal of clinical pharmacy and therapeutics</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2710.1976.tb00415.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1111%2Fj.1365-2710.1976.tb00415.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=3449561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADyaL2sXkvVekt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1987&pages=27-31&author=R.+A.+Lucasauthor=W.+J.+Bowtleauthor=R.+Ryden&title=Disposition+of+Vancomycin+in+Healthy+Volunteers+from+Oral+Solution+and+Semi-Solid+Matrix+Capsules&doi=10.1111%2Fj.1365-2710.1976.tb00415.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Disposition of vancomycin in healthy volunteers from oral solution and semi-solid matrix capsules</span></div><div class="casAuthors">Lucas, R. A.; Bowtle, W. J.; Ryden, R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacy and Therapeutics</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-31</span>CODEN:
                <span class="NLM_cas:coden">JCPTED</span>;
        ISSN:<span class="NLM_cas:issn">0269-4727</span>.
    </div><div class="casAbstract">Gastrointestinal availability of vancomycin from oral soln. and semi-solid matrix capsules was detd. in volunteers.  The capsule produced fecal, plasma and urine levels of the antibiotic which are similar to those obtained with the soln., and offers a viable, convenient oral dosage form.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjM31rDkBVBrVg90H21EOLACvtfcHk0lgnAqms1YU4Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXkvVekt7k%253D&md5=53c0ee15682856c500f73962c95f7b9f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2710.1976.tb00415.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2710.1976.tb00415.x%26sid%3Dliteratum%253Aachs%26aulast%3DLucas%26aufirst%3DR.%2BA.%26aulast%3DBowtle%26aufirst%3DW.%2BJ.%26aulast%3DRyden%26aufirst%3DR.%26atitle%3DDisposition%2520of%2520Vancomycin%2520in%2520Healthy%2520Volunteers%2520from%2520Oral%2520Solution%2520and%2520Semi-Solid%2520Matrix%2520Capsules%26jtitle%3DJournal%2520of%2520clinical%2520pharmacy%2520and%2520therapeutics%26date%3D1987%26volume%3D12%26spage%3D27%26epage%3D31%26doi%3D10.1111%2Fj.1365-2710.1976.tb00415.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pastan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottesman, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovelace, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutherford, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willingham, M. C.</span></span> <span> </span><span class="NLM_article-title">A Retrovirus Carrying an Mdr1 Cdna Confers Multidrug Resistance and Polarized Expression of P-Glycoprotein in Mdck Cells</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">4486</span>– <span class="NLM_lpage">4490</span>, <span class="refDoi"> DOI: 10.1073/pnas.85.12.4486</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1073%2Fpnas.85.12.4486" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=2898143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADyaL1cXkvVOnsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=1988&pages=4486-4490&author=I.+Pastanauthor=M.+M.+Gottesmanauthor=K.+Uedaauthor=E.+Lovelaceauthor=A.+V.+Rutherfordauthor=M.+C.+Willingham&title=A+Retrovirus+Carrying+an+Mdr1+Cdna+Confers+Multidrug+Resistance+and+Polarized+Expression+of+P-Glycoprotein+in+Mdck+Cells&doi=10.1073%2Fpnas.85.12.4486"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells</span></div><div class="casAuthors">Pastan, Ira; Gottesman, Michael M.; Ueda, Kazumitsu; Lovelace, Elizabeth; Rutherford, Angelina V.; Willingham, Mark C.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4486-90</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">A full-length cDNA for the human multidrug resistance gene 1 (MDR1) has been inserted into a retroviral vector contg. a murine Harvey sarcoma virus from which the viral oncogene was deleted.  Ecotropic and amphotropic virus was produced after transfection of this vector into ψ-2 and PA-12 packaging cell lines.  This virus conferred the full phenotype of multidrug resistance on mouse and human cell lines.  Viral titers of up to 2 × 105 drug-resistant colonies per mL were obsd.  Infected cells became resistant to colchicine, vinblastine, doxorubicin, VP16 (etoposide), and puromycin, but not cisplatin, indicating that the presence of the human MDR1 gene is sufficient to cause multidrug resistance.  When the dog kidney cell line MDCK was infected with the MDR1 virus, P-glycoprotein was expressed in a polarized manner on the upper surface of the cells, showing that the cloned cDNA also encodes information for polarized expression of P-glycoprotein.  The MDR1 virus should be useful for introducing this drug resistance gene into a variety of cell types for biol. expts. in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC3cSVZ7zWEbVg90H21EOLACvtfcHk0lgrdpYIUUa61A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXkvVOnsLw%253D&md5=78e8299b8a21cde221dbb3116dd89288</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1073%2Fpnas.85.12.4486&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.85.12.4486%26sid%3Dliteratum%253Aachs%26aulast%3DPastan%26aufirst%3DI.%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26aulast%3DUeda%26aufirst%3DK.%26aulast%3DLovelace%26aufirst%3DE.%26aulast%3DRutherford%26aufirst%3DA.%2BV.%26aulast%3DWillingham%26aufirst%3DM.%2BC.%26atitle%3DA%2520Retrovirus%2520Carrying%2520an%2520Mdr1%2520Cdna%2520Confers%2520Multidrug%2520Resistance%2520and%2520Polarized%2520Expression%2520of%2520P-Glycoprotein%2520in%2520Mdck%2520Cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1988%26volume%3D85%26spage%3D4486%26epage%3D4490%26doi%3D10.1073%2Fpnas.85.12.4486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Irvine, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolan, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selick, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grove, J. R.</span></span> <span> </span><span class="NLM_article-title">Mdck (Madin-Darby Canine Kidney) Cells: A Tool for Membrane Permeability Screening</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1021/js9803205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1021%2Fjs9803205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=9874698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADyaK1cXns1ylurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=1999&pages=28-33&author=J.+D.+Irvineauthor=L.+Takahashiauthor=K.+Lockhartauthor=J.+Cheongauthor=J.+W.+Tolanauthor=H.+E.+Selickauthor=J.+R.+Grove&title=Mdck+%28Madin-Darby+Canine+Kidney%29+Cells%3A+A+Tool+for+Membrane+Permeability+Screening&doi=10.1021%2Fjs9803205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening</span></div><div class="casAuthors">Irvine, Jennifer D.; Takahashi, Lori; Lockhart, Karen; Cheong, Jonathan; Tolan, John W.; Selick, H. E.; Grove, J. Russell</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-33</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The goal of this work was to investigate the use of MDCK (Madin-Darby canine kidney) cells as a possible tool for assessing the membrane permeability properties of early drug discovery compds.  Apparent permeability (Papp) values of 55 compds. with known human absorption values were detd. using MDCK cell monolayers.  For comparison, Papp values of the same compds. were also detd. using Caco-2 cells, a well-characterized in vitro model of intestinal drug absorption.  Monolayers were grown on 0.4-μm Transwell-COL membrane culture inserts. MDCK cells were seeded at high d. and cultured for 3 days, and Caco-2 cells were cultured under std. conditions for 21 to 25 days.  Compds. were tested using 100 μM donor solns. in transport medium (pH 7.4) contg. 1% DMSO.  The Papp values in MDCK cells correlated well with those in Caco-2 cells (r2 = 0.79). Spearman's rank correlation coeff. for MDCK Papp and human absorption was 0.58 compared with 0.54 for Caco-2 Papp and human absorption.  These results indicate that MDCK cells may be a useful tool for rapid membrane permeability screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolDvo0FQMg7bVg90H21EOLACvtfcHk0lgrdpYIUUa61A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXns1ylurk%253D&md5=ea421117433fa4067578476edde9444e</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjs9803205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjs9803205%26sid%3Dliteratum%253Aachs%26aulast%3DIrvine%26aufirst%3DJ.%2BD.%26aulast%3DTakahashi%26aufirst%3DL.%26aulast%3DLockhart%26aufirst%3DK.%26aulast%3DCheong%26aufirst%3DJ.%26aulast%3DTolan%26aufirst%3DJ.%2BW.%26aulast%3DSelick%26aufirst%3DH.%2BE.%26aulast%3DGrove%26aufirst%3DJ.%2BR.%26atitle%3DMdck%2520%2528Madin-Darby%2520Canine%2520Kidney%2529%2520Cells%253A%2520A%2520Tool%2520for%2520Membrane%2520Permeability%2520Screening%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D1999%26volume%3D88%26spage%3D28%26epage%3D33%26doi%3D10.1021%2Fjs9803205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thiel-Demby, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St John Williams, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellens, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayrton, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polli, J. W.</span></span> <span> </span><span class="NLM_article-title">Biopharmaceutics Classification System: Validation and Learnings of an in Vitro Permeability Assay</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1021/mp800122b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp800122b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWgt7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=11-18&author=V.+E.+Thiel-Dembyauthor=J.+E.+Humphreysauthor=L.+A.+St+John+Williamsauthor=H.+M.+Ellensauthor=N.+Shahauthor=A.+D.+Ayrtonauthor=J.+W.+Polli&title=Biopharmaceutics+Classification+System%3A+Validation+and+Learnings+of+an+in+Vitro+Permeability+Assay&doi=10.1021%2Fmp800122b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Biopharmaceutics Classification System: Validation and Learnings of an in Vitro Permeability Assay</span></div><div class="casAuthors">Thiel-Demby, Victoria E.; Humphreys, Joan E.; St. John Williams, Lisa A.; Ellens, Harma M.; Shah, Nipa; Ayrton, Andrew D.; Polli, Joseph W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-18</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Biopharmaceutics Classification System (BCS) is the scientific basis for classifying drugs based on their aq. soly. and intestinal permeability that supports in vivo bioavailability and bioequivalence waivers for immediate-release solid dosage form drugs.  One requirement of the BCS is that the permeability method must be validated.  In order to accommodate the variety of in vitro/in situ permeability models, the BCS Guidance gives a general framework for the validation requirements, necessitating implemented exptl. details to be selected by the applicant lab.  The objective of this work was to define the parameters for a cell based in vitro permeability method (e.g., cell type, pH, transport direction, time, and concn.) and validate the method to support formal BCS classification of drugs.  Twenty ref. drugs were selected and permeability values detd. using the Madin-Darby canine kidney type II cell line heterologously expressing the human P-glycoprotein transporter (MDCKII-MDR1).  A rank order relationship was established between the in vitro permeability value and human intestinal absorption values.  This relationship was as predicted and validates the MDCKII-MDR1 permeability method as defined by the BCS Guidance.  The final validated in vitro permeability method employs the MDCKII-MDR1 cell line incubated with the Pgp inhibitor GF120918.  It is a unidirectional apical-to-basolateral transport assay performed at apical pH values of 5.5 and 7.4 and a basolateral pH of 7.4.  Four ref. stds. (metoprolol, pindolol, labetalol and ranitidine) dosed and analyzed as a single cassette are included in each expt.  A strategy on selection of drug concns. and on how to deal with problematic compds. (i.e., those suffering from poor mass balance) is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZBvEmiKWNBLVg90H21EOLACvtfcHk0lg70P4vfjUJ1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWgt7vN&md5=b630091c50b109c4a4e9e902583f5b38</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fmp800122b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp800122b%26sid%3Dliteratum%253Aachs%26aulast%3DThiel-Demby%26aufirst%3DV.%2BE.%26aulast%3DHumphreys%26aufirst%3DJ.%2BE.%26aulast%3DSt%2BJohn%2BWilliams%26aufirst%3DL.%2BA.%26aulast%3DEllens%26aufirst%3DH.%2BM.%26aulast%3DShah%26aufirst%3DN.%26aulast%3DAyrton%26aufirst%3DA.%2BD.%26aulast%3DPolli%26aufirst%3DJ.%2BW.%26atitle%3DBiopharmaceutics%2520Classification%2520System%253A%2520Validation%2520and%2520Learnings%2520of%2520an%2520in%2520Vitro%2520Permeability%2520Assay%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2009%26volume%3D6%26spage%3D11%26epage%3D18%26doi%3D10.1021%2Fmp800122b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurley, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bull, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarty, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crackett, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVoss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragovich, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellwood, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaines, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gradl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribling, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harstad, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenny, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehler, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bir Kohli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labadie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liimatta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendonca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narukulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeve, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savage, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ubhayakar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Abbema, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliagas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avitabile-Woo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulagowski, J. J.</span></span> <span> </span><span class="NLM_article-title">Identification of C-2 Hydroxyethyl Imidazopyrrolopyridines as Potent Jak1 Inhibitors with Favorable Physicochemical Properties and High Selectivity over Jak2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4764</span>– <span class="NLM_lpage">4785</span>, <span class="refDoi"> DOI: 10.1021/jm4004895</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4004895" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsVWit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4764-4785&author=M.+Zakauthor=C.+A.+Hurleyauthor=S.+I.+Wardauthor=P.+Bergeronauthor=K.+Barrettauthor=M.+Balazsauthor=W.+S.+Blairauthor=R.+Bullauthor=P.+Chakravartyauthor=C.+Changauthor=P.+Crackettauthor=G.+Deshmukhauthor=J.+DeVossauthor=P.+S.+Dragovichauthor=C.+Eigenbrotauthor=C.+Ellwoodauthor=S.+Gainesauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=S.+Gradlauthor=P.+Griblingauthor=C.+Hammanauthor=E.+Harstadauthor=P.+Hewittauthor=A.+Johnsonauthor=T.+Johnsonauthor=J.+R.+Kennyauthor=M.+F.+Koehlerauthor=P.+Bir+Kohliauthor=S.+Labadieauthor=W.+P.+Leeauthor=J.+Liaoauthor=M.+Liimattaauthor=R.+Mendoncaauthor=R.+Narukullaauthor=R.+Pulkauthor=A.+Reeveauthor=S.+Savageauthor=S.+Shiaauthor=M.+Steffekauthor=S.+Ubhayakarauthor=A.+van+Abbemaauthor=I.+Aliagasauthor=B.+Avitabile-Wooauthor=Y.+Xiaoauthor=J.+Yangauthor=J.+J.+Kulagowski&title=Identification+of+C-2+Hydroxyethyl+Imidazopyrrolopyridines+as+Potent+Jak1+Inhibitors+with+Favorable+Physicochemical+Properties+and+High+Selectivity+over+Jak2&doi=10.1021%2Fjm4004895"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of C-2 Hydroxyethyl Imidazopyrrolopyridines as Potent JAK1 Inhibitors with Favorable Physicochemical Properties and High Selectivity over JAK2</span></div><div class="casAuthors">Zak, Mark; Hurley, Christopher A.; Ward, Stuart I.; Bergeron, Philippe; Barrett, Kathy; Balazs, Mercedesz; Blair, Wade S.; Bull, Richard; Chakravarty, Paroma; Chang, Christine; Crackett, Peter; Deshmukh, Gauri; DeVoss, Jason; Dragovich, Peter S.; Eigenbrot, Charles; Ellwood, Charles; Gaines, Simon; Ghilardi, Nico; Gibbons, Paul; Gradl, Stefan; Gribling, Peter; Hamman, Chris; Harstad, Eric; Hewitt, Peter; Johnson, Adam; Johnson, Tony; Kenny, Jane R.; Koehler, Michael F. T.; Bir Kohli, Pawan; Labadie, Sharada; Lee, Wyne P.; Liao, Jiangpeng; Liimatta, Marya; Mendonca, Rohan; Narukulla, Raman; Pulk, Rebecca; Reeve, Austin; Savage, Scott; Shia, Steven; Steffek, Micah; Ubhayakar, Savita; van Abbema, Anne; Aliagas, Ignacio; Avitabile-Woo, Barbara; Xiao, Yisong; Yang, Jing; Kulagowski, Janusz J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4764-4785</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein we report on the structure-based discovery of a C-2 hydroxyethyl moiety which provided consistently high levels of selectivity for JAK1 over JAK2 to the imidazopyrrolopyridine series of JAK1 inhibitors.  X-ray structures of a C-2 hydroxyethyl analog in complex with both JAK1 and JAK2 revealed differential ligand/protein interactions between the two isoforms and offered an explanation for the obsd. selectivity.  Anal. of historical data from related mols. was used to develop a set of physicochem. compd. design parameters to impart desirable properties such as acceptable membrane permeability, potent whole blood activity, and a high degree of metabolic stability.  This work culminated in the identification of a highly JAK1 selective compd. (31) exhibiting favorable oral bioavailability across a range of preclin. species and robust efficacy in a rat CIA model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP0DlLtJCYq7Vg90H21EOLACvtfcHk0lh58GrtLk8lrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsVWit74%253D&md5=0b0d1950adebf325cc434344f57ca139</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm4004895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4004895%26sid%3Dliteratum%253Aachs%26aulast%3DZak%26aufirst%3DM.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DWard%26aufirst%3DS.%2BI.%26aulast%3DBergeron%26aufirst%3DP.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DBull%26aufirst%3DR.%26aulast%3DChakravarty%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DCrackett%26aufirst%3DP.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DEllwood%26aufirst%3DC.%26aulast%3DGaines%26aufirst%3DS.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DGradl%26aufirst%3DS.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHamman%26aufirst%3DC.%26aulast%3DHarstad%26aufirst%3DE.%26aulast%3DHewitt%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DKoehler%26aufirst%3DM.%2BF.%26aulast%3DBir%2BKohli%26aufirst%3DP.%26aulast%3DLabadie%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DMendonca%26aufirst%3DR.%26aulast%3DNarukulla%26aufirst%3DR.%26aulast%3DPulk%26aufirst%3DR.%26aulast%3DReeve%26aufirst%3DA.%26aulast%3DSavage%26aufirst%3DS.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DSteffek%26aufirst%3DM.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3Dvan%2BAbbema%26aufirst%3DA.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DAvitabile-Woo%26aufirst%3DB.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26atitle%3DIdentification%2520of%2520C-2%2520Hydroxyethyl%2520Imidazopyrrolopyridines%2520as%2520Potent%2520Jak1%2520Inhibitors%2520with%2520Favorable%2520Physicochemical%2520Properties%2520and%2520High%2520Selectivity%2520over%2520Jak2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4764%26epage%3D4785%26doi%3D10.1021%2Fjm4004895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominy, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feeney, P. J.</span></span> <span> </span><span class="NLM_article-title">Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/S0169-409X(00)00129-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1016%2FS0169-409X%2800%2900129-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=11259830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitVOhs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2001&pages=3-26&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+Computational+Approaches+to+Estimate+Solubility+and+Permeability+in+Drug+Discovery+and+Development+Settings&doi=10.1016%2FS0169-409X%2800%2900129-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-26</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is greater than 500 and the calcd. Log P (CLogP) is greater than 5 (or MlogP >4.15).  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYDqa02g16urVg90H21EOLACvtfcHk0lh58GrtLk8lrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitVOhs7o%253D&md5=c60bb89da68f051c0ee7ac4c0468a0e4</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2800%2900129-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252800%252900129-0%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520Computational%2520Approaches%2520to%2520Estimate%2520Solubility%2520and%2520Permeability%2520in%2520Drug%2520Discovery%2520and%2520Development%2520Settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2001%26volume%3D46%26spage%3D3%26epage%3D26%26doi%3D10.1016%2FS0169-409X%2800%2900129-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paolini, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapland, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Hoorn, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span> <span> </span><span class="NLM_article-title">Global Mapping of Pharmacological Space</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">805</span>– <span class="NLM_lpage">815</span>, <span class="refDoi"> DOI: 10.1038/nbt1228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1038%2Fnbt1228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=16841068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFansb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=805-815&author=G.+V.+Paoliniauthor=R.+H.+Shaplandauthor=W.+P.+van+Hoornauthor=J.+S.+Masonauthor=A.+L.+Hopkins&title=Global+Mapping+of+Pharmacological+Space&doi=10.1038%2Fnbt1228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Global mapping of pharmacological space</span></div><div class="casAuthors">Paolini, Gaia V.; Shapland, Richard H. B.; van Hoorn, Willem P.; Mason, Jonathan S.; Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">805-815</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We present the global mapping of pharmacol. space by the integration of several vast sources of medicinal chem. structure-activity relationships (SAR) data.  Our comprehensive mapping of pharmacol. space enables us to identify confidently the human targets for which chem. tools and drugs have been discovered to date.  The integration of SAR data from diverse sources by unique canonical chem. structure, protein sequence and disease indication enables the construction of a ligand-target matrix to explore the global relationships between chem. structure and biol. targets.  Using the data matrix, we are able to catalog the links between proteins in chem. space as a polypharmacol. interaction network.  We demonstrate that probabilistic models can be used to predict pharmacol. from a large knowledge base.  The relationships between proteins, chem. structures and drug-like properties provide a framework for developing a probabilistic approach to drug discovery that can be exploited to increase research productivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV_CE47zZq8LVg90H21EOLACvtfcHk0livPcZJJGlnXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFansb8%253D&md5=f559b34692cc903a1b503deb07030c5d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnbt1228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1228%26sid%3Dliteratum%253Aachs%26aulast%3DPaolini%26aufirst%3DG.%2BV.%26aulast%3DShapland%26aufirst%3DR.%2BH.%26aulast%3Dvan%2BHoorn%26aufirst%3DW.%2BP.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DGlobal%2520Mapping%2520of%2520Pharmacological%2520Space%26jtitle%3DNat.%2520Biotechnol.%26date%3D2006%26volume%3D24%26spage%3D805%26epage%3D815%26doi%3D10.1038%2Fnbt1228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, M. A.</span></span> <span> </span><span class="NLM_article-title">Chemistry: Chemical Con Artists Foil Drug Discovery</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>513</i></span>,  <span class="NLM_fpage">481</span>– <span class="NLM_lpage">483</span>, <span class="refDoi"> DOI: 10.1038/513481a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.1038%2F513481a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=25254460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1WjsL7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=513&publication_year=2014&pages=481-483&author=J.+Baellauthor=M.+A.+Walters&title=Chemistry%3A+Chemical+Con+Artists+Foil+Drug+Discovery&doi=10.1038%2F513481a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Chemistry: Chemical con artists foil drug discovery</span></div><div class="casAuthors">Baell, Jonathan; Walters, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">513</span>
        (<span class="NLM_cas:issue">7519</span>),
    <span class="NLM_cas:pages">481-483</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Naivety about promiscuous, assay-duping mols. is polluting the literature and wasting resources, warn Jonathan Baell and Michael A. Walters.  Academic drug discoverers must be more vigilant.  Mols. that show the strongest activity in screening might not be the best starting points for drugs.  PAINS hits should almost always be ignored.  Even trained medicinal chemists have to be careful until they become experienced in screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJFYQ0B4VVoLVg90H21EOLACvtfcHk0livPcZJJGlnXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1WjsL7M&md5=f5788d81d006460c688e4b78e6200503</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2F513481a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F513481a%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%26aulast%3DWalters%26aufirst%3DM.%2BA.%26atitle%3DChemistry%253A%2520Chemical%2520Con%2520Artists%2520Foil%2520Drug%2520Discovery%26jtitle%3DNature%26date%3D2014%26volume%3D513%26spage%3D481%26epage%3D483%26doi%3D10.1038%2F513481a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hack, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rassokhin, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buyck, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seierstad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skalkin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ten Holte, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirzadegan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrafiotis, D. K.</span></span> <span> </span><span class="NLM_article-title">Library Enhancement through the Wisdom of Crowds</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">3275</span>– <span class="NLM_lpage">3286</span>, <span class="refDoi"> DOI: 10.1021/ci200446y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci200446y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyhtbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2011&pages=3275-3286&author=M.+D.+Hackauthor=D.+N.+Rassokhinauthor=C.+Buyckauthor=M.+Seierstadauthor=A.+Skalkinauthor=P.+ten+Holteauthor=T.+K.+Jonesauthor=T.+Mirzadeganauthor=D.+K.+Agrafiotis&title=Library+Enhancement+through+the+Wisdom+of+Crowds&doi=10.1021%2Fci200446y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Library Enhancement through the Wisdom of Crowds</span></div><div class="casAuthors">Hack, Michael D.; Rassokhin, Dmitrii N.; Buyck, Christophe; Seierstad, Mark; Skalkin, Andrew; ten Holte, Peter; Jones, Todd K.; Mirzadegan, Taraneh; Agrafiotis, Dimitris K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3275-3286</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We present a novel approach for enhancing the diversity of a chem. library rooted on the theory of the wisdom of crowds.  Our approach was motivated by a desire to tap into the collective experience of our global medicinal chem. community and involved four basic steps: (1) Candidate compds. for acquisition were screened using various structural and property filters in order to eliminate clearly nondrug-like matter. (2) The remaining compds. were clustered together with our inhouse collection using a novel fingerprint-based clustering algorithm that emphasizes common substructures and works with millions of mols. (3) Clusters populated exclusively by external compds. were identified as "diversity holes", and representative members of these clusters were presented to our global medicinal chem. community, who were asked to specify which ones they liked, disliked, or were indifferent to using a simple point-and-click interface. (4) The resulting votes were used to rank the clusters from most to least desirable, and to prioritize which ones should be targeted for acquisition.  Anal. of the voting results reveals interesting voter behaviors and distinct preferences for certain mol. property ranges that are fully consistent with lead-like profiles established through systematic anal. of large historical databases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAlOmFi56CvLVg90H21EOLACvtfcHk0livPcZJJGlnXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyhtbrM&md5=c6544962d51835903246e7a691069e11</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fci200446y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci200446y%26sid%3Dliteratum%253Aachs%26aulast%3DHack%26aufirst%3DM.%2BD.%26aulast%3DRassokhin%26aufirst%3DD.%2BN.%26aulast%3DBuyck%26aufirst%3DC.%26aulast%3DSeierstad%26aufirst%3DM.%26aulast%3DSkalkin%26aufirst%3DA.%26aulast%3Dten%2BHolte%26aufirst%3DP.%26aulast%3DJones%26aufirst%3DT.%2BK.%26aulast%3DMirzadegan%26aufirst%3DT.%26aulast%3DAgrafiotis%26aufirst%3DD.%2BK.%26atitle%3DLibrary%2520Enhancement%2520through%2520the%2520Wisdom%2520of%2520Crowds%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2011%26volume%3D51%26spage%3D3275%26epage%3D3286%26doi%3D10.1021%2Fci200446y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Houston, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galetin, A.</span></span> <span> </span><span class="NLM_article-title">Methods for Predicting in Vivo Pharmacokinetics Using Data from in Vitro Assays</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">940</span>– <span class="NLM_lpage">951</span>, <span class="refDoi"> DOI: 10.2174/138920008786485164</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=10.2174%2F138920008786485164" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=18991591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivF2nsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=940-951&author=J.+B.+Houstonauthor=A.+Galetin&title=Methods+for+Predicting+in+Vivo+Pharmacokinetics+Using+Data+from+in+Vitro+Assays&doi=10.2174%2F138920008786485164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Methods for predicting in vivo pharmacokinetics using data from in vitro assays</span></div><div class="casAuthors">Houston, J. Brian; Galetin, Aleksandra</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">940-951</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Strategies for optimizing in vivo predictions from in vitro data on metabolic stability and CYP inhibition are discussed.  Potential pitfalls and areas of inaccuracy are highlighted together with recommendations for best practice.  The use of both hepatic microsomes and isolated hepatocytes for the assessment of metabolic stability is discussed in terms of scaling from the in vitro system up to whole liver.  The importance of integrating metabolic stability data together with other drug pharmacokinetic characteristics (e.g., protein binding and red blood cell uptake) as well as blood flow are presented within the context of different liver models.  The assessment of CYP inhibition potential requires in vitro data on the inhibitor potency either in the form of Ki (for reversible inhibition) or Kl and kinact (for time-dependent inhibition).  The integration of these in vitro parameters together with other pharmacokinetic information is essential for the in vivo prediction.  While a qual. assessment may be made from the I/Ki ratio, a no. of addnl. victim drug and enzyme-related parameters are required for quant. prediction.  Of particular importance is the parameter fmCYP (the fraction of the metabolic clearance of the victim drug that is catalyzed by the enzyme subject to the inhibition).  Impact of other victim drug properties (e.g., fractional importance of the intestine) and enzyme properties (e.g., kdeg for time-dependent inhibition) on the drug-drug interaction prediction is discussed.  In addn., mechanisms by which false negatives and false positives may result from in vitro strategies are summarized.  Finally perspectives for future application and improvements in these predictions strategies are outlined.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5SQoxJv6217Vg90H21EOLACvtfcHk0lhgZ4VM_Hr0FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivF2nsbY%253D&md5=8ec402521f33f7704edc184f7cab9a35</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.2174%2F138920008786485164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920008786485164%26sid%3Dliteratum%253Aachs%26aulast%3DHouston%26aufirst%3DJ.%2BB.%26aulast%3DGaletin%26aufirst%3DA.%26atitle%3DMethods%2520for%2520Predicting%2520in%2520Vivo%2520Pharmacokinetics%2520Using%2520Data%2520from%2520in%2520Vitro%2520Assays%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2008%26volume%3D9%26spage%3D940%26epage%3D951%26doi%3D10.2174%2F138920008786485164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-ref28_1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koudriakova, T.</span>; <span class="NLM_string-name">Kreutter, K. D.</span>; <span class="NLM_string-name">Leonard, K.</span>; <span class="NLM_string-name">Rizzolio, M. C.</span>; <span class="NLM_string-name">Smith, R. C.</span>; <span class="NLM_string-name">Tichenor, M. S.</span>; <span class="NLM_string-name">Wang, A.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Inhibitors of the JAK Family of Kinases</span>. <span class="NLM_patent">US2018/0170931A1</span>, June 21, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=T.+Koudriakova&author=K.+D.+Kreutter&author=K.+Leonard&author=M.+C.+Rizzolio&author=R.+C.+Smith&author=M.+S.+Tichenor&author=A.+Wang&title=Small+Molecule+Inhibitors+of+the+JAK+Family+of+Kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=ref28_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKoudriakova%26aufirst%3DT.%26atitle%3DSmall%2520Molecule%2520Inhibitors%2520of%2520the%2520JAK%2520Family%2520of%2520Kinases%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-ref29_1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bacani, G. M.</span>; <span class="NLM_string-name">Chai, W.</span>; <span class="NLM_string-name">Koudriakova, T.</span>; <span class="NLM_string-name">Krawczuk, P. J.</span>; <span class="NLM_string-name">Kreutter, K. D.</span>; <span class="NLM_string-name">Leonard, K.</span>; <span class="NLM_string-name">Rizzolio, M. C.</span>; <span class="NLM_string-name">Seierstad, M.</span>; <span class="NLM_string-name">Smith, R. C.</span>; <span class="NLM_string-name">Tichenor, M. S.</span>; <span class="NLM_string-name">Venable, J. D.</span>; <span class="NLM_string-name">Wang, A.</span></span> <span> </span><span class="NLM_article-title">Imidazopyrrolopyridine as inhibitors of the jak family of kinases</span>. <span class="NLM_patent">WO2018/112382A1</span>, June 21, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=G.+M.+Bacani&author=W.+Chai&author=T.+Koudriakova&author=P.+J.+Krawczuk&author=K.+D.+Kreutter&author=K.+Leonard&author=M.+C.+Rizzolio&author=M.+Seierstad&author=R.+C.+Smith&author=M.+S.+Tichenor&author=J.+D.+Venable&author=A.+Wang&title=Imidazopyrrolopyridine+as+inhibitors+of+the+jak+family+of+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=ref29_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBacani%26aufirst%3DG.%2BM.%26atitle%3DImidazopyrrolopyridine%2520as%2520inhibitors%2520of%2520the%2520jak%2520family%2520of%2520kinases%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i62"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01439">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_07244"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.9b01439?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01439</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings of all compounds and cLogP, molecular weight, number of hydrogen bond donors, tPSA, JAK1 IC<sub>50</sub>, JAK2 IC<sub>50</sub>, JAK3IC<sub>50</sub>, Tyk2 IC<sub>50</sub>, and MDCK permeability (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01439/suppl_file/jm9b01439_si_001.csv">CSV</a>)</p></li><li><p class="inline">Histogram of JAK1 pIC<sub>50</sub>’s, correlation between JAK1 IC<sub>50</sub> and JAK2 IC<sub>50</sub>, correlation between JAK1 IC<sub>50</sub> and JAK3 IC<sub>50</sub>, correlation between JAK1 IC<sub>50</sub> and Tyk2 IC<sub>50</sub>, correlation of cLogP and tPSA to permeability (analogues excluding −CH<sub>2</sub>CONRR and −CH<sub>2</sub>NRCOR subset), and correlation of clogP and tPSA to permeability (−CH<sub>2</sub>CONRR and −CH<sub>2</sub>NRCOR subset) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01439/suppl_file/jm9b01439_si_002.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01439/suppl_file/jm9b01439_si_001.csv">jm9b01439_si_001.csv (27.33 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01439/suppl_file/jm9b01439_si_002.pdf">jm9b01439_si_002.pdf (524.35 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01439&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01439%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-6" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01439" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66797ae0b9ef1991","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
